<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7438404</article-id><article-id pub-id-type="doi">10.3389/fmicb.2020.01818</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Igor de Andrade</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/954805/overview"/></contrib><contrib contrib-type="author"><name><surname>Grosche</surname><given-names>Vict&#x000f3;ria Riquena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1031964/overview"/></contrib><contrib contrib-type="author"><name><surname>Bergamini</surname><given-names>Fernando Rodrigues Goulart</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/1039589/overview"/></contrib><contrib contrib-type="author"><name><surname>Sabino-Silva</surname><given-names>Robinson</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/181219/overview"/></contrib><contrib contrib-type="author"><name><surname>Jardim</surname><given-names>Ana Carolina Gomes</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/493324/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Laboratory of Virology, Institute of Biomedical Science, Federal University of Uberl&#x000e2;ndia</institution>, <addr-line>Uberl&#x000e2;ndia</addr-line>, <country>Brazil</country></aff><aff id="aff2"><sup>2</sup><institution>Institute of Biosciences, Language and Exact Sciences, S&#x000e3;o Paulo State University</institution>, <addr-line>S&#x000e3;o Jos&#x000e9; do Rio Preto</addr-line>, <country>Brazil</country></aff><aff id="aff3"><sup>3</sup><institution>Laboratory of Synthesis of Bioinspired Molecules, Institute do Chemistry, Federal University of Uberl&#x000e2;ndia</institution>, <addr-line>Uberl&#x000e2;ndia</addr-line>, <country>Brazil</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Physiology, Institute of Biomedical Sciences, Federal University of Uberl&#x000e2;ndia</institution>, <addr-line>Uberl&#x000e2;ndia</addr-line>, <country>Brazil</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Anna Kramvis, University of the Witwatersrand, Johannesburg, South Africa</p></fn><fn fn-type="edited-by"><p>Reviewed by: Olivier Terrier, UMR 5308 Centre International de Recherche en Infectiologie (CIRI), France; Maryam Dadar, Razi Vaccine and Serum Research Institute, Iran</p></fn><corresp id="c001">*Correspondence: Ana Carolina Gomes Jardim, <email>jardim@ufu.br</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>11</volume><elocation-id>1818</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Santos, Grosche, Bergamini, Sabino-Silva and Jardim.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Santos, Grosche, Bergamini, Sabino-Silva and Jardim</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Coronaviruses (CoVs) are a group of viruses from the family <italic>Coronaviridae</italic> that can infect humans and animals, causing mild to severe diseases. The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a global threat, urging the development of new therapeutic strategies. Here we present a selection of relevant compounds that have been described from 2005 until now as having <italic>in vitro</italic> and/or <italic>in vivo</italic> antiviral activities against human and/or animal CoVs. We also present compounds that have reached clinical trials as well as further discussing the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, through rationalization of the data presented herein, we wish to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates.</p></abstract><kwd-group><kwd>antivirals</kwd><kwd>coronaviruses</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>treatment</kwd></kwd-group><counts><fig-count count="2"/><table-count count="2"/><equation-count count="0"/><ref-count count="257"/><page-count count="23"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Coronaviruses (CoVs) were first identified in 1960 (<xref rid="B108" ref-type="bibr">Kahn and McIntosh, 2005</xref>) and were classified as members of the family <italic>Coronaviridae</italic>. CoVs are enveloped, single-stranded RNA viruses with a genome varying from 25 to 32 kb (<xref rid="B161" ref-type="bibr">Payne, 2017</xref>). The viral structure is primarily formed by the structural spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. The S, M, and E proteins are embedded in the viral envelope, which is a lipid bilayer derived from the host cell membrane. The N protein, on the other hand, interacts with the viral RNA into the core of the virion (<xref ref-type="fig" rid="F1">Figure 1</xref>; <xref rid="B67" ref-type="bibr">Fehr and Perlman, 2015</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Schematic structure of SARS-CoV-2. The viral structure is primarily formed by the structural proteins such as spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. The S, M, and E proteins are all embedded in the viral envelope, a lipid bilayer derived from the host cell membrane. The N protein interacts with the viral RNA in to the core of the virion.</p></caption><graphic xlink:href="fmicb-11-01818-g001"/></fig><p>These viruses can infect vertebrate animals, causing acute to chronic diseases in the respiratory, cardiac, enteric, and central nervous systems, both in animals and humans (<xref rid="B237" ref-type="bibr">Weiss and Navas-Martin, 2005</xref>). In animals, the most common CoVs are infectious bronchitis virus (IBV), feline CoV (FeCoV), and mouse hepatitis virus (MHV), which infect chickens, felines, and rodents, respectively (<xref rid="B50" ref-type="bibr">Cui et al., 2019</xref>). To date, there are seven known CoVs that cause diseases in humans: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and, most recently, SARS-CoV-2 (<xref rid="B79" ref-type="bibr">Graham et al., 2013</xref>; <xref rid="B28" ref-type="bibr">CDC, 2020a</xref>). The CoVs HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 cause mild symptoms, similar to a common cold (<xref rid="B161" ref-type="bibr">Payne, 2017</xref>). However, SARS-CoV, MERS-CoV, and SARS-CoV-2 can cause mild to severe symptoms related to upper respiratory infection such as fever, cough, dyspnea, pneumonia, and acute respiratory distress syndrome (ARDS), ultimately leading to death (<xref rid="B122" ref-type="bibr">Lai et al., 2020</xref>). The severe clinical condition generated especially by SARS-CoV-2 has been burdening public health systems worldwide (<xref rid="B96" ref-type="bibr">Hsu et al., 2020</xref>), evidencing the mandatory need for further research encompassing antiviral treatment against CoVs, which has somehow, until recently, been relatively ignored by broad pharmaceutical and medicinal fields (<xref rid="B138" ref-type="bibr">Lu et al., 2015</xref>; <xref rid="B50" ref-type="bibr">Cui et al., 2019</xref>).</p><p>CoVs are linked to a zoonotic transmission due to their ability to infect different species. This can lead to host jumps, allowing the emergence of new coronaviruses such as SARS-CoV, MERS-CoV, and SARS-CoV-2 (<xref rid="B138" ref-type="bibr">Lu et al., 2015</xref>; <xref rid="B180" ref-type="bibr">Reusken et al., 2016</xref>; <xref rid="B11" ref-type="bibr">Andersen et al., 2020</xref>). The transmission of CoVs is based on the fecal-oral route in animals (<xref rid="B118" ref-type="bibr">Kipar et al., 2010</xref>). In humans, CoV transmission occurs by direct contact with droplets when infected and recipient individuals are in close contact (about one meter). These infectious oral and respiratory droplets produced by talking, coughing, sneezing need to contact the mucosae (mouth and nose) or conjunctiva (eyes) of the recipient person. Additionally, indirect transmission can occur by touching a surface with viable CoV and subsequent contact with mouth, nose, or eyes (<xref rid="B224" ref-type="bibr">van Doremalen et al., 2020</xref>). Viral particles may remain viable on surfaces for several days, increasing the probability of infection by third parties (<xref rid="B224" ref-type="bibr">van Doremalen et al., 2020</xref>).</p><p>Recently, the emergence of SARS-CoV-2 was related to zoonotic transmission, but it is still not clear how this virus was first transmitted to humans (<xref rid="B11" ref-type="bibr">Andersen et al., 2020</xref>; <xref rid="B77" ref-type="bibr">Gorbalenya et al., 2020b</xref>). By phylogenetic analysis, the SARS-CoV-2 was grouped within bat SARS-related coronaviruses, suggesting that a host jump occurred (<xref rid="B26" ref-type="bibr">Cao et al., 2020a</xref>; <xref rid="B122" ref-type="bibr">Lai et al., 2020</xref>). Alarmingly, the high transmissibility of this new CoV allowed the rapid and efficient spread of the virus across the world so that it became a pandemic disease in just a few months (<xref rid="B28" ref-type="bibr">CDC, 2020a</xref>; <xref rid="B246" ref-type="bibr">Wu et al., 2020</xref>).</p><p>Due to the novelty of this disease, there is a lack of understanding of the SARS-CoV-2 replication process in host cells. The general mechanisms of entry into the host cell, replication, and release follow characteristics that have been described for other CoVs and have been partially confirmed for SARS-CoV-2. To date, it is known that the SARS-CoV-2 virion entries the host cells by the attachment of the S protein with angiotensin-converting enzyme 2 receptor (ACE2), defining SARS-CoV-2 tropism for cells that express this receptor, such as pulmonary, hepatic, gastrointestinal, and renal human cells (<xref rid="B44" ref-type="bibr">Chu et al., 2020</xref>; <xref rid="B93" ref-type="bibr">Hoffmann et al., 2020</xref>; <xref rid="B210" ref-type="bibr">Tai et al., 2020</xref>). The interaction of ACE2 with the receptor-binding domain (RBD) of the S protein triggers virion endocytosis and the formation of an endosome (<xref rid="B175" ref-type="bibr">Rabi et al., 2020</xref>). The S protein possesses two subunits, S1 and S2 (<xref rid="B230" ref-type="bibr">Walls et al., 2020</xref>). During endocytosis, an acid-dependent proteolytic cleavage of the S1 protein by cellular proteases, like cathepsin, TMPRRS2, and trypsin, exposes the S2 subunit, a fusion peptide that allows the fusion of the viral envelope with the endosome membrane, and consequently, releases the capsid into the cell cytoplasm (<xref rid="B20" ref-type="bibr">Belouzard et al., 2009</xref>; <xref rid="B143" ref-type="bibr">Matsuyama et al., 2020</xref>). In the cytoplasm, the CoV viral genome is uncoated, and the viral RNA is released. The positive-sense RNA viral genome is translated to produce nonstructural proteins (nsps) from two open reading frames (ORFs), ORF1a and ORF1b. The ORF1a encodes the polyprotein pp1a that is cleaved in 11 nsps, while the ORF1b encodes the polyprotein pp1ab, which is cleaved into 15 nsps. The proteolytic cleavage is performed by viral proteases nsp3 and nsp5 (<xref rid="B252" ref-type="bibr">Yogo et al., 1977</xref>; <xref rid="B123" ref-type="bibr">Lai and Stohlman, 1981</xref>; <xref rid="B114" ref-type="bibr">Kim et al., 2020</xref>). The nsps assemble to form a replicase-transcriptase complex (RTC) responsible for RNA synthesis, replication, and transcription of nine subgenomic RNAs (sgRNAs) (<xref rid="B67" ref-type="bibr">Fehr and Perlman, 2015</xref>; <xref rid="B37" ref-type="bibr">Chen W.-H. et al., 2020</xref>; <xref rid="B114" ref-type="bibr">Kim et al., 2020</xref>). The sgRNAs act as mRNAs for structural and accessory genes localized downstream of the replicase polyproteins. SARS-CoV-2 has six accessory proteins: 3a, 6, 7a, 7b, 8, and 10 (<xref rid="B114" ref-type="bibr">Kim et al., 2020</xref>). The structural proteins S, E, and M are translated from the sgRNAs and forwarded to the endoplasmic reticulum (ER) and are subsequently inserted into an intermediate compartment of ER with Golgi (ERGIC). There, viral genomes are encapsulated by N proteins and assembled with the structural proteins to form virions (<xref rid="B204" ref-type="bibr">Siu et al., 2008</xref>; <xref rid="B67" ref-type="bibr">Fehr and Perlman, 2015</xref>; <xref rid="B132" ref-type="bibr">Li et al., 2020</xref>). The M proteins bind to E protein and nucleocapsid, and then, the S protein is incorporated, forming a complete virion. Finally, the virions are transported to the cell surface in vesicles and released in a pathway mediated by exocytosis (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref rid="B67" ref-type="bibr">Fehr and Perlman, 2015</xref>; <xref rid="B114" ref-type="bibr">Kim et al., 2020</xref>; <xref rid="B132" ref-type="bibr">Li et al., 2020</xref>).</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>Schematic representation of SARS-CoV-2 replication cycle in host cells. SARS-CoV-2 attaches to the host cells by interaction between the ACE2 receptors and spike proteins. After entry, viral uncoating process results in the release of viral genome and replication stage occurs (translation and transcription). Structural proteins are produced in intermediate compartment of endoplasmic reticulum with Golgi complex and forwarded to assembly, packaging and virus release. Compounds with antiviral activity against SARS-CoV-2 are indicated in each step of virus replication cycle.</p></caption><graphic xlink:href="fmicb-11-01818-g002"/></fig><p>It is important to emphasize that SARS-CoV-2 shows different epidemiological and clinical features from the epidemics of SARS-CoV and MERS-CoV (<xref rid="B30" ref-type="bibr">Ceccarelli et al., 2020</xref>; <xref rid="B76" ref-type="bibr">Gorbalenya et al., 2020a</xref>, <xref rid="B77" ref-type="bibr">b</xref>). The high transmissibility of SARS-CoV-2 may be related to its entry into host cells (<xref rid="B209" ref-type="bibr">Sun et al., 2020</xref>). Although both SARS-CoV and SARS-CoV-2 glycoprotein S attach to ACE2 to enter the host cells, the binding affinity of SARS-CoV-2 is higher, thus enhancing its infectivity (<xref rid="B209" ref-type="bibr">Sun et al., 2020</xref>; <xref rid="B248" ref-type="bibr">Yan et al., 2020</xref>). Despite the relative homology between S1 and S2 amino acid sequences, a 1.2 &#x000c5; root-mean-square deviation at the 417 position (<xref rid="B139" ref-type="bibr">Lusvarghi and Bewley, 2016</xref>) of S2 protein in SARS-CoV-2 may be related to its higher infectiveness, contributing to a 10- to 20-fold higher kinetic affinity of SARS-CoV-2 ectodomain, as evidenced by Wrapp and co-workers, employing surface plasmon resonance measurements (<xref rid="B244" ref-type="bibr">Wrapp et al., 2020</xref>).</p><p>Considering the particularities of SARS-CoV-2 and the emergency caused by its outbreak, several strategies have been adopted to develop therapeutics and prophylactic measures against this virus. The strategies employed in these developments include: (i) utilization of bioinformatics for the prediction and investigation of potential ligands toward target molecules in the viral structure and/or replication (<xref rid="B5" ref-type="bibr">Ahmed et al., 2020</xref>, 2; <xref rid="B105" ref-type="bibr">Jeon et al., 2020</xref>, 2); (ii) employment of cell culture systems, permissive to CoVs (<xref rid="B22" ref-type="bibr">Caly et al., 2020</xref>; <xref rid="B137" ref-type="bibr">Liu et al., 2020</xref>), associated with pseudo particles, subgenomic replicons and/or full-length CoVs, seeking to assess cellular response or the effects of the compounds on the viral replicative cycle (<xref rid="B182" ref-type="bibr">Roberts et al., 2006</xref>; <xref rid="B93" ref-type="bibr">Hoffmann et al., 2020</xref>); (iii) the use of animal models, such as mice, mouse, guinea pig, hamster and non-human primates, for evaluating therapeutic options or antibody production in immunization (<xref rid="B157" ref-type="bibr">Natoli et al., 2020</xref>; <xref rid="B199" ref-type="bibr">Sheahan et al., 2020b</xref>), and (iv) clinical trials assessing the administration, distribution, metabolism, and toxicity profiles (ADMeTox) of potential therapeutics as well as immunization effects in humans (<xref rid="B47" ref-type="bibr">Clark et al., 2019</xref>).</p><p>Based in previous results in vaccine development for MERS-CoV and SARS-CoV and the similarity of those viruses with SARS-CoV-2 (<xref rid="B61" ref-type="bibr">Dhama et al., 2020</xref>), the current vaccine candidates are more focused on the S protein, since is a major inducer of neutralizing antibodies in infected patients (<xref rid="B230" ref-type="bibr">Walls et al., 2020</xref>). For this reason, efforts are concentrated on using approaches such as mRNA, DNA, viral vectors, or virus-like particles vaccines with a full-length S protein or S1 receptor-binding domain (RBD) to stimulate immune response and immunization (<xref rid="B5" ref-type="bibr">Ahmed et al., 2020</xref>; <xref rid="B33" ref-type="bibr">Chen Y. et al., 2020</xref>). The most promising vaccines are: (i) adenovirus-vectored AZD1222 produced by Oxford University (<xref rid="B217" ref-type="bibr">Thomas, 2020</xref>), a vaccine that is currently in clinical phase 3, being tested in several countries, including the United States, Brazil, and countries in Asia and Africa; (ii) mRNA-1273 associated with a lipidic nanoparticle (NCT04283461), which is currently in clinical phase 2; and (iii) inactivated virus vaccine, which is currently in clinical phase 1 (<xref rid="B153" ref-type="bibr">Mullard, 2020</xref>; <xref rid="B220" ref-type="bibr">Tu et al., 2020</xref>).</p><p>The high transmissibility and viral variability of the novel SARS-CoV-2, along with the lack of a vaccine or drugs to treat the infected patients, threaten the global health system. In this context, the development of effective antivirals is critical to provide short-term therapies able to reduce the severity of clinical outcomes of coronavirus disease 2019 (COVID-19) and to reduce the spread of SARS-CoV-2. Here, we summarize compounds described, from 2005 to date, to possess antiviral activity <italic>in vitro</italic> and/or <italic>in vivo</italic> against CoVs and critically compare molecules that could be further investigated by their clinical applicability (<xref rid="T1" ref-type="table">Table 1</xref>). We also discuss the compounds that have reached clinical trials (<xref rid="T2" ref-type="table">Table 2</xref>) as well as the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, we aim to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates.</p><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Compounds with antiviral activity against human and animal coronaviruses.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Compound</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition step</td><td valign="top" align="center" rowspan="1" colspan="1">EC50 or inhibition (%)</td><td valign="top" align="left" rowspan="1" colspan="1">CoVs</td><td valign="top" align="left" rowspan="1" colspan="1">Advantges and/or limitations</td><td valign="top" align="left" rowspan="1" colspan="1">References</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">NAAE</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">0.5 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, evaluated <italic>in silico</italic>, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B99" ref-type="bibr">Huentelman et al., 2004b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glycyrrhizin</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">300 mg L<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Natural molecule, highly tolerated but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B46" ref-type="bibr">Cinatl et al., 2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2-acetamido-&#x003b1;-<sc>D</sc>-Glucopyranosylamine derivative</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">40 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Semi-synthetic molecule, highly tolerated, and more potent inhibitor but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B92" ref-type="bibr">Hoever et al., 2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tetrahydroquinoline oxocarbazate (CID 23631927)</td><td valign="top" align="left" rowspan="1" colspan="1">Entry (Cathepsin L)</td><td valign="top" align="center" rowspan="1" colspan="1">273 nM</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B194" ref-type="bibr">Shah et al., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SSAA09E1</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">6.7 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SSAA09E2</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">3.1 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SSAA09E3</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">9.7 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Emodin</td><td valign="top" align="left" rowspan="1" colspan="1">Entry and Post-Entry</td><td valign="top" align="center" rowspan="1" colspan="1">50 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Natural molecule, highly tolerated but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B91" ref-type="bibr">Ho et al., 2007</xref>; <xref rid="B193" ref-type="bibr">Schwarz et al., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Griffithsin (GRFT)</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">0.16 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-OC43</td><td valign="top" align="left" rowspan="1" colspan="1">Natural molecule, highly tolerated, with a broad-spectrum effect (human and animal CoVs); protected against infection and improved survival in animal assay (Balb/c)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B158" ref-type="bibr">O&#x02019;Keefe et al., 2010</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">0.18 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-229E</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">0.61 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.032 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">0.057 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">BCoV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">0.23 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">MHV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Eremomycin derivate 27</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">5.4 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">FIPV</td><td valign="top" align="left" rowspan="1" colspan="1">The precursor molecule (Eremomycin) is used to treat bacterial infections; may facilitate clinical assays, but knowledge of the mechanism of action is lacking</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B15" ref-type="bibr">Balzarini et al., 2006</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">14 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Eremomycin derivate 39</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">12 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">FIPV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">22 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mucroporin-M1</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">14.46 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, moderately tolerated, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B131" ref-type="bibr">Li et al., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tyr-Lys-Tyr-Arg-Tyr-Leu</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">14 mM</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule specifically designed to bind S protein of SARS-CoV; highly tolerated, does not impair ACE2 activity but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B208" ref-type="bibr">Struck et al., 2012</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">14 mM</td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TAPI-2</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">65%</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Good effects in vitro assays but had no effect on <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B84" ref-type="bibr">Haga et al., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Monoclonal antibody 47D11</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="center" rowspan="1" colspan="1">0.57 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Human antibody, specifically to SARS-CoV-2, highly tolerated and easily applicable</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B231" ref-type="bibr">Wang et al., 2020a</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AVLQSGFR</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">2.7 &#x000d7; 10<sup>&#x02013;2</sup> mg mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B69" ref-type="bibr">Gan et al., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Phe-Phe dipeptide inhibitor C (JMF1521)</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">0.18 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but lacks <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B202" ref-type="bibr">Shie et al., 2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dipeptidyl EP128533</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">3.6 &#x003bc;M or 1.4 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced but has contrasting effects in the literature and did not inhibit the virus in <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B256" ref-type="bibr">Zhang et al., 2006</xref>; <xref rid="B55" ref-type="bibr">Day et al., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GC373</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">0.2 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-229E</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, seems to interact with SARS-CoV 3CLpro, but there are no <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>, <xref rid="B116" ref-type="bibr">2013</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.3 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">FIPV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">MHV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.3 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">TGEV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.7 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">BCV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.15 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">FCoV-WSU</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GC376</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">0.15 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-229E</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, seems to interact with SARS-CoV 3CLpro, but there are no <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>, <xref rid="B116" ref-type="bibr">2013</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.2 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">FIPV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1.1 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">MHV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.15 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">TGEV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.6 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">BCV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.40 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">FCoV-WSU</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6-azauridine</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">32 nM</td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B174" ref-type="bibr">Pyrc et al., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no in vivo assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B176" ref-type="bibr">Ramajayam et al., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b2;-<sc>D</sc>-N<sup>4</sup>-hydroxycytidine</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">10 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, and improved pulmonary function and decreased viral load in lung of infected mice</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B17" ref-type="bibr">Barnard et al., 2004</xref>; <xref rid="B199" ref-type="bibr">Sheahan et al., 2020b</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">400 nM</td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">0.08&#x02013;0.3 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">0.024 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">20 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, good results in MERS-CoV. However, meta-analyses indicate limited efficacy.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B187" ref-type="bibr">Saijo et al., 2005</xref>; <xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acyclic sugar scaffold of acyclovir</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">23 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B163" ref-type="bibr">Peters et al., 2015</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">8.8 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">HCoV-NL63</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, derivate from Acyclovir, easily produced, but there are no in vivo assays</td><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Niclosamide</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">0.1 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Drug already in use to treat helminthic infections; good inhibition <italic>in vitro</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B245" ref-type="bibr">Wu et al., 2004</xref>; <xref rid="B238" ref-type="bibr">Wen et al., 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mycophenolic acid (MPA)</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">2.87 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Good effects <italic>in vitro</italic> with MERS-CoV but did not inhibit SARS-CoV in <italic>in vitro</italic> and <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B46" ref-type="bibr">Cinatl et al., 2003</xref>; <xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref>; <xref rid="B87" ref-type="bibr">Hart et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TP29 peptide</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">60 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">MHV</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited two species of CoV in mice; also improved survival and induced INF-I. Inhibited CoV in cell lines. Synthetic compound designed for nonstructural proteins.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B235" ref-type="bibr">Wang et al., 2015</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">200 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="justify" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bananins</td><td valign="top" align="left" rowspan="1" colspan="1">Replication</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;10 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, easily produced, but there are no <italic>in vivo</italic> assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B214" ref-type="bibr">Tanner et al., 2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nitazoxanide</td><td valign="top" align="left" rowspan="1" colspan="1">Host Enzymes</td><td valign="top" align="center" rowspan="1" colspan="1">0.92 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Drug already in use to treat viral infections; good inhibition <italic>in vitro</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B185" ref-type="bibr">Rossignol, 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tizoxanide</td><td valign="top" align="left" rowspan="1" colspan="1">Host Enzymes</td><td valign="top" align="center" rowspan="1" colspan="1">0.83 &#x003bc;g mL<sup>&#x02013;1</sup></td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Drug derived from Nitazoxanide; good inhibition <italic>in vitro</italic></td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B185" ref-type="bibr">Rossignol, 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Saracatinib</td><td valign="top" align="left" rowspan="1" colspan="1">Tyrosine Kinases</td><td valign="top" align="center" rowspan="1" colspan="1">2.9 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">MERS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic molecule, highly tolerated, used to treat Alzheimer&#x02019;s disease and easily produced but there are no in vivo assays</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B203" ref-type="bibr">Shin et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cyclosporin A (CsA)</td><td valign="top" align="left" rowspan="1" colspan="1">Hosts Cyclophilin Family Enzymes</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x02013;32 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV, MERS-CoV and MHV</td><td valign="top" align="left" rowspan="1" colspan="1">Drug already used to treat several chronic and infectious diseases with broad-spectrum activity among CoVs</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B59" ref-type="bibr">de Wilde et al., 2011</xref>, <xref rid="B58" ref-type="bibr">2013</xref>; <xref rid="B165" ref-type="bibr">Pfefferle et al., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alisporivir</td><td valign="top" align="left" rowspan="1" colspan="1">Hosts Cyclophilin Family Enzymes</td><td valign="top" align="center" rowspan="1" colspan="1">8.3 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Analog of CsA and has a strong inhibition <italic>in vitro</italic> against SARS-CoV and other CoVs</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B56" ref-type="bibr">de Wilde et al., 2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Interference RNA (iRNAs)</td><td valign="top" align="left" rowspan="1" colspan="1">Viral Proteins Translation</td><td valign="top" align="center" rowspan="1" colspan="1">70%</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Different approach, specific targeting of viral proteins; can block replication steps and has no cytotoxicity</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B6" ref-type="bibr">&#x000c5;kerstr&#x000f6;m et al., 2007</xref></td></tr><tr><td valign="top" align="justify" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Viral Proteins Translation</td><td valign="top" align="center" rowspan="1" colspan="1">99%</td><td valign="top" align="left" rowspan="1" colspan="1">SECoV</td><td valign="top" align="left" rowspan="1" colspan="1">Different approach, specific targeting of viral proteins; can block replication steps and has no cytotoxicity</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B130" ref-type="bibr">Li et al., 2019</xref></td></tr></tbody></table><table-wrap-foot><attrib><italic>EC50: effective concentration of 50%; NE: not evaluated.</italic></attrib></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>Ongoing clinical trials of candidate drugs against SARS-CoV-2 in COVID-19 patients.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Drug</td><td valign="top" align="left" rowspan="1" colspan="1">Cell culture assays</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition step <italic>in vitro</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Animal assays</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical trials</td><td valign="top" align="left" rowspan="1" colspan="1">Outcomes in clinical trials</td><td valign="top" align="left" rowspan="1" colspan="1">Advantages and/or limitations</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Remdesivir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV, MERS-CoV, and SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Replication (RdRp)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited EBOV and SARS-CoV in both infected mice and monkeys</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical case and clinical trial against SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Did not provide antiviral effects or improved clinical outcomes</td><td valign="top" align="left" rowspan="1" colspan="1">This is a multicentre, double-blind, placebo-controlled clinical trial, but more studies might be needed to confirm, since this includes 255 people, and the drug has some adverse effects.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lopinavir and Ritonavir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV and MERS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">Replication (protease inhibitor)</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical trial with SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Did not provide antiviral effects or improved clinical outcomes in severe patients, but, in early infections, clinical outcomes were improved.</td><td valign="top" align="left" rowspan="1" colspan="1">This drug combination is used for other human CoVs, but the study was not multicentre, double-blind, and placebo-controlled. More studies are necessary to confirm, since it had only 199 people and the drug showed some adverse effects.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b2;</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV, MERS-CoV, MHV, and HCoV-229E</td><td valign="top" align="left" rowspan="1" colspan="1">Host Factors (inducing immune response)</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV, MERS-CoV, MHV, and HCoV-229E</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical trial with SARS-CoV-2 and is used for other diseases</td><td valign="top" align="left" rowspan="1" colspan="1">Do not have effect alone</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b2; is indicated to be safe, with few adverse effects, but in clinical trials, it is only effective when associated with other drugs.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Umifenovir</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Observational study with 81 patients</td><td valign="top" align="left" rowspan="1" colspan="1">Did not provide antiviral effects or improved clinical outcomes</td><td valign="top" align="left" rowspan="1" colspan="1">This is an observational study and might suffer bias from lack and/or loss of information and data. It is an applicable study, since it demonstrates a tendency, and the drug is already used to treat Influenza viruses.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Corsticosteroids (dexamethasone)</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Host factors (controlling immune response)</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical trial with 454 treated patients</td><td valign="top" align="left" rowspan="1" colspan="1">Reduced death by one-third in invasive mechanical ventilation patients and one-fifth in oxygen without invasive mechanical ventilation patients; however, did not impair mortality in patients without respiratory support</td><td valign="top" align="left" rowspan="1" colspan="1">This is a multicentre, double-blind, placebo-controlled clinical trial. More studies are needed to understand better the effect on different phases of COVID-19. May be a good alternative for treating hyperinflammation and hypersecretion of cytokines.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ivermectin</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited SARS-CoV-2 and arboviruses (CHIKV and DENV)</td><td valign="top" align="left" rowspan="1" colspan="1">Replication (nonstructural proteins)</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Clinical trials are beginning</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Ivermectin is safe for use in humans since it is used to treat several parasitic infections.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of IL-6</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Ongoing clinical trials with SARS-CoV-2 patients; one with 100 patients concluded.</td><td valign="top" align="left" rowspan="1" colspan="1">Positive effects: improved inflammatory markers and decreased the need for ventilatory support in patients</td><td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab is already used to treat viral infections, controlling immune response, impairing cytokine storms, improving antiviral response, and providing the best clinical outcomes.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chloroquine</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="left" rowspan="1" colspan="1">Improved outcomes in FCoV positive cats</td><td valign="top" align="left" rowspan="1" colspan="1">Several clinical trials are being conducted</td><td valign="top" align="left" rowspan="1" colspan="1">Impairs virus replication and has anti-inflammatory activities</td><td valign="top" align="left" rowspan="1" colspan="1">Chloroquine possesses important side effects and is indicated only in severe cases. However, there are some studies with contrasting results regarding its safety, since it can cause arrhythmias, hypoglycemia, neuropsychiatric effects, and depression.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hydroxychlo-roquine</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Several clinical trials are being conducted</td><td valign="top" align="left" rowspan="1" colspan="1">Less toxic option, impairs virus replication</td><td valign="top" align="left" rowspan="1" colspan="1">Hydroxychloroquine improved patients&#x02019; outcomes, including when associated with azithromycin. Less toxic option than chloroquine treatment, but there are studies with contrasting results regarding its safety, since it can cause arrhythmias, hypoglycemia, neuropsychiatric effects, and depression.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Convalescent Plasma</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Entry</td><td valign="top" align="left" rowspan="1" colspan="1">NE</td><td valign="top" align="left" rowspan="1" colspan="1">Case report</td><td valign="top" align="left" rowspan="1" colspan="1">Improved outcomes and suppressed viremia.</td><td valign="top" align="left" rowspan="1" colspan="1">Administration poses a risk to patients since it is related to donor-dependent variability and compatibility. Antibody titers may interfere with its activity. In addition, it might cause side effects in lung and the cardiovascular system.</td></tr></tbody></table><table-wrap-foot><attrib><italic>EC50: effective concentration of 50%; NE: not evaluated.</italic></attrib></table-wrap-foot></table-wrap></sec><sec id="S2"><title>Inhibitors of the CoV Replicative Cycle</title><sec id="S2.SS1"><title>Inhibitors of CoV Entry Into Host Cells</title><p>The entry of human CoVs into the host cells is mainly related to the binding of viral S protein to the ACE2 receptor (<xref rid="B166" ref-type="bibr">Prabakaran et al., 2004</xref>; <xref rid="B209" ref-type="bibr">Sun et al., 2020</xref>). Therefore, it is reasonable to hypothesize that compounds affecting this interaction could be potential antivirals (<xref rid="B166" ref-type="bibr">Prabakaran et al., 2004</xref>).</p><p>In this context, a survey encompassing <italic>in silico</italic> studies of more than 140 thousand potential S-protein-inhibiting drugs indicated that the molecule <italic>N</italic>-(2-aminoethyl)-1 aziridineethanamine (NAAE) showed the highest docking grade (-23.7 kcal/mol) (<xref rid="B99" ref-type="bibr">Huentelman et al., 2004b</xref>). The activity of NAAE was further confirmed by employing an <italic>in vitro</italic> enzymatic inhibitory assay, using a human recombinant ACE2. In this assay, ACE2 removed the C-terminal dinitrophenyl moiety that quenched the inherent fluorescence of the 7-methoxycoumain group, increasing the fluorescence when ACE2 was active (<xref rid="B99" ref-type="bibr">Huentelman et al., 2004b</xref>). The results showed that NAAE inhibited the ACE2 enzymatic activity with the half maximal inhibitory concentration (IC<sub>50</sub>) of 57 &#x003bc;mol mL<sup>&#x02212;1</sup> (<xref rid="B99" ref-type="bibr">Huentelman et al., 2004b</xref>). In addition, 293T cells expressing ACE2 receptor were incubated with NAAE and then with S glycoprotein-expressing 293T cells, and measurement of &#x003b2;-galactosidase activity (reported gene in cell-cell fusion) was performed. NAAE at 0.5 &#x003bc;M inhibited 50% of SARS-CoVs spike protein-mediated cell fusion, suggesting that NAAE might be a candidate for treating SARS infection by impairing viral attachment via interference with ACE2 (<xref rid="B99" ref-type="bibr">Huentelman et al., 2004b</xref>). However, a detailed explanation of how NAAE is a more efficient ligand to ACE2 than other compounds was not attempted by the authors.</p><p>Ramos-Tovar and Muriel reported the antiviral activity of Glycyrrhizin (GL), a major constituent from licorice root (<xref rid="B177" ref-type="bibr">Ramos-Tovar and Muriel, 2019</xref>), which was able to inhibit SARS-CoV entry into Vero cells with an effective concentration of 50% (EC<sub>50</sub>) of 300 mg L<sup>&#x02013;1</sup> and a cytotoxicity concentration of 50% (CC<sub>50</sub>) of &#x0003e;20.000 mg L<sup>&#x02013;1</sup>. GL was less effective when the administration occurred during the viral adsorption period than when it was administered after entry into host cells. Cumulative effects were observed when this compound was administered both during and after entry into host cells, which indicates a significantly potent inhibitor against the virus under the tested conditions (<xref rid="B46" ref-type="bibr">Cinatl et al., 2003</xref>). Additionally, the antiviral activity of 15 GL derivates against SARS-CoV was assessed (<xref rid="B92" ref-type="bibr">Hoever et al., 2005</xref>). Conjugation on both acidic moieties of the GL disaccharide group with 2-acetamido-&#x003b1;-<sc>D</sc>-glucopyranosylamine, benzylcysteine, and Gly-Leu peptide generated compounds with an increase of 10- to 70-fold in anti-SARS-CoV activity when compared to GL itself (<xref rid="B92" ref-type="bibr">Hoever et al., 2005</xref>). For the case of 2-acetamido-&#x003b1;-<sc>D</sc>-glucopyranosylamine derivative, it was speculated that viral entry was inhibited through <italic>N</italic>-acetylglycosamine binding onto S-protein carbohydrates. Other derivatives such as the introduction of heterocyclic amides such as 6-amine-thiouracil induced a higher cytotoxicity profile.</p><p>The endossomal cathepsins are essential enzymes in viral entry into host cells (<xref rid="B97" ref-type="bibr">Huang et al., 2006</xref>), and cathepsin L has been pointed to as playing a crucial role in membrane fusion with the endosomes (<xref rid="B20" ref-type="bibr">Belouzard et al., 2009</xref>; <xref rid="B143" ref-type="bibr">Matsuyama et al., 2020</xref>). In this context, Shah and coworkers demonstrated the effective activity of tetrahydroquinoline oxocarbazate (CID 23631927), an oxocarbazate inhibitor of cathepsin L, against SARS-CoV. Employing a pseudovirus system with a luciferase reporter to infect 293T cells, the compound inhibited viral entry with an EC<sub>50</sub> of 273 &#x003b7;M and CC<sub>50</sub> &#x0003e; 100 &#x003bc;M (<xref rid="B194" ref-type="bibr">Shah et al., 2010</xref>). The authors also showed that the compound CID 23631927 seems to bind with a lower inhibition constant (K<sub><italic>i</italic></sub>) to cathepsin L, improving the compound/cathepsin L interaction. This might be related to its optimized structure, with stronger hydrophobic interactions and better hydrogen bonds between the compound and cathepsin L (<xref rid="B194" ref-type="bibr">Shah et al., 2010</xref>).</p><p>An extensive study screened a library of compounds following Lipinski&#x02019;s rule (<xref rid="B135" ref-type="bibr">Lipinski et al., 2001</xref>) and identified three noncytotoxic compounds capable of inhibiting SARS-CoV pseudoparticle entry into 293T cells (<xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref>). <italic>N</italic>-(9,10-dioxo-9,10-dihydroanthracen-2-yl)benzamide (SSAA09E1) blocked early interactions of SARS-CoV S protein with ACE2 (EC<sub>50</sub> of 6.7 &#x003bc;M and CC<sub>50</sub> &#x0003e; 100 &#x003bc;M), whereas <italic>N</italic>-[[4-(4-methylpiperazin-1-yl)phenyl]methyl]-1,2-oxazole-5-carboxamide (SSAA09E2) affected cathepsin L activity (EC<sub>50</sub> of 3.1 &#x003bc;M and CC<sub>50</sub> &#x0003e; 100 &#x003bc;M). Conversely, [(Z)-1-thiophen-2-ylethylideneamino]thiourea (SSAA09E3) prevented the fusion of the viral envelope with host membrane cells by direct interaction with spike protein (EC<sub>50</sub> of 9.7 &#x003bc;M and CC<sub>50</sub> &#x0003e; 20 &#x003bc;M) (<xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref>). The compound SSAA09E3 presented the highest cytotoxic, probably due to the interactions with host proteins. The authors suggested that since these three compounds are derived from molecules with antiviral activities and presented good oral bioavailability and rapid systemic distribution in animal models, they might exhibit interesting pharmacokinetics (<xref rid="B2" ref-type="bibr">Adedeji et al., 2013</xref>).</p><p>Other compounds also demonstrated to inhibit CoV entry, for example, emodin (6-methyl-1,3,8-trihydroxyanthraquinone), a component from <italic>Rheum officinale</italic> roots, which at 50 &#x003bc;M inhibited the infectivity of S protein-pseudotype retrovirus from SARS-CoV in Vero cells by about 80% (<xref rid="B91" ref-type="bibr">Ho et al., 2007</xref>). Besides the entry activity, emodin was described to have an additional post-entry antiviral action. The authors suggested that emodin might be impairing virus release by affecting 3a viral protein, which is related to ion channels in infected Vero cells (<xref rid="B193" ref-type="bibr">Schwarz et al., 2011</xref>). This effect may play an important role in immune response.</p><p>The exploitation of other natural compounds such as proteins as potential anti-CoV drugs has also been performed. Griffithsin (GRFT) is a protein isolated from the red alga <italic>Griffithsia</italic> sp. that has shown powerful viral entry inhibition against several enveloped viruses, such as the human immunodeficiency virus (HIV). GRFT is capable of binding to terminal mannoses of oligosaccharides and also to glycans localized on the viral envelope glycoproteins (<xref rid="B139" ref-type="bibr">Lusvarghi and Bewley, 2016</xref>). GFRT did not present cytotoxicity in Vero cells, human ileocecal colorectal adenocarcinoma cells, human diploid fibroblast cells, and rhesus monkey kidney cells. Its broad-spectrum antiviral activity <italic>in vitro</italic> was demonstrated against several CoVs such as SARS-CoV (EC<sub>50</sub> of 0.61 &#x003bc;g mL<sup>&#x02212;1</sup>), bovine coronavirus (BCoV) (EC<sub>50</sub> of 0.057 &#x003bc;g mL<sup>&#x02013;1</sup>), MHV (EC<sub>50</sub> of 0.23 &#x003bc;g mL<sup>&#x02013;1</sup>), HCoV-OC43 (EC<sub>50</sub> of 0.16 &#x003bc;g mL<sup>&#x02013;1</sup>), HCoV-229E (EC<sub>50</sub> of 0.18 &#x003bc;g mL<sup>&#x02013;1</sup>), and HCoV-NL63 (EC<sub>50</sub> &#x0003c; 0.032 &#x003bc;g mL<sup>&#x02013;1</sup>) (<xref rid="B158" ref-type="bibr">O&#x02019;Keefe et al., 2010</xref>). In another study, GRFT inhibited the early stages of MERS-CoV infection in HEK-293T cells (<xref rid="B148" ref-type="bibr">Millet et al., 2016</xref>). Furthermore, GRFT improved survival in SARS-CoV-infected mice and protected the Balb/c female mice against infection by binding with S protein (<xref rid="B158" ref-type="bibr">O&#x02019;Keefe et al., 2010</xref>). Altogether, this evidence indicates that GRFT can be considered as a potential SARS-CoV-2 entry inhibitor with activity against S proteins.</p><p>Antiviral activity by entry inhibition was also evaluated by employing antibacterial chemotherapeutics. Vancomycin, eremomycin, and teicoplanin glycopeptide compounds used to treat infections caused by Gram-positive bacteria (<xref rid="B167" ref-type="bibr">Preobrazhenskaya and Olsufyeva, 2004</xref>), as well as hydrophobic derivatives of these drugs, were described to possess antiviral activity against HIV (<xref rid="B168" ref-type="bibr">Printsevskaya et al., 2005</xref>). A study showed that vancomycin, eremomycin, and teicoplanin were not toxic to Vero and T lymphoblast (CEM) cells. Nonetheless, these compounds were not able to inhibit feline CoV (FIPV) and SARS-CoV in assays employing such cell lines. Conversely, the eremomycin derivative molecules labeled 27 and 39 showed the best inhibition profiles against FIPV (EC<sub>50</sub> of 5.4 and 12 &#x003bc;M, respectively) and SARS-CoV (EC<sub>50</sub> of 14 and 22 &#x003bc;M, respectively) (<xref rid="B15" ref-type="bibr">Balzarini et al., 2006</xref>).</p><p>Cationic antimicrobial peptides (AMPs) are another type of peptides that have been considered as potential broad-spectrum antiviral agents. For instance, mucroporin is an AMP found in <italic>Lychas mucronatus</italic> scorpion venom (<xref rid="B52" ref-type="bibr">Dai et al., 2008</xref>). Mucroporin was then optimized synthetically, generating mucroporin-M1, which was able to inhibit measles virus (MeV), SARS-CoV, and influenza H5N1. Specifically, mucroporin M-1 affected SARS-CoV pseudovirus entry, with EC<sub>50</sub> of 14.46 &#x003bc;g mL<sup>&#x02013;1</sup> and CC<sub>50</sub> of 61.58 &#x003bc;g mL<sup>&#x02013;1</sup>, by virucidal activity in HeLa-ACE2 cells (<xref rid="B131" ref-type="bibr">Li et al., 2011</xref>). The activity of this synthetic peptide seems to be related to positive charges of the hydrophilic site, which can enhance the interaction with the viral surface, inactivating the viral particle.</p><p>Other potential antiviral peptides were selected by Struck and colleges. Through the exploitation of bioinformatics tools, the authors were able to predict sixteen peptides with effective binding onto the receptor-binding domain (RDB) present in S proteins of CoVs. These compounds were then synthesized, and the hexapeptide Tyr-Lys-Tyr-Arg-Tyr-Leu at 14 mM inhibited SARS-CoV and HCoV-NL63 infection in Vero cells without triggering cytotoxicity (<xref rid="B208" ref-type="bibr">Struck et al., 2012</xref>). This peptide was designed specifically to bind to the site of interaction with S protein and does not interfere with ACE2 receptor activity, so it might be a good candidate for blocking SARS-CoV-2 entry without impairing host metabolism. Taking into consideration that cellular factors such as the Tumor Necrosis Factor-alpha (TNF-&#x003b1;) converting enzyme (TACE) facilitate SARS-CoV entry (<xref rid="B85" ref-type="bibr">Haga et al., 2008</xref>), it is reasonable to suggest that TACE inhibitors could hinder SARS-CoV infection. In this context, TAPI-2, a compound able to inhibit TACE, has shown potent antiviral activity, promoting a 65% blockade of SARS-CoV entry in HEK-293T cells. However, the compound did not affect the virus titer in <italic>in vivo</italic> assays (<xref rid="B84" ref-type="bibr">Haga et al., 2010</xref>). The authors suggested that since SARS-CoV attaches to additional receptors such as DC-SIGN and L-SIGN (<xref rid="B104" ref-type="bibr">Jeffers et al., 2004</xref>; <xref rid="B86" ref-type="bibr">Han et al., 2007</xref>), viral entry might be not be impaired by this molecule.</p><p>In addition to amino acid-based inhibitors, monoclonal antibodies (mAbs) have attracted attention due to their use in infectious and chronic disease treatments (<xref rid="B80" ref-type="bibr">Green et al., 2000</xref>; <xref rid="B88" ref-type="bibr">Haynes et al., 2009</xref>; <xref rid="B164" ref-type="bibr">Pettitt et al., 2013</xref>; <xref rid="B53" ref-type="bibr">D&#x02019;Amato et al., 2014</xref>), overcoming drawbacks caused in polyclonal Abs therapy, such as those related to donor compatibility (<xref rid="B142" ref-type="bibr">Marasco and Sui, 2007</xref>). Human neutralizing Abs against human CoVs have been generated, targeting S glycoproteins to impair viral entry (<xref rid="B21" ref-type="bibr">Belouzard et al., 2012</xref>; <xref rid="B179" ref-type="bibr">Reguera et al., 2012</xref>). Notably, several mAbs were identified as inhibitors of MERS-CoV and SARS-CoV infections both <italic>in vitro</italic> and <italic>in vivo</italic>, protecting cells and animals when administered 24 h prior to or post-infection (<xref rid="B134" ref-type="bibr">Lip et al., 2006</xref>; <xref rid="B257" ref-type="bibr">Zhu et al., 2007</xref>; <xref rid="B3" ref-type="bibr">Agnihothram et al., 2014</xref>; <xref rid="B196" ref-type="bibr">Shanmugaraj et al., 2020</xref>). The mAbs are developed by merging B lymphocytes and myeloma cells, producing hybridomas capable of recognizing antigens and producing a single Ab class to bind specific epitopes (<xref rid="B136" ref-type="bibr">Lipman et al., 2005</xref>). For that reason, mAb cross-reactivity among different coronaviruses seems to be ineffective (<xref rid="B219" ref-type="bibr">Totura and Bavari, 2019</xref>). In the particular case of SARS-CoV-2, Wang and coworkers produced mAbs using 51 lineages of SARS-S hybridoma cells and identified 47D11 H2L2-neutralizing Ab through ELISA assays. This antibody was produced using mice cells; therefore, it was further modified to produce a fully human immunoglobulin IgG1, producing the human monoclonal antibody 47D11. The results showed that 47D11 bound to the RBD region and inhibited SARS-CoV-2 entry in Vero cells with an EC<sub>50</sub> of 0.57 &#x003bc;g mL<sup>&#x02212;1</sup> (<xref rid="B231" ref-type="bibr">Wang et al., 2020a</xref>). In this context, this mAb can be used alone or in association with other compounds to treat COVID-19.</p></sec><sec id="S2.SS2"><title>Inhibitors of Post-entry Stages of the CoV Replicative Cycle</title><p>Among the proteins that are pivotal for CoV viral replication are the main proteases (Mpro) such as the chymotrypsin-like protease (3CLpro) and the papain-like proteases (PPL). These enzymes process viral polyproteins and control replicase complex activity (<xref rid="B10" ref-type="bibr">Anand et al., 2003</xref>), figuring as very attractive targets for drug development against CoVs. Several natural products and synthetic peptides have been reported to inhibit Mpro (<xref rid="B45" ref-type="bibr">Cinatl et al., 2005</xref>; <xref rid="B229" ref-type="bibr">Vuong et al., 2020</xref>).</p><p>Gan and coworkers used molecular docking methods to select the octapeptide Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg as Mpro inhibitor of SARS-CoV and evaluated its antiviral activity in infected Vero cells. The octapeptide presented an EC<sub>50</sub> of 2.7 &#x000d7; 10<sup>&#x02013;2</sup> mg mL<sup>&#x02013;1</sup> and a CC<sub>50</sub> &#x0003e; 100 mg mL<sup>&#x02013;1</sup>, resulting in a selectivity index of over 3,704 (<xref rid="B69" ref-type="bibr">Gan et al., 2006</xref>). Moreover, five Phe-Phe dipeptide inhibitors (A-E) were designed and selected <italic>in silico</italic> to interact with 3CLpro and showed to be able to protect Vero cells from the cytopathic effect (CPE) caused by SARS-CoV. C analog (JMF1521) was obtained by the condensation of Phe-Phe dipeptide unsaturated ester with cinnamic acid and exhibited the highest activity, with an EC<sub>50</sub> of 0.18 &#x003bc;M and CC<sub>50</sub> &#x0003e; 200 &#x003bc;M (<xref rid="B202" ref-type="bibr">Shie et al., 2005</xref>). The authors also performed enzymatic assay to evaluate the activity of JMF1521 on 3CLpro and showed that the peptide inhibited the 3CLpro activity with an inhibition constant of 0.52 &#x003bc;M. The results suggested that this analog disposes a rather rigid coplanar structure in the N-terminal motif that results in more effective hydrogen bonds with the enzyme residues (<xref rid="B202" ref-type="bibr">Shie et al., 2005</xref>).</p><p>Another example of a dipeptide-based compound that can act as a protease inhibitor is dipeptidyl EP128533 (<xref rid="B256" ref-type="bibr">Zhang et al., 2006</xref>), which showed antiviral activity against SARS-CoV in Vero cells, with EC<sub>50</sub> and CC<sub>50</sub> values of 3.6 and &#x0003e;100 &#x003bc;M, respectively (<xref rid="B256" ref-type="bibr">Zhang et al., 2006</xref>). In accordance with that study, it was also demonstrated that EP128533 inhibited SARS-CoV with an EC<sub>50</sub> of 1.4 &#x003bc;g mL<sup>&#x02212;1</sup> and CC<sub>50</sub> &#x0003e; 100 &#x003bc;g mL<sup>&#x02212;1</sup> (<xref rid="B55" ref-type="bibr">Day et al., 2009</xref>). However, the compound was not efficient in reducing the effects of viral replication in BALB/c mice (<xref rid="B55" ref-type="bibr">Day et al., 2009</xref>). The authors proposed that EP128533 is relatively insoluble and that its lack of activity might be related to a low bioavailability in the animal models.</p><p>The dipeptides GC373 (dipeptidyl aldehyde) and GC376 (dipeptidyl bisulfite adduct salt from GC373) were also designed and synthesized as protease inhibitors of the 3CLpro enzyme (<xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>). Their activity was assessed <italic>in vitro</italic>, and the results showed that GC373 inhibited HCoV-229E (EC<sub>50</sub> of 0.2 &#x003bc;M), feline infectious peritonitis virus (FIPV, EC<sub>50</sub> of 0.3 &#x003bc;M), MHV (EC<sub>50</sub> of 2 &#x003bc;M), transmissible gastroenteritis virus (TGEV, EC<sub>50</sub> of 0.3 &#x003bc;M), and bovine coronavirus (BCV, EC<sub>50</sub> of 0.7 &#x003bc;M) (<xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>). GC376 also inhibited HCoV-229E (EC<sub>50</sub> of 0.15 &#x003bc;M), FIPV (EC<sub>50</sub> of 0.2 &#x003bc;M), MHV (EC<sub>50</sub> of 1.1 &#x003bc;M), TGEV (EC<sub>50</sub> of 0.15 &#x003bc;M), and BCV (EC<sub>50</sub> of 0.6 &#x003bc;M). The 3CLpro activity of these compounds against SARS-CoV was also analyzed. GC373 and GC376 inhibited enzymatic activity of SARS-CoV 3CLpro, with inhibition constants of 50% of 3.48 and 4.35 &#x003bc;M, respectively (<xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>). However, the activity of these compounds was not evaluated using infected cells or animal models. Additionally, the effects of GC373 and GC376 were assessed against feline coronavirus WSU (FCoV-WSU) (EC<sub>50</sub> values for GC373 and GC376 were 0.15 and 0.40 &#x003bc;M, respectively) (<xref rid="B116" ref-type="bibr">Kim et al., 2013</xref>). Moreover, the authors described that concomitant treatment with these compounds can improve the antiviral effect against feline coronaviruses and noted that, since the 3CLpro is conserved among CoVs, it might present broad-spectrum activity (<xref rid="B116" ref-type="bibr">Kim et al., 2013</xref>).</p><p>RNA-dependent RNA polymerase (RdRp) also figures as a promising target for antivirals. In viral replication, RdRp is responsible for catalyzing the replication of the viral RNA using a complementary RNA as a template. Therefore, compounds that interfere in this process are excellent drug candidates for treating viral infections (<xref rid="B70" ref-type="bibr">Ganeshpurkar et al., 2019</xref>). Nucleoside analogs of pyrimidine interfere in uridine triphosphate (UTP) metabolism, directly affecting viral replication (<xref rid="B154" ref-type="bibr">Murphy and Middleton, 2012</xref>), as demonstrated by &#x003b2;-<sc>D</sc>-N<sup>4</sup>-hydroxycytidine (NHC), which inhibited SARS-CoV (EC<sub>50</sub> of 10 &#x003bc;M and CC<sub>50</sub> &#x0003e; 100 &#x003bc;M) and HCoV-NL63 (EC<sub>50</sub> of 400 nM and CC<sub>50</sub> &#x0003e; 100 &#x003bc;M) (<xref rid="B17" ref-type="bibr">Barnard et al., 2004</xref>). NHC presented a potent antiviral activity against SARS-CoV-2 in infected Vero (IC<sub>50</sub> of 0.3 &#x003bc;M and CC<sub>50</sub> of &#x0003e; 10 &#x003bc;M) and Calu-3 cells (IC<sub>50</sub> of 0.08 &#x003bc;M and CC<sub>50</sub> &#x0003e; 100 &#x003bc;M) (<xref rid="B199" ref-type="bibr">Sheahan et al., 2020b</xref>). The authors assessed the broad-spectrum antiviral activity of NHC against MERS-CoV (IC<sub>50</sub> 0.024 &#x003bc;M) and SARS-CoV (IC<sub>50</sub> 0.14 &#x003bc;M) (<xref rid="B199" ref-type="bibr">Sheahan et al., 2020b</xref>) and also evaluated the NHC effect in SARS-CoV- and MERS-CoV-infected mice. NHC improved pulmonary function and decreased viral load in lung, and the authors proposed that NHC might be useful for emerging CoVs. Another pyrimidine analog with potential antiviral activity is 6-azauridine, which inhibited HCoV-NL63 replication in LLC-MK2 cells with an EC<sub>50</sub> of 32 nM and CC<sub>50</sub> of 80 &#x003bc;M (<xref rid="B174" ref-type="bibr">Pyrc et al., 2006</xref>).</p><p>Ribavirin is a synthetic nucleoside analog of guanosine used for the treatment of patients chronically infected by the hepatitis C virus (HCV) (<xref rid="B172" ref-type="bibr">PubChem, 2005c</xref>). The antiviral activities of ribavirin against several RNA viruses have been described, and it also presents broad-spectrum antiviral activities for CoVs (<xref rid="B31" ref-type="bibr">Chan et al., 2013</xref>; <xref rid="B200" ref-type="bibr">Shen et al., 2016</xref>). Its activities were described for SARS-CoV <italic>in vitro</italic> (EC<sub>50</sub> of 20 &#x003bc;g mL<sup>&#x02212;1</sup> and CC<sub>50</sub> &#x0003e; 200 &#x003bc;g mL<sup>&#x02212;1</sup>) (<xref rid="B187" ref-type="bibr">Saijo et al., 2005</xref>). Nevertheless, no viral load reduction was observed <italic>in vivo</italic> when employing BALB/c mice (<xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref>). The <italic>in vitro</italic> decrease of ribavirin efficacy was demonstrated to be associated with the excision of its nucleoside analogs by conserved coronavirus proofreading mechanisms (<xref rid="B68" ref-type="bibr">Ferron et al., 2017</xref>). Moreover, ribavirin showed good results for the treatment of critical MERS-CoV patients (<xref rid="B9" ref-type="bibr">Al-Tawfiq et al., 2014</xref>), and the combined treatment of ribavirin with type I Interferons (IFN-I) in primate models improved MERS disease symptoms (<xref rid="B65" ref-type="bibr">Falzarano et al., 2013b</xref>). Although ribavirin has been given as part of treatment regimens for SARS and MERS patients, meta-analyses of cases of study have found limited efficacy of its activities in treating patients with highly pathogenic coronavirus respiratory syndromes (<xref rid="B152" ref-type="bibr">Morra et al., 2018</xref>).</p><p>What is more, a nucleoside analog based on the acyclic sugar scaffold of acyclovir showed antiviral potential against coronaviruses (<xref rid="B213" ref-type="bibr">Tan et al., 2004</xref>). Peters and contributors demonstrated that this compound has powerful antiviral activity against MERS-CoV (EC<sub>50</sub> and CC<sub>50</sub> of 23 and 71 &#x003bc;M, respectively) and HCoV-NL63 (EC<sub>50</sub> and CC<sub>50</sub> of 8.8 and 120 &#x003bc;M, respectively) (<xref rid="B163" ref-type="bibr">Peters et al., 2015</xref>). However, the authors did not suggest mechanisms by which this analog impairs viral replication, leaving open to question whether it acts like its precursor acyclovir, impairing viral replication or by an alternative mechanism of action.</p><p>In terms of other drug options for the post-entry stages of the viral replicative cycle, it is possible to report the activities of Niclosamide, a drug used in antihelminthic treatment (<xref rid="B110" ref-type="bibr">Katz, 1977</xref>). Niclosamide presented antiviral activity on post-entry steps of SARS-CoV infection in Vero cells, with an EC<sub>50</sub> of 1&#x02013;3 &#x003bc;M and CC<sub>50</sub> of 250 &#x003bc;M (<xref rid="B245" ref-type="bibr">Wu et al., 2004</xref>). Similarly, this compound suppressed the cytopathic effect of SARS-CoV at a concentration &#x0003c;1 &#x003bc;M and inhibited viral replication with an EC<sub>50</sub> value of less than 0.1 &#x003bc;M in Vero E6 cells (<xref rid="B238" ref-type="bibr">Wen et al., 2007</xref>). Both authors suggested that Niclosamide impairs post-entry steps. However, this effect seems to not be related to an interaction with 3CLpro.</p><p>An additional potential compound is mycophenolic acid (MPA), an antibiotic derived from penicillium fungal species (<xref rid="B171" ref-type="bibr">PubChem, 2005b</xref>), which inhibited MERS-CoV replication in Vero cells with an EC<sub>50</sub> of 2.87 &#x003bc;M (<xref rid="B87" ref-type="bibr">Hart et al., 2014</xref>). However, MPA was not active against SARS-CoV in either <italic>in vitro</italic> or <italic>in vivo</italic> assay (<xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref>). The data suggested that MPA inhibits the enzyme IMP dehydrogenase, inducing apoptosis on alveolar macrophages and consequently inhibiting or suppressing cellular immune responses that are important for preventing or limiting viral infection (<xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref>).</p><p>Bananins, on the other hand, are a class of adamantane-based compounds conjugated with a pyridoxal moiety (vitamin B6) (<xref rid="B112" ref-type="bibr">Kesel, 2003</xref>). These molecules showed effective inhibition of SARS-CoV in FRhK-4 cells, with EC<sub>50</sub> &#x0003c; 10 &#x003bc;M and CC<sub>50</sub> of 390 &#x003bc;M. On the basis of both time addition and ATPase assays, the authors proposed that the action of bananin is mainly on the post-entry step of virus replication and may be related to an effect on the helicase function and/or on components of cellular pathways (<xref rid="B214" ref-type="bibr">Tanner et al., 2005</xref>).</p><p>Finally, the nonstructural protein 10 (nsp10) of CoVs was described as being responsible for a stimulatory effect on nsp16, a classical S-adenosylmethionine-dependent (nucleoside-2&#x02019;-<italic>O</italic>)-methyltransferase that acts in RNA binding or catalysis. The peptide TP29 was designed as a ligand to MHV nsp10 and presented broad-spectrum activity, inhibiting SARS-CoV (EC<sub>50</sub> of 200 &#x003bc;M) and MHV (EC<sub>50</sub> of 60 &#x003bc;M) replication in infected cell lines (<xref rid="B235" ref-type="bibr">Wang et al., 2015</xref>). The authors also assessed TP29 activity in MHV infected mice and demonstrated that treatment improved survival, decreased viral load in liver, and induced type 1 IFN. Based on these data, it was suggested that TP29 impaired nsp10/nsp16 2&#x02019;-<italic>O</italic>-MTase activity, dysregulating the genome replication process.</p></sec><sec id="S2.SS3"><title>Looking Toward Host Machinery: A Different Approach to CoV Treatment</title><p>Targeting the host process during viral infection figures as a promising alternative for drug development and can play an important role in abrogating viral replication (<xref rid="B191" ref-type="bibr">Sayce et al., 2010</xref>; <xref rid="B221" ref-type="bibr">Ullah et al., 2019</xref>). Nitazoxanide is a broad-spectrum antiviral agent exploited for the treatment of, for instance, influenza A and B viruses, as well as Ebola virus (EBOV) (<xref rid="B184" ref-type="bibr">Rossignol, 2014</xref>; <xref rid="B103" ref-type="bibr">Jasenosky et al., 2019</xref>), with its activity related to the interference in host-regulated pathways during viral replication (<xref rid="B185" ref-type="bibr">Rossignol, 2016</xref>). <italic>In vitro</italic> studies demonstrated that Nitazoxanide was able to inhibit MERS-CoV in LLC-MK2 cells, with an EC<sub>50</sub> of 0.92 &#x003bc;g mL<sup>&#x02013;1</sup>. The authors suggested that nitazoxanide affects pro-inflammatory cytokines and suppresses their overproduction (<xref rid="B185" ref-type="bibr">Rossignol, 2016</xref>).</p><p>Another host-target compound is Saracatinib (AZD0530), a tyrosine kinase (SFK) inhibitor. This compound suppressed the early stages of the MERS-CoV replicative cycle in Huh7 cells (EC<sub>50</sub> of 2.9 &#x003bc;M and CC<sub>50</sub> &#x0003e; 50 &#x003bc;M), possibly by affecting the SFK pathways (<xref rid="B203" ref-type="bibr">Shin et al., 2018</xref>). SFK possesses a central function in signaling pathways such as ERK/MAPK and PI3K/AKT (<xref rid="B216" ref-type="bibr">Thomas and Brugge, 1997</xref>), which are strictly related to CoV infection. Therefore, SFK inhibition might promote viral clearance and can be used in association with other drugs (<xref rid="B203" ref-type="bibr">Shin et al., 2018</xref>).</p><p>Moreover, Cyclosporin A (CsA), a peptide with activity on the cyclophilin family of host enzymes (isomerases that act as chaperones) (<xref rid="B170" ref-type="bibr">PubChem, 2005a</xref>; <xref rid="B54" ref-type="bibr">Davis et al., 2010</xref>), inhibited SARS-CoV (100% inhibition at 16 &#x003bc;M), HCoV-229E (75% inhibition at 16 &#x003bc;M), and MHV (100% inhibition at 16 &#x003bc;M) in human and animal infected cell culture. CsA presented broad-spectrum antiviral activity against CoVs, and it seems to interfere with genome replication/transcription during CoV infections (<xref rid="B59" ref-type="bibr">de Wilde et al., 2011</xref>, <xref rid="B58" ref-type="bibr">2013</xref>; <xref rid="B165" ref-type="bibr">Pfefferle et al., 2011</xref>). Alisporivir, a non-immunosuppressive cyclosporin A analog, inhibited the replication of SARS-CoV in Vero E6 infected cells at low-micromolar concentrations (EC<sub>50</sub> of 8.3 &#x003bc;M; CC<sub>50</sub> &#x0003e; 50 &#x003bc;M). This compound also showed broad-spectrum anti-CoV activity, inhibiting MERS-CoV EMC/2012 (EC<sub>50</sub> of 3.6 &#x003bc;M), MERS-CoV N3/Jordan (EC<sub>50</sub> of 3 &#x003bc;M), and SARS-CoV MA-15 (EC<sub>50</sub> of 1.3 &#x003bc;M) <italic>in vitro</italic> (<xref rid="B56" ref-type="bibr">de Wilde et al., 2017</xref>). However, the authors demonstrated that Alisporivir did not enhance survival in CoV-infected mice (<xref rid="B56" ref-type="bibr">de Wilde et al., 2017</xref>).</p><p>Other biomolecules that are promising as drug antivirals are interference RNAs (iRNAs). These macromolecules are small non-coding RNAs associated with controlling the expression of genetic information (<xref rid="B243" ref-type="bibr">Wilson and Doudna, 2013</xref>) and have been described as promising candidates for the treatment of hepatitis B virus (HBV), HCV, HIV, and human T-cell lymphotropic virus (HTLV) infections (<xref rid="B140" ref-type="bibr">Ma et al., 2007</xref>; <xref rid="B195" ref-type="bibr">Shah and Schaffer, 2011</xref>; <xref rid="B190" ref-type="bibr">Sanan-Mishra et al., 2017</xref>). Short interference RNAs (siRNAs) were described as being effective for <italic>in vitro</italic> antiviral treatment of FIPV, a type of FCoV (<xref rid="B145" ref-type="bibr">McDonagh et al., 2011</xref>, <xref rid="B146" ref-type="bibr">2015</xref>). Most recently, Li and colleagues designed and synthesized siRNAs that targeted the M and N genes of swine and porcine coronaviruses (SECoV and PDCoV, respectively). These siRNAs inhibited up to 99% of the expression of these proteins in both Vero and LLC-PK1 infected cells (<xref rid="B130" ref-type="bibr">Li et al., 2019</xref>). Additionally, synthetic siRNAs targeting the structural proteins E, M, and N of SARS-CoV have also been developed and showed reductions of the target gene expressions in Vero cells (<xref rid="B201" ref-type="bibr">Shi et al., 2005</xref>). Moreover, siRNAs targeting the structural proteins 7a, 7b, 3a, 3b, and S reduced SARS-CoV progeny in Vero cells by approximately 70% (<xref rid="B6" ref-type="bibr">&#x000c5;kerstr&#x000f6;m et al., 2007</xref>). The different authors propose that treatment with siRNAs can improve treatment-resistance among viruses and that these molecules can be designed to target multiple proteins, aiming at broad-spectrum activity.</p></sec><sec id="S2.SS4"><title>Ongoing Clinical Evaluations With Candidate Drugs Against SARS-CoV-2</title><p>The current situation of COVID-19 pandemic has accentuated the urgency of the demand for effective treatments. Based on previous data concerning activities against other viruses and empirical knowledge from treatments used in case reports, several drugs have entered clinical trial phases to access their therapeutic potential against SARS-CoV-2. In this section, we discuss the current knowledge on the most promising candidates for the treatment of COVID-19. Data for these drugs are summarized in <xref rid="T2" ref-type="table">Table 2</xref>.</p><p>The nucleoside analog Remdesivir (GS-5734) is a monophosphoramidate prodrug that has been described as having antiviral activity against the EBOV in non-human primates (<xref rid="B236" ref-type="bibr">Warren et al., 2016</xref>, 57). Its activity was assessed in human airway epithelial (HAE) cells infected with SARS-CoV (EC<sub>50</sub> of 0.069 &#x003bc;M and CC<sub>50</sub> &#x0003e; 10 &#x003bc;M) and MERS-CoV (EC<sub>50</sub> of 0.074 &#x003bc;M and CC<sub>50</sub> &#x0003e; 10 &#x003bc;M) and was demonstrated to inhibit RdRp of these viruses. Also, GS-5734 reduced infectious virus production of bat CoV by 1.5 to 2.0 log<sub>10</sub> in HAE cells and reduced virus titers and virus-induced lung pathologies in a SARS-CoV assay <italic>in vivo</italic> (<xref rid="B197" ref-type="bibr">Sheahan et al., 2017</xref>). This compound also reduced the severity of MERS-CoV disease, virus replication, and damage in the lungs of rhesus macaques (<xref rid="B60" ref-type="bibr">De Wit et al., 2020</xref>). The clinical efficacy of GS-5734 has been assessed by several clinical trials in different countries like France (NCT04365725), Canada (NCT04330690), and the United States (NCT04292899), which have been conducted based on the first reported treatment of COVID-19 with Remdesivir in Washington, United States (<xref rid="B94" ref-type="bibr">Holshue et al., 2020</xref>). In the first findings from Wang and coworkers, which were from a randomized, double-blind, multicenter, and placebo-controlled trial with 255 patients, Remdesivir did not present significant antiviral effects against SARS-CoV-2, nor did it improve clinical outcomes (<xref rid="B234" ref-type="bibr">Wang et al., 2020d</xref>). To date, there are several active clinical trials registered in the PubMed database involving this compound. However, most of them presented no conclusive outcomes.</p><p>Another two candidates are Lopinavir and Ritonavir, which are protease inhibitors used in association to treat HIV infections (<xref rid="B51" ref-type="bibr">Cvetkovic and Goa, 2003</xref>; <xref rid="B149" ref-type="bibr">Mills et al., 2009</xref>). Lopinavir demonstrated antiviral activities, protecting cells from MERS-CoV infection (EC<sub>50</sub> of 8 &#x003bc;M) and reducing viral loads in animal assays (<xref rid="B57" ref-type="bibr">de Wilde et al., 2014</xref>; <xref rid="B117" ref-type="bibr">Kim et al., 2015</xref>). Ritonavir also demonstrated anti-MERS-CoV activities with an EC<sub>50</sub> of 24.9 &#x003bc;M (<xref rid="B198" ref-type="bibr">Sheahan et al., 2020a</xref>). It is important to point out that these results do not agree with another work that was unable to demonstrate <italic>in vitro</italic> antiviral activity of Lopinavir against MERS-CoV (<xref rid="B31" ref-type="bibr">Chan et al., 2013</xref>). In clinical assays for MERS-CoV, the association of Lopinavir with Ritonavir reduced adverse clinical outcomes and viral load in infected patients (<xref rid="B198" ref-type="bibr">Sheahan et al., 2020a</xref>; <xref rid="B250" ref-type="bibr">Yao et al., 2020a</xref>). In particular, for SARS-CoV, Lopinavir and Ritonavir presented a low to medium antiviral activity <italic>in vitro</italic>, and <italic>in vivo</italic> assays have not been performed yet (<xref rid="B250" ref-type="bibr">Yao et al., 2020a</xref>). In addition, Lopinavir and Ritonavir played an important role in the clinical outcome of SARS-CoV-infected patients by reducing symptoms and the period of hospitalization, representing a possibility for the treatment of SARS-CoV-2 (<xref rid="B43" ref-type="bibr">Chu et al., 2004</xref>). Cao and collaborators conducted a randomized clinical trial with 199 patients with severe COVID-19 (<xref rid="B27" ref-type="bibr">Cao et al., 2020b</xref>). Treatment of the patients with the association Lopinavir/Ritonavir did not improve symptoms, nor impaired detectable viral RNA when compared to standard care (supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation). Additionally, the treatment generated relevant adverse effects in some of the patients (<xref rid="B27" ref-type="bibr">Cao et al., 2020b</xref>). The authors proposed that the low efficacy of Lopinavir with Ritonavir might be associated with the time of administration, since individuals that were treated at the onset of the disease had improved clinical results (<xref rid="B27" ref-type="bibr">Cao et al., 2020b</xref>). Later, it was shown that the association of lopinavir and ritonavir with interferon-&#x003b2;1 and ribavirin to treat mild to moderate COVID-19 patients alleviated symptoms and decreased the durations of viral infection and hospital stay (<xref rid="B100" ref-type="bibr">Hung et al., 2020</xref>). This might be related to their inducing cellular immune response, impairing virus replication.</p><p>The type 1 interferons (IFN-I) have also been employed in clinical trials. These proteins belong to the cytokine family and are associated with the immune response in viral infections, thus playing major roles in antiviral immunity due to their immunomodulatory properties (<xref rid="B189" ref-type="bibr">Samuel, 2001</xref>). Therefore, they are commonly employed in the treatment of several diseases such as Hepatitis C (<xref rid="B121" ref-type="bibr">Kobayashi et al., 1993</xref>). There are two subtypes of IFN-I, alpha (IFN-&#x003b1;) and beta (IFN-&#x003b2;) (<xref rid="B189" ref-type="bibr">Samuel, 2001</xref>). IFN-&#x003b2; is associated with more potent activity (<xref rid="B32" ref-type="bibr">Chan et al., 2015</xref>) and is therefore capitalized on in the treatment for multiple sclerosis patients (<xref rid="B13" ref-type="bibr">Axtell et al., 2010</xref>). Due to its more potent inhibition profile, it was associated with potent antiviral effects against SARS-CoV, MERS-CoV, MHV, and HCoV-229E <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="B206" ref-type="bibr">Sperber and Hayden, 1989</xref>; <xref rid="B226" ref-type="bibr">Vass&#x000e3;o et al., 2000</xref>; <xref rid="B89" ref-type="bibr">Hensley et al., 2004</xref>; <xref rid="B64" ref-type="bibr">Falzarano et al., 2013a</xref>; <xref rid="B32" ref-type="bibr">Chan et al., 2015</xref>). IFN-&#x003b2;, in particular, has a protective effect in endothelial cells, up-regulating CD73 and consequently stimulating the anti-inflammatory molecules and maintenance of endothelial barrier (<xref rid="B19" ref-type="bibr">Bellingan et al., 2014</xref>; <xref rid="B188" ref-type="bibr">Sallard et al., 2020</xref>). However, a clinical trial with 301 patients showed that this effect was not sufficient to decrease mortality in SARS patients (<xref rid="B178" ref-type="bibr">Ranieri et al., 2020</xref>). Therefore, in SARS-CoV-2, IFN-&#x003b2; has been associated with other drugs in clinical trials, improving outcomes in COVID-19 patients as in lopinavir or ribavirin (<xref rid="B100" ref-type="bibr">Hung et al., 2020</xref>).</p><p>COVID-19 patients with mild to severe symptoms can develop hyperinflammation and hypercytokinaemia, which can lead to multiple organ failure and death (<xref rid="B147" ref-type="bibr">Mehta et al., 2020</xref>). The employment of corticosteroids has shown to be an alternative for overcoming the cytokine storm and hyperinflammation due to its activities on immune cells (<xref rid="B242" ref-type="bibr">Wilkinson et al., 1991</xref>). Such a capitalization was previously reported in SARS-CoV patients during the 2002&#x02013;2003 epidemic (<xref rid="B40" ref-type="bibr">Chihrin and Loutfy, 2005</xref>). For SARS-CoV-2, corticosteroids can improve the clinical condition of patients, reducing hyperinflammation and the development of ARDS, with faster improvement of symptoms (<xref rid="B233" ref-type="bibr">Wang et al., 2020c</xref>; <xref rid="B253" ref-type="bibr">Zha et al., 2020</xref>). However, contrasting data concerning the efficacy of these drugs was described recently, showing that corticosteroids did not improve symptoms in COVID-19 patients (<xref rid="B253" ref-type="bibr">Zha et al., 2020</xref>). Moreover, dexamethasone emerged as a potential drug for treating COVID-19 patients, as shown by the results of a randomized, controlled, open-lab, and multicenter trial that assessed the effects of dexamethasone in 454 patients, described to date in pre-print findings (<xref rid="B95" ref-type="bibr">Horby et al., 2020</xref>). Data suggested that dexamethasone reduced death in one-third of patients in invasive mechanical ventilation and one-fifth of patients in non-invasive oxygen mechanical ventilation. However, it did not impair mortality in patients with no respiratory support (<xref rid="B95" ref-type="bibr">Horby et al., 2020</xref>). Other trials have been conducted, such as NCT043274011, but considering the preliminary results, the WHO suggested that treatment with dexamethasone may be applied during the third phase of COVID-19, when the hyperinflammation is determined, and respiratory support is needed.</p><p>Another antiviral drug assayed toward SARS-CoV-2 is Umifenovir, a licensed antiviral exploited for the prophylaxis and treatment of influenza viruses (Arbidol), which demonstrated good pharmacokinetics when absorbed by the organism (<xref rid="B169" ref-type="bibr">Proskurnina et al., 2020</xref>). This drug has an antiviral effect against SARS-CoV <italic>in vitro</italic> at 50 &#x003bc;g mL<sup>&#x02013;1</sup> (<xref rid="B113" ref-type="bibr">Khamitov et al., 2008</xref>). Lian and coworkers coordinated an observational study with 81 patients with moderate to severe SARS-CoV-2 infection (<xref rid="B133" ref-type="bibr">Lian et al., 2020</xref>) that demonstrated that Umifenovir neither shortened the hospitalization period nor improved prognosis in infected patients (<xref rid="B133" ref-type="bibr">Lian et al., 2020</xref>).</p><p>Broad-spectrum drugs used against parasitic infections such as Ivermectin (<xref rid="B24" ref-type="bibr">Campbell, 2012</xref>; <xref rid="B124" ref-type="bibr">Laing et al., 2017</xref>) have also been investigated due to their antiviral activity against Dengue virus (DENV), Influenza A viruses, Chikungunya virus (CHIKV), and HIV (<xref rid="B215" ref-type="bibr">Tay et al., 2013</xref>; <xref rid="B78" ref-type="bibr">G&#x000f6;tz et al., 2016</xref>; <xref rid="B225" ref-type="bibr">Varghese et al., 2016</xref>; <xref rid="B22" ref-type="bibr">Caly et al., 2020</xref>). The activity of Ivermectin is based on impairing several stages of viral replication, for instance, interfering with nonstructural proteins (<xref rid="B225" ref-type="bibr">Varghese et al., 2016</xref>). Caly and collaborators assessed the effect of Ivermectin on SARS-CoV-2 replication in Vero cells, showing that, at 5 &#x003bc;M, the compound presented no toxicity to cells and inhibited up to 99% of viral replication by a possible antiviral effect on viral release, which is consistent with previous data on its activity against other RNA viruses (<xref rid="B215" ref-type="bibr">Tay et al., 2013</xref>; <xref rid="B22" ref-type="bibr">Caly et al., 2020</xref>). Clinical trials have been conducted in different medical centers in Argentina (NCT04381884), Mexico (NCT04391127), Spain (NCT04390022), and the United States (NCT04374279) to assess the clinical implications of the use of Ivermectin for COVID-19. However, to the best of our knowledge, there are no published results on this topic. NCT04343092, a phase 1 clinical trial in Iraq, was conducted to its completion and evaluated the efficacy of Ivermectin in COVID-19 patients, so the results might be published soon.</p><p>According to Guan and colleagues, approximately 15.7% of Chinese patients with COVID-19 developed severe pneumonia and cytokine release syndrome (CRS), an important factor leading to rapid progression of the disease (<xref rid="B42" ref-type="bibr">Chousterman et al., 2017</xref>; <xref rid="B83" ref-type="bibr">Guan et al., 2020</xref>). In this context, one of the key cytokines involved in infection-induced cytokine storm is interleukin 6 (IL-6) (<xref rid="B192" ref-type="bibr">Scheller and Rose-John, 2006</xref>; <xref rid="B254" ref-type="bibr">Zhang et al., 2020a</xref>). Tocilizumab is an IL-6 receptor antagonist approved by the US FDA for the treatment of severe CRS (<xref rid="B81" ref-type="bibr">Grupp et al., 2013</xref>) and figures as an interesting drug to treat the cytokine storm caused by SARS-CoV-2 (<xref rid="B255" ref-type="bibr">Zhang et al., 2020b</xref>). The treatment of patients with severe COVID-19 with Tocilizumab presented no complications in the 21 assisted patients, with an average age of 56.8 &#x000b1; 16.5 and no history of illness deterioration or death. Thus, it immediately improved the clinical outcome and appeared to be an effective treatment for reducing mortality (<xref rid="B247" ref-type="bibr">Xu et al., 2020</xref>). Another study employing the treatment of COVID-19 patients with Tocilizumab for 14 days reinforced these observations. The treatment was observed to cause an effective decrease in inflammatory markers, radiological improvement, and a reduction in ventilatory support requirements for these patients (<xref rid="B7" ref-type="bibr">Alattar et al., 2020</xref>). Additionally, Toniati and collaborators administered Tocilizumab in 100 patients in Italy (average age of 62 years old) who had been diagnosed with COVID-19 pneumonia and ARDS and required ventilatory support. Overall, at 10 days of follow-up, the respiratory condition was improved or stabilized in 77% of the patients, and, based on these data, the response to this drug in patients with severe COVID-19 was rapid, sustained, and associated with significant clinical improvement (<xref rid="B218" ref-type="bibr">Toniati et al., 2020</xref>).</p><p>Chloroquine is a 9-aminoquinole that increases the pH in acidic vesicles (<xref rid="B144" ref-type="bibr">Mauthe et al., 2018</xref>) and possesses antiviral activities against HIV and other viruses (<xref rid="B102" ref-type="bibr">Jacobson et al., 2016</xref>; <xref rid="B8" ref-type="bibr">Al-Bari, 2017</xref>). Chloroquine was described as an entry inhibitor of SARS-CoV infection in Vero cells and prevented cell-to-cell spread of the virus (<xref rid="B228" ref-type="bibr">Vincent et al., 2005</xref>). Furthermore, it affected the entry and post-entry stages of the replicative cycle of FCoV in <italic>Felis catus</italic> cells and monocytes. Additionally, an <italic>in vivo</italic> study in cats demonstrated that treatment with chloroquine improved the clinical score of treated groups when compared to the untreated group (<xref rid="B211" ref-type="bibr">Takano et al., 2013</xref>). Chloroquine also had its anti-CoV activities tested in Vero cells (EC<sub>50</sub> of 5.47 &#x003bc;M) (<xref rid="B232" ref-type="bibr">Wang et al., 2020b</xref>; <xref rid="B251" ref-type="bibr">Yao et al., 2020b</xref>). Despite the performance of chloroquine <italic>in vitro</italic>, clinical studies conducted in China and France showed contradictory clinical data (<xref rid="B34" ref-type="bibr">Chen J. et al., 2020</xref>; <xref rid="B38" ref-type="bibr">Chen Z. et al., 2020</xref>; <xref rid="B71" ref-type="bibr">Gao et al., 2020</xref>; <xref rid="B151" ref-type="bibr">Molina et al., 2020</xref>). Gao and collaborators indicated that chloroquine phosphate was recommended to treat COVID-19-associated pneumonia only during urgent clinical demand because of its antiviral and anti-inflammatory activities (<xref rid="B71" ref-type="bibr">Gao et al., 2020</xref>). Hydroxychloroquine is an analog of chloroquine that was described as having antiviral activity, inhibiting SARS-CoV-2 <italic>in vitro</italic> with an EC<sub>50</sub> of 0.72 &#x003bc;M (<xref rid="B137" ref-type="bibr">Liu et al., 2020</xref>; <xref rid="B251" ref-type="bibr">Yao et al., 2020b</xref>). In clinical trials, an open-label non-randomized study by Gautret and colleagues affirmed that hydroxychloroquine reduced symptoms from SARS-CoV-2 patients and that association with azithromycin could reinforce its effects (<xref rid="B73" ref-type="bibr">Gautret et al., 2020</xref>). However, these results have been questioned. The study had a small sample size, and there were limitations in the methodologies (<xref rid="B106" ref-type="bibr">Juurlink, 2020</xref>).</p><p>Recent studies have been contradicting the safety of chloroquine and hydroxychloroquine use, as these drugs presented severe side effects that interfered with their clinical use, even during short-course therapies (<xref rid="B106" ref-type="bibr">Juurlink, 2020</xref>; <xref rid="B137" ref-type="bibr">Liu et al., 2020</xref>). Apart from the mild adverse effects, such as pruritus, nausea, and headache, these drugs can predispose patients to life-threatening arrhythmias, an effect that may be enhanced by concomitant use of azithromycin (<xref rid="B41" ref-type="bibr">Chorin et al., 2020</xref>). Both chloroquine and hydroxychloroquine interfere with ventricular repolarization, leading to prolongation of the cardiac QT interval and an increased risk of torsades de pointes (TdP), which is a risk especially for patients with cardiac disease, for children, or for those taking other drugs that delay repolarization (<xref rid="B155" ref-type="bibr">Mzayek et al., 2007</xref>; <xref rid="B173" ref-type="bibr">Pukrittayakamee et al., 2014</xref>; <xref rid="B106" ref-type="bibr">Juurlink, 2020</xref>; <xref rid="B223" ref-type="bibr">Ursing et al., 2020</xref>). Others possible types of damage are hypoglycemia, even in non-diabetic patients (<xref rid="B222" ref-type="bibr">Un&#x000fc;bol et al., 2011</xref>; <xref rid="B63" ref-type="bibr">El-Solia et al., 2018</xref>); neuropsychiatric effects, including agitation, insomnia, confusion, paranoia, depression, psychosis, and suicidal ideation (<xref rid="B150" ref-type="bibr">Mohan et al., 1981</xref>); hypersensitivity reactions, such as severe cutaneous adverse reactions (<xref rid="B23" ref-type="bibr">Cameron et al., 2014</xref>; <xref rid="B75" ref-type="bibr">Girijala et al., 2019</xref>); and drug&#x02013;drug interactions, which are improved by genetic variability (genetic polymorphisms of hepatic cytochrome P450 enzyme 2D6 (CYP2D6), responsible for chloroquine metabolization) (<xref rid="B119" ref-type="bibr">Kirchheiner et al., 2008</xref>; <xref rid="B126" ref-type="bibr">Lee et al., 2016</xref>). There is a lack of reliable information on target concentrations or doses for COVID-19, and so doses that proved effective and safe in malaria for both adults and children are considered for the treatment (<xref rid="B205" ref-type="bibr">Smith, 2020</xref>). Recently, the WHO stopped the hydroxychloroquine arm of the Solidarity trial to treat COVID-19 based on an absence of effectiveness in reducing the mortality of hospitalized COVID-19 patients (<xref rid="B241" ref-type="bibr">WHO, 2020c</xref>). Besides, the FDA also cautioned against the administration of hydroxychloroquine or chloroquine in COVID-19 patients, mainly due to the risk of heart rhythm issues (<xref rid="B66" ref-type="bibr">FDA, 2020</xref>). From these results, it is evident that the use of these drugs for COVID-19 requires further investigation.</p><p>An alternative treatment for COVID-19 is the utilization of convalescent plasma (CP) (<xref rid="B35" ref-type="bibr">Chen L. et al., 2020</xref>). This treatment refers to plasma therapy based on plasma or plasma derivatives, obtained from donors who were previously infected and have developed antibodies. This plasma/derivative is, in its turn, transfused into individuals with acute SARS-CoV-2 infection (<xref rid="B72" ref-type="bibr">Garraud, 2017</xref>; <xref rid="B25" ref-type="bibr">Cao and Shi, 2020</xref>). Even though the mechanism of action of convalescent plasma therapy is not fully understood, it presented great results in the treatment of patients with SARS during the SARS-CoV outbreak in Hong Kong in the early 2000s (<xref rid="B39" ref-type="bibr">Cheng et al., 2005</xref>). It is possible that the efficacy of CP therapy is due to the fact that the antibodies from convalescent plasma might suppress viremia (<xref rid="B35" ref-type="bibr">Chen L. et al., 2020</xref>). Duan and colleagues reported CP transfusion to rescue ten severe cases of SARS-CoV-2 adult patients. The study showed that one dose (200 mL) of CP significantly increased or maintained the neutralizing antibodies at a high level, leading to the disappearance of viremia in 7 days. Clinical symptoms rapidly improved within 3 days, and radiological examination showed varying degrees of absorption of lung lesions within 7 days. According to these results, CP can also provide a promising rescue option for severe COVID-19 (<xref rid="B62" ref-type="bibr">Duan et al., 2020</xref>). However, the author suggested key points to guarantee the effectiveness of CP therapy: Ab titers and the treatment time point. Firstly, taking into consideration previous knowledge from MERS-CoV CP therapy, Abs in plasma donor must have a titer equal or higher of 1:80 (<xref rid="B120" ref-type="bibr">Ko et al., 2018</xref>). This titer is only found in recently recovered patients, since antibody levels decrease 4 months after the disease. Secondly, patients receiving CP treatment prior to 14 days post-infection responded better than patients treated after 14 days (<xref rid="B62" ref-type="bibr">Duan et al., 2020</xref>).</p></sec></sec><sec id="S3"><title>Perspectives</title><p>This review aimed to summarize and discuss data from the literature regarding compounds that possess anti-CoVs activities and that could be further exploited for the treatment of human and animal CoVs. Furthermore, we described ongoing clinical trials for SARS-CoV-2 in order to elucidate the current findings and discussed the relevant features concerning candidate drugs against SARS-CoV-2.</p><p>As previously mentioned, most human-related CoVs emerged by zoonotic transmission from animals (<xref rid="B101" ref-type="bibr">Huynh et al., 2012</xref>; <xref rid="B49" ref-type="bibr">Coleman and Frieman, 2014</xref>; <xref rid="B180" ref-type="bibr">Reusken et al., 2016</xref>). Since <italic>Coronaviridae</italic> seem to have a very well conserved genome and structures among their viruses (<xref rid="B98" ref-type="bibr">Huentelman et al., 2004a</xref>; <xref rid="B82" ref-type="bibr">Guan et al., 2012</xref>; <xref rid="B249" ref-type="bibr">Yang and Leibowitz, 2015</xref>; <xref rid="B141" ref-type="bibr">Madhugiri et al., 2018</xref>), it is possible to hypothesize that compounds with antiviral activities against different human and/or animal CoVs (broad-spectrum activity) could be potential candidates for SARS-CoV-2 treatment. In a less optimistic scenario, the chemical structures of such compounds and their pharmacological outcomes have the potential to set some light on the drug design of possible anti-SARS-CoV-2 drugs.</p><p>Among the strategies for drug design, targeting host-immune factors or using iRNAs figure as promising alternatives for antiviral drug development. Also, the exploitation of <italic>in silico</italic> studies for drug screening to seek specific targets, as well as for a better comprehension of their interactions with viral biomolecules, has been shown as a promising tool for expediting drug development. By narrowing down the number of drug candidates, <italic>in silico</italic> studies have the potential to avoid the laborious and generally costly synthesis of many of these compounds (<xref rid="B128" ref-type="bibr">Lengauer and Sing, 2006</xref>; <xref rid="B227" ref-type="bibr">Villegas-Rosales et al., 2012</xref>). Nevertheless, several predicted compounds in the literature have only been screened by <italic>in silico</italic> and/or interaction assays (<xref rid="B36" ref-type="bibr">Chen et al., 2005</xref>; <xref rid="B107" ref-type="bibr">Kaeppler et al., 2005</xref>; <xref rid="B127" ref-type="bibr">Lee et al., 2005</xref>; <xref rid="B115" ref-type="bibr">Kim et al., 2012</xref>; <xref rid="B12" ref-type="bibr">Arya et al., 2020</xref>; <xref rid="B14" ref-type="bibr">Balasubramaniam and Reis, 2020</xref>), which ultimately hinders the proper assessment of the antiviral activities of the compounds. Therefore, it is imperative that these studies be associated with <italic>in vitro</italic> and <italic>in vivo</italic> assays in order to confirm the predicted activities in biological models and also to evaluate pharmacological outcomes (<xref rid="B156" ref-type="bibr">National Research Council (US) Committee on Applications of Toxicogenomic Technologies to Predictive Toxicology, 2007</xref>). Therefore, this review encompassed only compounds that have been evaluated by, at least, <italic>in vitro</italic> models (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p>In this context, from the molecules and drugs described as having <italic>in vitro</italic> activity, we highlighted the most promising to suggest further evaluation using <italic>in vivo</italic> systems of CoV infection, especially SARS-CoV-2 infection. The compounds are: NAAE, Glycyrrhizin, 2-acetamido-&#x003b1;-<sc>D</sc>-Glucopyranosylamine derivative, Tetrahydroquinoline oxocarbazate (CID 23631927), SSAA09E1, 2 and 3, Emodin, Eremomycin 27 and 29, Mucroporin-M1, Monoclonal antibody 47D11, AVLQSGFR, Phe-Phe dipeptide inhibitor C (JMF1521), GC373 and 376, 6-azauridine, Acyclic sugar scaffold of acyclovir, and Bananins. As described above, these compounds were capable of significantly impairing CoV infection in cell cultures and might enable important progress into the treatment of described CoVs as well as viruses that might be responsible for future viral outbreaks.</p><p>Here, we also described compounds that were evaluated <italic>in vivo</italic> to elucidate their role in the pathogenesis of CoVs as well as to assess possible adverse effects. It is important to emphasize that there is a lack of <italic>in vivo</italic> model assays, representing a delay in anti-CoV drug development, which directly impacts the SARS-CoV-2 pandemic. Here, we identified some studies that employed animal models, such as in Balb/c mice and C57BL/6, to evaluate the antiviral effect of compounds in CoV infection (<xref rid="B46" ref-type="bibr">Cinatl et al., 2003</xref>; <xref rid="B187" ref-type="bibr">Saijo et al., 2005</xref>; <xref rid="B16" ref-type="bibr">Barnard et al., 2006</xref>; <xref rid="B256" ref-type="bibr">Zhang et al., 2006</xref>; <xref rid="B55" ref-type="bibr">Day et al., 2009</xref>; <xref rid="B87" ref-type="bibr">Hart et al., 2014</xref>). The <italic>in vivo</italic> assays allow the gathering of knowledge regarding the ADMeTox profile of these compounds in complex biological systems, the viral titers in different organs, host immune responses to the infection, and also potential tissue damage caused by the viruses in the presence or absence of candidate drugs, which represents an advance in understanding pathologies caused by viral infections (<xref rid="B1" ref-type="bibr">Adachi and Miura, 2014</xref>). It is also important to emphasize that protocols used in studies of animal-related viruses are not easily translated onto human CoVs, since these viruses are classified to different biological safety levels, representing a risk of infection to scientists (<xref rid="B18" ref-type="bibr">Bayot and King, 2020</xref>; <xref rid="B29" ref-type="bibr">CDC, 2020b</xref>). Additionally, the pathologies induced by animal CoVs are mostly related to gastrointestinal symptoms, differently to what is observed for human-related CoVs, which mostly affect the upper respiratory system (<xref rid="B162" ref-type="bibr">Pedersen et al., 1984</xref>; <xref rid="B49" ref-type="bibr">Coleman and Frieman, 2014</xref>). The development of refined and secure protocols to study SARS-CoV-2 infection and its treatment options is required. Bearing in mind the obstacles cited above, assessment of the effect in animal models and further translation to humans remains one of the main challenges.</p><p>However, some of the studies were able to assess the antiviral effects of some compounds <italic>in vivo</italic>. The most relevant compounds we propose that may represent immediate candidates to clinical trials, considering the urgency of COVID-19, are Griffithsin (GRFT), &#x003b2;-<sc>D</sc>-N<sup>4</sup>-hydroxycytidine (NHC), TP29, Cyclosporin A (CsA), Alisporivir, iRNAs, Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and Ribavirin. These compounds abrogated CoV infection <italic>in vitro</italic> and <italic>in vivo</italic> and improved the symptoms and survival of animals. In addition, Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and Ribavirin are molecules licensed to treat diseases such as those from viral and helminthic infections or Alzheimer&#x02019;s disease, representing possibilities for clinical trials as repurposed drugs.</p><p>Regarding clinical trials, most drugs discussed in this review presented adverse effects such as nausea, headache, diarrhea, urticaria, pathologies related to the gastrointestinal system, and interference with liver enzymes (<xref rid="B186" ref-type="bibr">Ruiz-Irastorza et al., 2010</xref>; <xref rid="B211" ref-type="bibr">Takano et al., 2013</xref>; <xref rid="B183" ref-type="bibr">Roques et al., 2018</xref>; <xref rid="B250" ref-type="bibr">Yao et al., 2020a</xref>). Remdesivir, Lopinavir and Ritonavir, and Umifenovir are drugs employed for the treatment of other viral infections such as EBOV and SARS-CoV, but, in the clinical trials with COVID-19 patients, these treatments did not reduce symptoms and/or decrease viral load. Tocilizumab, Chloroquine, and Hydroxychloroquine have been demonstrated to inhibit SARS-CoV-2 <italic>in vitro</italic> and, in some clinical trials, reduced COVID-19 symptoms, the period of hospitalization, and the viral load in patients despite the strong adverse effects of Chloroquine (<xref rid="T2" ref-type="table">Table 2</xref>). Even so, recent studies are contradicting the safety profiles of Chloroquine and Hydroxychloroquine, since they might cause arrhythmia in patients, representing risk for a considerable number of patients (<xref rid="B106" ref-type="bibr">Juurlink, 2020</xref>).</p><p>Ongoing studies have been evaluating IFN-&#x003b2; and Ivermectin as treatments against COVID-19. IFN- &#x003b2; can be associated with other drugs, collaborating to control immune response against the viral infection (<xref rid="T2" ref-type="table">Table 2</xref>). On the other hand, corticosteroids, such as dexamethasone, sound promising, but there are some issues related to their use. These compounds induce immunosuppression and, when administered during initial phases (viral replication), might dysregulate T-cell production and activation of B cells for antibody secretion, which are essential for viral clearance (<xref rid="B48" ref-type="bibr">Cohn, 1991</xref>; <xref rid="B74" ref-type="bibr">Giles et al., 2018</xref>). Furthermore, convalescent plasma therapy is an alternative approach that presented positive effects in studies on SARS-CoV-2/COVID-19 patients. However, its safety is not well defined due to donor-dependent variability and compatibility (antibody titers and other factors vary among donors), which might cause severe adverse effects in lung and cardiovascular system and, in some cases, may even transmit diseases (<xref rid="B181" ref-type="bibr">Roback and Guarner, 2020</xref>).</p><p>Despite the finding regarding these drugs, it is important to take some aspects into consideration: i) the trials were generally conducted with a significant number of patients in each study, but potentially not enough to expand the results to public healthcare; ii) some of the studies were observational, which means they were based on public data that may not be well documented, leaving information gaps about particular health issues; additionally, the outcomes in patients are defined by their own circumstances, and not by an investigator; iii) some studies were not placebo-controlled and double-blind, so the placebo effect cannot be discarded (<xref rid="B111" ref-type="bibr">Kernan et al., 1999</xref>; <xref rid="B90" ref-type="bibr">Hess and Abd-Elsayed, 2019</xref>); iv) the trials were conducted by selecting a group of COVID-19 patients, considering mild, moderate or severe cases, and different outcomes can be expected in each situation since viral load, the progression of the disease, and immune response are additional factors (<xref rid="B111" ref-type="bibr">Kernan et al., 1999</xref>; <xref rid="B90" ref-type="bibr">Hess and Abd-Elsayed, 2019</xref>). Therefore, drugs with no effect in severe cases cannot be rejected as a possible treatment in mild to severe cases. When these aspects are not considered, the investigators might be open to commiting type I or II error in trials (<xref rid="B111" ref-type="bibr">Kernan et al., 1999</xref>; <xref rid="B90" ref-type="bibr">Hess and Abd-Elsayed, 2019</xref>). For that matter, it is also important to consider that SARS-CoV-2 is a new virus and that we currently have limited knowledge about its physiopathology. Finally, the development of new treatment options is critical, and efforts have been focused on targeting therapies that aim to improve patient outcome by increasing antiviral activity associated with minimal toxicity.</p><p>Another point to be considered in CoV treatment is that RNA viruses are known to have high levels of mutations (error rate) in the replication process (<xref rid="B70" ref-type="bibr">Ganeshpurkar et al., 2019</xref>). This can result in resistance to antiviral treatment, as observed for HIV, HCV, and Influenza viruses (<xref rid="B125" ref-type="bibr">Laplante and St George, 2014</xref>; <xref rid="B129" ref-type="bibr">Li and Chung, 2019</xref>; <xref rid="B159" ref-type="bibr">Olearo et al., 2019</xref>; <xref rid="B212" ref-type="bibr">Takashita, 2020</xref>). A recent study in pre-print pointed to the genomic variability of SARS-CoV-2 and the intra-patient capacity of polymorphic quasispecies, which may offer resistance to antiviral drugs (<xref rid="B109" ref-type="bibr">Karamitros et al., 2020</xref>). In addition, previous studies demonstrated that the use of Chloroquine analogs for decades against malaria has established chloroquine-resistant Plasmodium strains (<xref rid="B207" ref-type="bibr">Stocks et al., 2002</xref>; <xref rid="B8" ref-type="bibr">Al-Bari, 2017</xref>; <xref rid="B4" ref-type="bibr">Aguiar et al., 2018</xref>). Due to the beneficial immunomodulatory effects of analogs on the severe inflammatory complications of several viral diseases, such as HIV and SARS-CoV infections, these drugs have been tested indiscriminately (<xref rid="B102" ref-type="bibr">Jacobson et al., 2016</xref>; <xref rid="B8" ref-type="bibr">Al-Bari, 2017</xref>). However, there is a possibility that prophylactic exposure to pro-apoptotic chloroquine drugs caused natural selection for strains of viruses and other parasites that have enhanced anti-apoptotic abilities (<xref rid="B160" ref-type="bibr">Parris, 2004</xref>). Despite the side effects, the wide use of some drugs during the SARS-CoV-2 pandemic might raise concerns regarding the emergence of resistant viral strains in the future, and we emphasize the lack of information on the resistance associated with these drugs in the treatment of viral infections.</p></sec><sec id="S4"><title>Conclusion</title><p>The spread of SARS-CoV-2 worldwide is classified as a pandemic and represents a threat to global public health. By July 4, 2020, SARS-CoV-2 had infected 10,922,324 people and had caused 523,011 deaths around the world (<xref rid="B240" ref-type="bibr">WHO, 2020b</xref>). In this context, compounds described to possess antiviral activity against human and/or animal coronaviruses could provide relevant information for the development of novel SARS-CoV-2 treatments. Herein, we presented and discussed the most promising compounds that can figure as possible candidates for clinical trials. Moreover, ongoing clinical trials evaluating possible COVID-19 therapies were also highlighted.</p><p>From what was presented in this review, a plethora of different potential compounds can be capitalized as possible drugs or even set points for further drug development seeking to mitigate the SARS-CoV-2/COVID-19 outbreak. However, time, resources, and new experimental protocols are essential for advancing an efficacious treatment. In addition, and despite the urgency of treatment protocols, it is important to point out the striking need for the establishment of fail-proof regulatory initiatives that could prevent impacts on the healthcare of patients that could, otherwise, be avoided by a more stringent control.</p><p>In this context, this review describes drugs that might be overlooked for future analysis and could possibly become effective antiviral treatments. As a final remark, we conclude that, to date, there is no &#x0201c;one hundred percent&#x0201d; effective antiviral therapy against SARS-CoV-2/COVID-19 and that further research is needed to achieve the best therapeutic protocol, which may not be based on a unique drug but rather on a combination of active antivirals.</p></sec><sec id="S5"><title>Author Contributions</title><p>IS: drafting the manuscript and literature review. VG: drafting the manuscript and illustration. FB, RS-S, and AJ: critical revision, editing, and approval of the final version. All of the authors read and approved the final manuscript.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> The authors received financial support from the FAPEMIG (Minas Gerais Research Foundation APQ-00587-14 &#x02013; SICONV 793988/2013; APQ-02872-16 and APQ-03385-18) and from CAPES (Coordination for the Improvement of Higher Education &#x02013; #1678329P). AJ received a productivity fellowship from the CNPq (National Counsel of Technological and Scientific Development &#x02013; 311219/2019-5). The Brazilian funding agencies CNPq, CAPES, and FAPEMIG provide financial support to the National Institute of Science and Technology in Theranostics and Nanobiotechnology &#x02013; INCT-Teranano (CNPq-465669/2014-0). RS-S received a fellowship from FAU/UFU and PrInt CAPES/UFU. AJ, RS-S, and FB are grateful to CAPES &#x02013; Prevention and Combat of Outbreaks, Endemics, Epidemics and Pandemics - Finance Code #88881.506794/2020-01.</p></fn></fn-group><ack><p>We thank the OSF Preprints database (<ext-link ext-link-type="uri" xlink:href="https://osf.io/preprints/">https://osf.io/preprints/</ext-link>) for publishing the pre-print version of this manuscript on May 01, 2020 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.31219/osf.io/ycjgq">https://doi.org/10.31219/osf.io/ycjgq</ext-link>).</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>A.</given-names></name><name><surname>Miura</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Animal model studies on viral infections.</article-title>
<source><italic>Front. Microbiol.</italic></source>
<volume>5</volume>:<issue>672</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2014.00672</pub-id>
<?supplied-pmid 25520715?><pub-id pub-id-type="pmid">25520715</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adedeji</surname><given-names>A. O.</given-names></name><name><surname>Severson</surname><given-names>W.</given-names></name><name><surname>Jonsson</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Weiss</surname><given-names>S. R.</given-names></name><name><surname>Sarafianos</surname><given-names>S. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>87</volume>
<fpage>8017</fpage>&#x02013;<lpage>8028</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00998-13</pub-id>
<?supplied-pmid 23678171?><pub-id pub-id-type="pmid">23678171</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agnihothram</surname><given-names>S.</given-names></name><name><surname>Gopal</surname><given-names>R.</given-names></name><name><surname>Yount</surname><given-names>B. L.</given-names></name><name><surname>Donaldson</surname><given-names>E. F.</given-names></name><name><surname>Menachery</surname><given-names>V. D.</given-names></name><name><surname>Graham</surname><given-names>R. L.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>209</volume>
<fpage>995</fpage>&#x02013;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit609</pub-id>
<?supplied-pmid 24253287?><pub-id pub-id-type="pmid">24253287</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>A. C. C.</given-names></name><name><surname>Murce</surname><given-names>E.</given-names></name><name><surname>Cortopassi</surname><given-names>W. A.</given-names></name><name><surname>Pimentel</surname><given-names>A. S.</given-names></name><name><surname>Almeida</surname><given-names>M. M. F. S.</given-names></name><name><surname>Barros</surname><given-names>D. C. S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity.</article-title>
<source><italic>Int. J. Parasitol. Drugs Drug Resist.</italic></source>
<volume>8</volume>
<fpage>459</fpage>&#x02013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpddr.2018.10.002</pub-id>
<?supplied-pmid 30396013?><pub-id pub-id-type="pmid">30396013</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S. F.</given-names></name><name><surname>Quadeer</surname><given-names>A. A.</given-names></name><name><surname>McKay</surname><given-names>M. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies.</article-title>
<source><italic>Viruses</italic></source>
<volume>12</volume>:<issue>254</issue>. <pub-id pub-id-type="doi">10.3390/v12030254</pub-id>
<?supplied-pmid 32106567?><pub-id pub-id-type="pmid">32106567</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c5;kerstr&#x000f6;m</surname><given-names>S.</given-names></name><name><surname>Mirazimi</surname><given-names>A.</given-names></name><name><surname>Tan</surname><given-names>Y.-J.</given-names></name></person-group> (<year>2007</year>). <article-title>Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>73</volume>
<fpage>219</fpage>&#x02013;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2006.10.008</pub-id>
<?supplied-pmid 17112601?><pub-id pub-id-type="pmid">17112601</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alattar</surname><given-names>R.</given-names></name><name><surname>Ibrahim</surname><given-names>T. B. H.</given-names></name><name><surname>Shaar</surname><given-names>S. H.</given-names></name><name><surname>Abdalla</surname><given-names>S.</given-names></name><name><surname>Shukri</surname><given-names>K.</given-names></name><name><surname>Daghfal</surname><given-names>J. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tocilizumab for the treatment of severe coronavirus disease 2019.</article-title>
<source><italic>J. Med. Virol.</italic></source> Online ahead of print. <pub-id pub-id-type="doi">10.1002/jmv.25964</pub-id>
<?supplied-pmid 32369191?><pub-id pub-id-type="pmid">32369191</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Bari</surname><given-names>M. A. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.</article-title>
<source><italic>Pharmacol. Res. Perspect.</italic></source>
<volume>5</volume>
<fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1002/prp2.293</pub-id>
<?supplied-pmid 28596841?><pub-id pub-id-type="pmid">28596841</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>J. A.</given-names></name><name><surname>Momattin</surname><given-names>H.</given-names></name><name><surname>Dib</surname><given-names>J.</given-names></name><name><surname>Memish</surname><given-names>Z. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.</article-title>
<source><italic>Int. J. Infect. Dis.</italic></source>
<volume>20</volume>
<fpage>42</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.12.003</pub-id>
<?supplied-pmid 24406736?><pub-id pub-id-type="pmid">24406736</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>K.</given-names></name><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Wadhwani</surname><given-names>P.</given-names></name><name><surname>Mesters</surname><given-names>J. R.</given-names></name><name><surname>Hilgenfeld</surname><given-names>R.</given-names></name></person-group> (<year>2003</year>). <article-title>Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.</article-title>
<source><italic>Science</italic></source>
<volume>300</volume>
<fpage>1763</fpage>&#x02013;<lpage>1767</lpage>. <pub-id pub-id-type="doi">10.1126/science.1085658</pub-id>
<?supplied-pmid 12746549?><pub-id pub-id-type="pmid">12746549</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>K. G.</given-names></name><name><surname>Rambaut</surname><given-names>A.</given-names></name><name><surname>Lipkin</surname><given-names>W. I.</given-names></name><name><surname>Holmes</surname><given-names>E. C.</given-names></name><name><surname>Garry</surname><given-names>R. F.</given-names></name></person-group> (<year>2020</year>). <article-title>The proximal origin of SARS-CoV-2.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>26</volume>
<fpage>450</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id>
<?supplied-pmid 32284615?><pub-id pub-id-type="pmid">32284615</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>R.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Prashar</surname><given-names>V.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs.</article-title>
<source><italic>ChemRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.26434/chemrxiv.11860011.v2.</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axtell</surname><given-names>R. C.</given-names></name><name><surname>de Jong</surname><given-names>B. A.</given-names></name><name><surname>Boniface</surname><given-names>K.</given-names></name><name><surname>van der Voort</surname><given-names>L. F.</given-names></name><name><surname>Bhat</surname><given-names>R.</given-names></name><name><surname>De Sarno</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>T helper type 1 and 17 cells determine efficacy of interferon-&#x003b2; in multiple sclerosis and experimental encephalomyelitis.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>16</volume>
<fpage>406</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2110</pub-id>
<?supplied-pmid 20348925?><pub-id pub-id-type="pmid">20348925</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramaniam</surname><given-names>M.</given-names></name><name><surname>Reis</surname><given-names>R. J. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins.</article-title>
<source><italic>ChemRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.26434/chemrxiv.12084822</pub-id>
<?supplied-pmid 32511290?><pub-id pub-id-type="pmid">32511290</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Egberink</surname><given-names>H.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Van Ranst</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>72</volume>
<fpage>20</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2006.03.005</pub-id>
<?supplied-pmid 16675038?><pub-id pub-id-type="pmid">16675038</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnard</surname><given-names>D. L.</given-names></name><name><surname>Day</surname><given-names>C. W.</given-names></name><name><surname>Bailey</surname><given-names>K.</given-names></name><name><surname>Heiner</surname><given-names>M.</given-names></name><name><surname>Montgomery</surname><given-names>R.</given-names></name><name><surname>Lauridsen</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>71</volume>
<fpage>53</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2006.03.001</pub-id>
<?supplied-pmid 16621037?><pub-id pub-id-type="pmid">16621037</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnard</surname><given-names>D. L.</given-names></name><name><surname>Hubbard</surname><given-names>V. D.</given-names></name><name><surname>Burton</surname><given-names>J.</given-names></name><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Morrey</surname><given-names>J. D.</given-names></name><name><surname>Otto</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine.</article-title>
<source><italic>Antivir. Chem. Chemother.</italic></source>
<volume>15</volume>
<fpage>15</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1177/095632020401500102</pub-id>
<?supplied-pmid 15074711?><pub-id pub-id-type="pmid">15074711</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bayot</surname><given-names>M. L.</given-names></name><name><surname>King</surname><given-names>K. C.</given-names></name></person-group> (<year>2020</year>). <source><italic>Biohazard Levels</italic></source>
<publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>.</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellingan</surname><given-names>G.</given-names></name><name><surname>Maksimow</surname><given-names>M.</given-names></name><name><surname>Howell</surname><given-names>D. C.</given-names></name><name><surname>Stotz</surname><given-names>M.</given-names></name><name><surname>Beale</surname><given-names>R.</given-names></name><name><surname>Beatty</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.</article-title>
<source><italic>Lancet Respir. Med.</italic></source>
<volume>2</volume>
<fpage>98</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(13)70259-5</pub-id><pub-id pub-id-type="pmid">24503265</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Chu</surname><given-names>V. C.</given-names></name><name><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>106</volume>
<fpage>5871</fpage>&#x02013;<lpage>5876</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0809524106</pub-id>
<?supplied-pmid 19321428?><pub-id pub-id-type="pmid">19321428</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Millet</surname><given-names>J. K.</given-names></name><name><surname>Licitra</surname><given-names>B. N.</given-names></name><name><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein.</article-title>
<source><italic>Viruses</italic></source>
<volume>4</volume>
<fpage>1011</fpage>&#x02013;<lpage>1033</lpage>. <pub-id pub-id-type="doi">10.3390/v4061011</pub-id>
<?supplied-pmid 22816037?><pub-id pub-id-type="pmid">22816037</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L.</given-names></name><name><surname>Druce</surname><given-names>J. D.</given-names></name><name><surname>Catton</surname><given-names>M. G.</given-names></name><name><surname>Jans</surname><given-names>D. A.</given-names></name><name><surname>Wagstaff</surname><given-names>K. M.</given-names></name></person-group> (<year>2020</year>). <article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>178</volume>:<issue>104787</issue>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id>
<?supplied-pmid 32251768?><pub-id pub-id-type="pmid">32251768</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>M. C.</given-names></name><name><surname>Word</surname><given-names>A. P.</given-names></name><name><surname>Dominguez</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus.</article-title>
<source><italic>Dermatol. Online J.</italic></source>
<volume>20</volume>:<issue>13030/qt1q90q0h5</issue>.</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>W. C.</given-names></name></person-group> (<year>2012</year>). <source><italic>Ivermectin and Abamectin.</italic></source>
<publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer Science &#x00026; Business Media</publisher-name>.</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>H.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Convalescent plasma: possible therapy for novel coronavirus disease 2019.</article-title>
<source><italic>Transfusion</italic></source>
<volume>60</volume>
<fpage>1078</fpage>&#x02013;<lpage>1083</lpage>. <pub-id pub-id-type="doi">10.1111/trf.15797</pub-id>
<?supplied-pmid 32359090?><pub-id pub-id-type="pmid">32359090</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Wan</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.</article-title>
<source><italic>Cell Discov.</italic></source>
<volume>6</volume>:<issue>11</issue>. <pub-id pub-id-type="doi">10.1038/s41421-020-0147-1</pub-id>
<?supplied-pmid 32133153?><pub-id pub-id-type="pmid">32133153</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>A trial of lopinavir&#x02013;ritonavir in adults hospitalized with severe covid-19.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>382</volume>
<fpage>1787</fpage>&#x02013;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id>
<?supplied-pmid 32187464?><pub-id pub-id-type="pmid">32187464</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><collab>CDC</collab> (<year>2020a</year>). <source><italic>Coronavirus | Human Coronavirus Types | CDC.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/types.html">https://www.cdc.gov/coronavirus/types.html</ext-link>
<comment>(accessed March 31, 2020)</comment></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><collab>CDC</collab> (<year>2020b</year>). <source><italic>Information for Laboratories about Coronavirus (COVID-19).</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html">https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html</ext-link>
<comment>(accessed June 12, 2020)</comment></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceccarelli</surname><given-names>M.</given-names></name><name><surname>Berretta</surname><given-names>M.</given-names></name><name><surname>Rullo</surname><given-names>E. V.</given-names></name><name><surname>Nunnari</surname><given-names>G.</given-names></name><name><surname>Cacopardo</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Differences and similarities between severe acute respiratory syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?</article-title>
<source><italic>Eur. Rev. Med. Pharmacol. Sci.</italic></source>
<volume>24</volume>
<fpage>2781</fpage>&#x02013;<lpage>2783</lpage>.<pub-id pub-id-type="pmid">32196628</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. F. W.</given-names></name><name><surname>Chan</surname><given-names>K.-H.</given-names></name><name><surname>Kao</surname><given-names>R. Y. T.</given-names></name><name><surname>To</surname><given-names>K. K. W.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name><name><surname>Li</surname><given-names>C. P. Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Broad-spectrum antivirals for the emerging middle east respiratory syndrome coronavirus.</article-title>
<source><italic>J. Infect.</italic></source>
<volume>67</volume>
<fpage>606</fpage>&#x02013;<lpage>616</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2013.09.029</pub-id>
<?supplied-pmid 24096239?><pub-id pub-id-type="pmid">24096239</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. F.-W.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Yeung</surname><given-names>M.-L.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Jia</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Treatment with lopinavir/ritonavir or interferon-&#x003b2;1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>212</volume>
<fpage>1904</fpage>&#x02013;<lpage>1913</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv392</pub-id>
<?supplied-pmid 26198719?><pub-id pub-id-type="pmid">26198719</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis.</article-title>
<source><italic>J. Med. Virol.</italic></source>
<volume>92</volume>
<fpage>418</fpage>&#x02013;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id>
<?supplied-pmid 31967327?><pub-id pub-id-type="pmid">31967327</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].</article-title>
<source><italic>Zhejiang Xue Xue Bao Yi Xue Ban J. Zhejiang Univ. Med. Sci.</italic></source>
<volume>49</volume>
<fpage>215</fpage>&#x02013;<lpage>219</lpage>.</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Convalescent plasma as a potential therapy for COVID-19.</article-title>
<source><italic>Lancet Infect. Dis.</italic></source>
<volume>20</volume>
<fpage>398</fpage>&#x02013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30141-9</pub-id><pub-id pub-id-type="pmid">32113510</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.-R.</given-names></name><name><surname>Wang</surname><given-names>Y.-C.</given-names></name><name><surname>Lin</surname><given-names>Y. W.</given-names></name><name><surname>Chou</surname><given-names>S.-Y.</given-names></name><name><surname>Chen</surname><given-names>S.-F.</given-names></name><name><surname>Liu</surname><given-names>L. T.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.</article-title>
<source><italic>Bioorg. Med. Chem. Lett.</italic></source>
<volume>15</volume>
<fpage>3058</fpage>&#x02013;<lpage>3062</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2005.04.027</pub-id>
<?supplied-pmid 15896959?><pub-id pub-id-type="pmid">15896959</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.-H.</given-names></name><name><surname>Strych</surname><given-names>U.</given-names></name><name><surname>Hotez</surname><given-names>P. J.</given-names></name><name><surname>Bottazzi</surname><given-names>M. E.</given-names></name></person-group> (<year>2020</year>). <article-title>The SARS-CoV-2 Vaccine Pipeline: an Overview.</article-title>
<source><italic>Curr. Trop. Med. Rep.</italic></source>
<volume>3</volume>
<fpage>1</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/s40475-020-00201-6</pub-id>
<?supplied-pmid 32219057?><pub-id pub-id-type="pmid">32219057</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.</article-title>
<source><italic>medRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.03.22.20040758</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>R.</given-names></name><name><surname>Soo</surname><given-names>Y. O. Y.</given-names></name><name><surname>Wong</surname><given-names>W. S.</given-names></name><name><surname>Lee</surname><given-names>C. K.</given-names></name><name><surname>Ng</surname><given-names>M. H. L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong.</article-title>
<source><italic>Eur. J. Clin. Microbiol. Infect. Dis.</italic></source>
<volume>24</volume>
<fpage>44</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-004-1271-9</pub-id>
<?supplied-pmid 15616839?><pub-id pub-id-type="pmid">15616839</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chihrin</surname><given-names>S.</given-names></name><name><surname>Loutfy</surname><given-names>M. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Overview of antiviral and anti-inflammatory treatment for severe acute respi ratory syndrome.</article-title>
<source><italic>Expert Rev. Anti Infect. Ther.</italic></source>
<volume>3</volume>
<fpage>251</fpage>&#x02013;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1586/14787210.3.2.251</pub-id>
<?supplied-pmid 15918782?><pub-id pub-id-type="pmid">15918782</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chorin</surname><given-names>E.</given-names></name><name><surname>Dai</surname><given-names>M.</given-names></name><name><surname>Shulman</surname><given-names>E.</given-names></name><name><surname>Wadhwani</surname><given-names>L.</given-names></name><name><surname>Cohen</surname><given-names>R. B.</given-names></name><name><surname>Barbhaiya</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin.</article-title>
<source><italic>medRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.04.02.20047050</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chousterman</surname><given-names>B. G.</given-names></name><name><surname>Swirski</surname><given-names>F. K.</given-names></name><name><surname>Weber</surname><given-names>G. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Cytokine storm and sepsis disease pathogenesis.</article-title>
<source><italic>Semin. Immunopathol.</italic></source>
<volume>39</volume>
<fpage>517</fpage>&#x02013;<lpage>528</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-017-0639-8</pub-id>
<?supplied-pmid 28555385?><pub-id pub-id-type="pmid">28555385</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C. M.</given-names></name><name><surname>Cheng</surname><given-names>V. C. C.</given-names></name><name><surname>Hung</surname><given-names>I. F. N.</given-names></name><name><surname>Wong</surname><given-names>M. M. L.</given-names></name><name><surname>Chan</surname><given-names>K. H.</given-names></name><name><surname>Chan</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.</article-title>
<source><italic>Thorax</italic></source>
<volume>59</volume>
<fpage>252</fpage>&#x02013;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id>
<?supplied-pmid 14985565?><pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>J. F.-W.</given-names></name><name><surname>Yuen</surname><given-names>T. T.-T.</given-names></name><name><surname>Shuai</surname><given-names>H.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study.</article-title>
<source><italic>Lancet Microbe</italic></source>
<volume>1</volume>
<fpage>e14</fpage>&#x02013;<lpage>e23</lpage>. <pub-id pub-id-type="doi">10.1016/S2666-5247(20)30004-5</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Michaelis</surname><given-names>M.</given-names></name><name><surname>Hoever</surname><given-names>G.</given-names></name><name><surname>Preiser</surname><given-names>W.</given-names></name><name><surname>Doerr</surname><given-names>H. W.</given-names></name></person-group> (<year>2005</year>). <article-title>Development of antiviral therapy for severe acute respiratory syndrome.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>66</volume>
<fpage>81</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.03.002</pub-id>
<?supplied-pmid 15878786?><pub-id pub-id-type="pmid">15878786</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Morgenstern</surname><given-names>B.</given-names></name><name><surname>Bauer</surname><given-names>G.</given-names></name><name><surname>Chandra</surname><given-names>P.</given-names></name><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Doerr</surname><given-names>H. W.</given-names></name></person-group> (<year>2003</year>). <article-title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.</article-title>
<source><italic>Lancet</italic></source>
<volume>361</volume>
<fpage>2045</fpage>&#x02013;<lpage>2046</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13615-X</pub-id><pub-id pub-id-type="pmid">12814717</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>L. T.</given-names></name><name><surname>Watkins</surname><given-names>L.</given-names></name><name><surname>Pi&#x000f1;a</surname><given-names>I. L.</given-names></name><name><surname>Elmer</surname><given-names>M.</given-names></name><name><surname>Akinboboye</surname><given-names>O.</given-names></name><name><surname>Gorham</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Increasing diversity in clinical trials: overcoming critical barriers.</article-title>
<source><italic>Curr. Probl. Cardiol.</italic></source>
<volume>44</volume>
<fpage>148</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1016/j.cpcardiol.2018.11.002</pub-id>
<?supplied-pmid 30545650?><pub-id pub-id-type="pmid">30545650</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>L. A.</given-names></name></person-group> (<year>1991</year>). <article-title>The influence of corticosteroids on host defense mechanisms.</article-title>
<source><italic>J. Vet. Intern. Med.</italic></source>
<volume>5</volume>
<fpage>95</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1111/j.1939-1676.1991.tb00939.x</pub-id>
<?supplied-pmid 2061872?><pub-id pub-id-type="pmid">2061872</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>C. M.</given-names></name><name><surname>Frieman</surname><given-names>M. B.</given-names></name></person-group> (<year>2014</year>). <article-title>Coronaviruses: important emerging human pathogens.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>88</volume>
<fpage>5209</fpage>&#x02013;<lpage>5212</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03488-13</pub-id>
<?supplied-pmid 24600003?><pub-id pub-id-type="pmid">24600003</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group> (<year>2019</year>). <article-title>Origin and evolution of pathogenic coronaviruses.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>17</volume>
<fpage>181</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-018-0118-9</pub-id>
<?supplied-pmid 30531947?><pub-id pub-id-type="pmid">30531947</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cvetkovic</surname><given-names>R. S.</given-names></name><name><surname>Goa</surname><given-names>K. L.</given-names></name></person-group> (<year>2003</year>). <article-title>Lopinavir/Ritonavir.</article-title>
<source><italic>Drugs</italic></source>
<volume>63</volume>
<fpage>769</fpage>&#x02013;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-200363080-00004</pub-id>
<?supplied-pmid 12662125?><pub-id pub-id-type="pmid">12662125</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Mucroporin, the first cationic host defense peptide from the venom of lychas mucronatus.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>52</volume>
<fpage>3967</fpage>&#x02013;<lpage>3972</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00542-08</pub-id>
<?supplied-pmid 18779362?><pub-id pub-id-type="pmid">18779362</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amato</surname><given-names>G.</given-names></name><name><surname>Stanziola</surname><given-names>A.</given-names></name><name><surname>Sanduzzi</surname><given-names>A.</given-names></name><name><surname>Liccardi</surname><given-names>G.</given-names></name><name><surname>Salzillo</surname><given-names>A.</given-names></name><name><surname>Vitale</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.</article-title>
<source><italic>Multidiscip. Respir. Med.</italic></source>
<volume>9</volume>:<issue>23</issue>. <pub-id pub-id-type="doi">10.1186/2049-6958-9-23</pub-id>
<?supplied-pmid 24735949?><pub-id pub-id-type="pmid">24735949</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>T. L.</given-names></name><name><surname>Walker</surname><given-names>J. R.</given-names></name><name><surname>Campagna-Slater</surname><given-names>V.</given-names></name><name><surname>Finerty</surname><given-names>P. J.</given-names></name><name><surname>Paramanathan</surname><given-names>R.</given-names></name><name><surname>Bernstein</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases.</article-title>
<source><italic>PLoS Biol.</italic></source>
<volume>8</volume>:<issue>e1000439</issue>. <pub-id pub-id-type="doi">10.1371/journal.pbio.1000439</pub-id>
<?supplied-pmid 20676357?><pub-id pub-id-type="pmid">20676357</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>C. W.</given-names></name><name><surname>Baric</surname><given-names>R.</given-names></name><name><surname>Cai</surname><given-names>S. X.</given-names></name><name><surname>Frieman</surname><given-names>M.</given-names></name><name><surname>Kumaki</surname><given-names>Y.</given-names></name><name><surname>Morrey</surname><given-names>J. D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.</article-title>
<source><italic>Virology</italic></source>
<volume>395</volume>
<fpage>210</fpage>&#x02013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2009.09.023</pub-id>
<?supplied-pmid 19853271?><pub-id pub-id-type="pmid">19853271</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>A. H.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name><name><surname>Beugeling</surname><given-names>C.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Martellaro</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.</article-title>
<source><italic>Virus Res.</italic></source>
<volume>228</volume>
<fpage>7</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2016.11.011</pub-id>
<?supplied-pmid 27840112?><pub-id pub-id-type="pmid">27840112</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>A. H.</given-names></name><name><surname>Jochmans</surname><given-names>D.</given-names></name><name><surname>Posthuma</surname><given-names>C. C.</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name><name><surname>Nieuwkoop</surname><given-names>S.</given-names></name><name><surname>van</surname></name><etal/></person-group> (<year>2014</year>). <article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>58</volume>
<fpage>4875</fpage>&#x02013;<lpage>4884</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.03011-14</pub-id>
<?supplied-pmid 24841269?><pub-id pub-id-type="pmid">24841269</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>A. H.</given-names></name><name><surname>Raj</surname><given-names>V. S.</given-names></name><name><surname>Oudshoorn</surname><given-names>D.</given-names></name><name><surname>Bestebroer</surname><given-names>T. M.</given-names></name><name><surname>van Nieuwkoop</surname><given-names>S.</given-names></name><name><surname>Limpens</surname><given-names>R. W. A. L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-&#x003b1; treatment.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>94</volume>
<fpage>1749</fpage>&#x02013;<lpage>1760</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.052910-0</pub-id>
<?supplied-pmid 23620378?><pub-id pub-id-type="pmid">23620378</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>A. H.</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name><name><surname>van der Meer</surname><given-names>Y.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Narayanan</surname><given-names>K.</given-names></name><name><surname>Makino</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Cyclosporin A inhibits the replication of diverse coronaviruses.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>92</volume>
<fpage>2542</fpage>&#x02013;<lpage>2548</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.034983-0</pub-id>
<?supplied-pmid 21752960?><pub-id pub-id-type="pmid">21752960</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Wit</surname><given-names>E.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Cronin</surname><given-names>J.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Thomas</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>117</volume>
<fpage>6771</fpage>&#x02013;<lpage>6776</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1922083117</pub-id>
<?supplied-pmid 32054787?><pub-id pub-id-type="pmid">32054787</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhama</surname><given-names>K.</given-names></name><name><surname>Sharun</surname><given-names>K.</given-names></name><name><surname>Tiwari</surname><given-names>R.</given-names></name><name><surname>Dadar</surname><given-names>M.</given-names></name><name><surname>Malik</surname><given-names>Y. S.</given-names></name><name><surname>Singh</surname><given-names>K. P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.</article-title>
<source><italic>Hum. Vaccines Immunother.</italic></source>
<volume>2020</volume>
<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2020.1735227</pub-id>
<?supplied-pmid 32186952?><pub-id pub-id-type="pmid">32186952</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>117</volume>
<fpage>9490</fpage>&#x02013;<lpage>9496</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id>
<?supplied-pmid 32253318?><pub-id pub-id-type="pmid">32253318</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Solia</surname><given-names>A.</given-names></name><name><surname>Al-Otaibi</surname><given-names>K.</given-names></name><name><surname>Ai-Hwiesh</surname><given-names>A. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis.</article-title>
<source><italic>BMJ Case Rep.</italic></source>
<volume>2018</volume>:<issue>bcr2017223639</issue>. <pub-id pub-id-type="doi">10.1136/bcr-2017-223639</pub-id>
<?supplied-pmid 29669768?><pub-id pub-id-type="pmid">29669768</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Martellaro</surname><given-names>C.</given-names></name><name><surname>Callison</surname><given-names>J.</given-names></name><name><surname>Munster</surname><given-names>V. J.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group> (<year>2013a</year>). <article-title>Inhibition of novel &#x003b2; coronavirus replication by a combination of interferon-&#x003b1;2b and ribavirin.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>3</volume>:<issue>1686</issue>. <pub-id pub-id-type="doi">10.1038/srep01686</pub-id>
<?supplied-pmid 23594967?><pub-id pub-id-type="pmid">23594967</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Rasmussen</surname><given-names>A. L.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>D. P.</given-names></name><etal/></person-group> (<year>2013b</year>). <article-title>Treatment with interferon-&#x003b1;2b and ribavirin improves outcome in MERS-CoV&#x02013;infected rhesus macaques.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>19</volume>
<fpage>1313</fpage>&#x02013;<lpage>1317</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3362</pub-id>
<?supplied-pmid 24013700?><pub-id pub-id-type="pmid">24013700</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><collab>FDA</collab> (<year>2020</year>). <source><italic>FDA Cautions Against use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical trial due to Risk of Heart Rhythm Problems.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or">https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or</ext-link>
<comment>(accessed July 5, 2020)</comment></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A. R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Coronaviruses: an overview of their replication and pathogenesis.</article-title>
<source><italic>Methods Mol. Biol. Clifton NJ</italic></source>
<volume>1282</volume>
<fpage>1</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2438-7_1</pub-id>
<?supplied-pmid 25870870?><pub-id pub-id-type="pmid">25870870</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferron</surname><given-names>F.</given-names></name><name><surname>Subissi</surname><given-names>L.</given-names></name><name><surname>De Morais</surname><given-names>A. T. S.</given-names></name><name><surname>Le</surname><given-names>N. T. T.</given-names></name><name><surname>Sevajol</surname><given-names>M.</given-names></name><name><surname>Gluais</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U S.A.</italic></source>
<volume>115</volume>
<fpage>E162</fpage>&#x02013;<lpage>E171</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1718806115</pub-id>
<?supplied-pmid 29279395?><pub-id pub-id-type="pmid">29279395</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>Y.-R.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>Y.-D.</given-names></name><name><surname>Rao</surname><given-names>C.-M.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>J.-S.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase.</article-title>
<source><italic>Peptides</italic></source>
<volume>27</volume>
<fpage>622</fpage>&#x02013;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2005.09.006</pub-id>
<?supplied-pmid 16242214?><pub-id pub-id-type="pmid">16242214</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ganeshpurkar</surname><given-names>A.</given-names></name><name><surname>Gutti</surname><given-names>G.</given-names></name><name><surname>Singh</surname><given-names>S. K.</given-names></name></person-group> (<year>2019</year>). &#x0201c;<article-title>Chapter 1 - RNA-dependent RNA polymerases and their emerging roles in antiviral therapy</article-title>,&#x0201d; in <source><italic>Viral Polymerases</italic></source>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Gupta</surname><given-names>S. P.</given-names></name></person-group> (<publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>1</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-815422-9.00001-2</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.</article-title>
<source><italic>Biosci. Trends</italic></source>
<volume>14</volume>
<fpage>72</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.5582/BST.2020.01047</pub-id>
<?supplied-pmid 32074550?><pub-id pub-id-type="pmid">32074550</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garraud</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>Use of convalescent plasma in Ebola virus infection.</article-title>
<source><italic>Transfus. Apher. Sci.</italic></source>
<volume>56</volume>
<fpage>31</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.transci.2016.12.014</pub-id>
<?supplied-pmid 28094110?><pub-id pub-id-type="pmid">28094110</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Hoang</surname><given-names>V. T.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.</article-title>
<source><italic>Int. J. Antimicrob. Agents</italic></source>
<volume>20</volume>:<issue>105949</issue>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id>
<?supplied-pmid 32205204?><pub-id pub-id-type="pmid">32205204</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giles</surname><given-names>A. J.</given-names></name><name><surname>Hutchinson</surname><given-names>M.-K. N. D.</given-names></name><name><surname>Sonnemann</surname><given-names>H. M.</given-names></name><name><surname>Jung</surname><given-names>J.</given-names></name><name><surname>Fecci</surname><given-names>P. E.</given-names></name><name><surname>Ratnam</surname><given-names>N. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.</article-title>
<source><italic>J. Immunother. Cancer</italic></source>
<volume>6</volume>:<issue>51</issue>. <pub-id pub-id-type="doi">10.1186/s40425-018-0371-5</pub-id>
<?supplied-pmid 29891009?><pub-id pub-id-type="pmid">29891009</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girijala</surname><given-names>R. L.</given-names></name><name><surname>Siddiqi</surname><given-names>I.</given-names></name><name><surname>Kwak</surname><given-names>Y.</given-names></name><name><surname>Wright</surname><given-names>D.</given-names></name><name><surname>Patel</surname><given-names>D. B.</given-names></name><name><surname>Goldberg</surname><given-names>L. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Pustular DRESS syndrome secondary to hydroxychloroquine with EBV reactivation.</article-title>
<source><italic>J. Drugs Dermatol. JDD</italic></source>
<volume>18</volume>
<fpage>207</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">30811149</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A. E.</given-names></name><name><surname>Baker</surname><given-names>S. C.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name><name><surname>de Groot</surname><given-names>R. J.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Gulyaeva</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Severe acute respiratory syndrome-related coronavirus: the species and its viruses &#x02013; a statement of the Coronavirus study group.</article-title>
<source><italic>BioRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.02.07.937862</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A. E.</given-names></name><name><surname>Baker</surname><given-names>S. C.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name><name><surname>de Groot</surname><given-names>R. J.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Gulyaeva</surname><given-names>A. A.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.</article-title>
<source><italic>Nat. Microbiol.</italic></source>
<volume>5</volume>
<fpage>536</fpage>&#x02013;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id>
<?supplied-pmid 32123347?><pub-id pub-id-type="pmid">32123347</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;tz</surname><given-names>V.</given-names></name><name><surname>Magar</surname><given-names>L.</given-names></name><name><surname>Dornfeld</surname><given-names>D.</given-names></name><name><surname>Giese</surname><given-names>S.</given-names></name><name><surname>Pohlmann</surname><given-names>A.</given-names></name><name><surname>H&#x000f6;per</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>6</volume>:<issue>23138</issue>. <pub-id pub-id-type="doi">10.1038/srep23138</pub-id>
<?supplied-pmid 26988202?><pub-id pub-id-type="pmid">26988202</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R. L.</given-names></name><name><surname>Donaldson</surname><given-names>E. F.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2013</year>). <article-title>A decade after SARS: strategies for controlling emerging coronaviruses.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>11</volume>
<fpage>836</fpage>&#x02013;<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3143</pub-id>
<?supplied-pmid 24217413?><pub-id pub-id-type="pmid">24217413</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>M. C.</given-names></name><name><surname>Murray</surname><given-names>J. L.</given-names></name><name><surname>Hortobagyi</surname><given-names>G. N.</given-names></name></person-group> (<year>2000</year>). <article-title>Monoclonal antibody therapy for solid tumors.</article-title>
<source><italic>Cancer Treat. Rev.</italic></source>
<volume>26</volume>
<fpage>269</fpage>&#x02013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1053/ctrv.2000.0176</pub-id>
<?supplied-pmid 10913382?><pub-id pub-id-type="pmid">10913382</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grupp</surname><given-names>S. A.</given-names></name><name><surname>Kalos</surname><given-names>M.</given-names></name><name><surname>Barrett</surname><given-names>D.</given-names></name><name><surname>Aplenc</surname><given-names>R.</given-names></name><name><surname>Porter</surname><given-names>D. L.</given-names></name><name><surname>Rheingold</surname><given-names>S. R.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Chimeric antigen receptor&#x02013;modified T cells for acute lymphoid leukemia.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>368</volume>
<fpage>1509</fpage>&#x02013;<lpage>1518</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1215134</pub-id>
<?supplied-pmid 23527958?><pub-id pub-id-type="pmid">23527958</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>B.-J.</given-names></name><name><surname>Su</surname><given-names>Y.-P.</given-names></name><name><surname>Wu</surname><given-names>H.-Y.</given-names></name><name><surname>Brian</surname><given-names>D. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Genetic evidence of a long-range RNA-RNA interaction between the genomic 5&#x02019; untranslated region and the nonstructural protein 1 coding region in murine and bovine Coronaviruses.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>86</volume>
<fpage>4631</fpage>&#x02013;<lpage>4643</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06265-11</pub-id>
<?supplied-pmid 22345457?><pub-id pub-id-type="pmid">22345457</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.</given-names></name><name><surname>Ni</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Ou</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of Coronavirus disease 2019 in China.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>382</volume>
<fpage>1708</fpage>&#x02013;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id>
<?supplied-pmid 32109013?><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>S.</given-names></name><name><surname>Nagata</surname><given-names>N.</given-names></name><name><surname>Okamura</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>N.</given-names></name><name><surname>Sata</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>85</volume>
<fpage>551</fpage>&#x02013;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.12.001</pub-id>
<?supplied-pmid 19995578?><pub-id pub-id-type="pmid">19995578</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>S.</given-names></name><name><surname>Yamamoto</surname><given-names>N.</given-names></name><name><surname>Nakai-Murakami</surname><given-names>C.</given-names></name><name><surname>Osawa</surname><given-names>Y.</given-names></name><name><surname>Tokunaga</surname><given-names>K.</given-names></name><name><surname>Sata</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Modulation of TNF- -converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF- production and facilitates viral entry.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>105</volume>
<fpage>7809</fpage>&#x02013;<lpage>7814</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0711241105</pub-id>
<?supplied-pmid 18490652?><pub-id pub-id-type="pmid">18490652</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>D. P.</given-names></name><name><surname>Lohani</surname><given-names>M.</given-names></name><name><surname>Cho</surname><given-names>M. W.</given-names></name></person-group> (<year>2007</year>). <article-title>Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome Coronavirus entry.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>81</volume>
<fpage>12029</fpage>&#x02013;<lpage>12039</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00315-07</pub-id>
<?supplied-pmid 17715238?><pub-id pub-id-type="pmid">17715238</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>B. J.</given-names></name><name><surname>Dyall</surname><given-names>J.</given-names></name><name><surname>Postnikova</surname><given-names>E.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Kindrachuk</surname><given-names>J.</given-names></name><name><surname>Johnson</surname><given-names>R. F.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Interferon-&#x003b2; and mycophenolic acid are potent inhibitors of middle east respiratory syndrome coronavirus in cell-based assays.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>95</volume>
<fpage>571</fpage>&#x02013;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.061911-0</pub-id>
<?supplied-pmid 24323636?><pub-id pub-id-type="pmid">24323636</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>L. M.</given-names></name><name><surname>Caidi</surname><given-names>H.</given-names></name><name><surname>Radu</surname><given-names>G. U.</given-names></name><name><surname>Miao</surname><given-names>C.</given-names></name><name><surname>Harcourt</surname><given-names>J. L.</given-names></name><name><surname>Tripp</surname><given-names>R. A.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>200</volume>
<fpage>439</fpage>&#x02013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1086/600108</pub-id>
<?supplied-pmid 19545210?><pub-id pub-id-type="pmid">19545210</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>L. E.</given-names></name><name><surname>Fritz</surname><given-names>E. A.</given-names></name><name><surname>Jahrling</surname><given-names>P. B.</given-names></name><name><surname>Karp</surname><given-names>C.</given-names></name><name><surname>Huggins</surname><given-names>J. W.</given-names></name><name><surname>Geisbert</surname><given-names>T. W.</given-names></name></person-group> (<year>2004</year>). <article-title>Interferon-&#x003b2; 1a and SARS Coronavirus Replication.</article-title>
<source><italic>Emerg. Infect. Dis.</italic></source>
<volume>10</volume>
<fpage>317</fpage>&#x02013;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.3201/eid1002.030482</pub-id>
<?supplied-pmid 15030704?><pub-id pub-id-type="pmid">15030704</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>A. S.</given-names></name><name><surname>Abd-Elsayed</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). &#x0201c;<article-title>Observational studies: uses and limitations</article-title>,&#x0201d; in <source><italic>Pain: A Review Guide</italic></source>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Abd-Elsayed</surname><given-names>A.</given-names></name></person-group> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>123</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-99124-5_31</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>T.-Y.</given-names></name><name><surname>Wu</surname><given-names>S.-L.</given-names></name><name><surname>Chen</surname><given-names>J.-C.</given-names></name><name><surname>Li</surname><given-names>C.-C.</given-names></name><name><surname>Hsiang</surname><given-names>C.-Y.</given-names></name></person-group> (<year>2007</year>). <article-title>Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>74</volume>
<fpage>92</fpage>&#x02013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2006.04.014</pub-id>
<?supplied-pmid 16730806?><pub-id pub-id-type="pmid">16730806</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoever</surname><given-names>G.</given-names></name><name><surname>Baltina</surname><given-names>L.</given-names></name><name><surname>Michaelis</surname><given-names>M.</given-names></name><name><surname>Kondratenko</surname><given-names>R.</given-names></name><name><surname>Baltina</surname><given-names>L.</given-names></name><name><surname>Tolstikov</surname><given-names>G. A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Antiviral activity of glycyrrhizic acid derivatives against SARS-Coronavirus.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>48</volume>
<fpage>1256</fpage>&#x02013;<lpage>1259</lpage>. <pub-id pub-id-type="doi">10.1021/jm0493008</pub-id>
<?supplied-pmid 15715493?><pub-id pub-id-type="pmid">15715493</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.</article-title>
<source><italic>Cell</italic></source>
<volume>181</volume>
<fpage>271.e8</fpage>&#x02013;<lpage>280.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>
<?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M. L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K. H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>First case of 2019 novel coronavirus in the united states.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>382</volume>
<fpage>929</fpage>&#x02013;<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id>
<?supplied-pmid 32004427?><pub-id pub-id-type="pmid">32004427</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horby</surname><given-names>P.</given-names></name><name><surname>Lim</surname><given-names>W. S.</given-names></name><name><surname>Emberson</surname><given-names>J.</given-names></name><name><surname>Mafham</surname><given-names>M.</given-names></name><name><surname>Bell</surname><given-names>J.</given-names></name><name><surname>Linsell</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report.</article-title>
<source><italic>medRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.06.22.20137273</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>L. Y.</given-names></name><name><surname>Chia</surname><given-names>P. Y.</given-names></name><name><surname>Lim</surname><given-names>J. F.</given-names></name></person-group> (<year>2020</year>). <article-title>The novel Coronavirus (SARS-CoV-2) epidemic.</article-title>
<source><italic>Ann. Acad. Med. Singapore</italic></source>
<volume>49</volume>
<fpage>1</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>I.-C.</given-names></name><name><surname>Bosch</surname><given-names>B. J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Lee</surname><given-names>K. H.</given-names></name><name><surname>Ghiran</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>281</volume>
<fpage>3198</fpage>&#x02013;<lpage>3203</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M508381200</pub-id>
<?supplied-pmid 16339146?><pub-id pub-id-type="pmid">16339146</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huentelman</surname><given-names>M. J.</given-names></name><name><surname>Zubcevic</surname><given-names>J.</given-names></name><name><surname>Hern&#x000e1;ndez Prada</surname><given-names>J. A.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Dimitrov</surname><given-names>D. S.</given-names></name><name><surname>Raizada</surname><given-names>M. K.</given-names></name><etal/></person-group> (<year>2004a</year>). <article-title>Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor.</article-title>
<source><italic>Hypertension</italic></source>
<volume>44</volume>
<fpage>903</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1161/01.HYP.0000146120.29648.36</pub-id><pub-id pub-id-type="pmid">15492138</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huentelman</surname><given-names>M. J.</given-names></name><name><surname>Zubcevic</surname><given-names>J.</given-names></name><name><surname>Katovich</surname><given-names>M. J.</given-names></name><name><surname>Raizada</surname><given-names>M. K.</given-names></name></person-group> (<year>2004b</year>). <article-title>Cloning and characterization of a secreted form of angiotensin-converting enzyme 2.</article-title>
<source><italic>Regul. Pept.</italic></source>
<volume>122</volume>
<fpage>61</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.regpep.2004.05.003</pub-id>
<?supplied-pmid 15380922?><pub-id pub-id-type="pmid">15380922</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>I. F.-N.</given-names></name><name><surname>Lung</surname><given-names>K.-C.</given-names></name><name><surname>Tso</surname><given-names>E. Y.-K.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Chung</surname><given-names>T. W.-H.</given-names></name><name><surname>Chu</surname><given-names>M.-Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.</article-title>
<source><italic>Lancet Lond. Engl.</italic></source>
<volume>395</volume>
<fpage>1695</fpage>&#x02013;<lpage>1704</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31042-4</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yount</surname><given-names>B.</given-names></name><name><surname>Smith</surname><given-names>A.</given-names></name><name><surname>Sturges</surname><given-names>L.</given-names></name><name><surname>Olsen</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Evidence supporting a zoonotic origin of human Coronavirus strain NL63.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>86</volume>
<fpage>12816</fpage>&#x02013;<lpage>12825</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00906-12</pub-id>
<?supplied-pmid 22993147?><pub-id pub-id-type="pmid">22993147</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>J. M.</given-names></name><name><surname>Bosinger</surname><given-names>S. E.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Belaunzaran-Zamudio</surname><given-names>P.</given-names></name><name><surname>Matining</surname><given-names>R. M.</given-names></name><name><surname>Wilson</surname><given-names>C. C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>The effect of chloroquine on immune activation and interferon signatures associated with HIV-1.</article-title>
<source><italic>AIDS Res. Hum. Retroviruses</italic></source>
<volume>32</volume>
<fpage>636</fpage>&#x02013;<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1089/aid.2015.0336</pub-id>
<?supplied-pmid 26935044?><pub-id pub-id-type="pmid">26935044</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasenosky</surname><given-names>L. D.</given-names></name><name><surname>Cadena</surname><given-names>C.</given-names></name><name><surname>Mire</surname><given-names>C. E.</given-names></name><name><surname>Borisevich</surname><given-names>V.</given-names></name><name><surname>Haridas</surname><given-names>V.</given-names></name><name><surname>Ranjbar</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits ebola virus.</article-title>
<source><italic>iScience</italic></source>
<volume>19</volume>
<fpage>1279</fpage>&#x02013;<lpage>1290</lpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2019.07.003</pub-id>
<?supplied-pmid 31402258?><pub-id pub-id-type="pmid">31402258</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffers</surname><given-names>S. A.</given-names></name><name><surname>Tusell</surname><given-names>S. M.</given-names></name><name><surname>Gillim-Ross</surname><given-names>L.</given-names></name><name><surname>Hemmila</surname><given-names>E. M.</given-names></name><name><surname>Achenbach</surname><given-names>J. E.</given-names></name><name><surname>Babcock</surname><given-names>G. J.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>101</volume>
<fpage>15748</fpage>&#x02013;<lpage>15753</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403812101</pub-id>
<?supplied-pmid 15496474?><pub-id pub-id-type="pmid">15496474</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>S.</given-names></name><name><surname>Ko</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Choi</surname><given-names>I.</given-names></name><name><surname>Byun</surname><given-names>S. Y.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>64</volume>
<fpage>e00819</fpage>&#x02013;<lpage>e00820</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00819-20</pub-id>
<?supplied-pmid 32366720?><pub-id pub-id-type="pmid">32366720</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juurlink</surname><given-names>D. N.</given-names></name></person-group> (<year>2020</year>). <article-title>Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.</article-title>
<source><italic>CMAJ</italic></source>
<volume>192</volume>
<fpage>E450</fpage>&#x02013;<lpage>E453</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.200528</pub-id>
<?supplied-pmid 32269021?><pub-id pub-id-type="pmid">32269021</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaeppler</surname><given-names>U.</given-names></name><name><surname>Stiefl</surname><given-names>N.</given-names></name><name><surname>Schiller</surname><given-names>M.</given-names></name><name><surname>Vicik</surname><given-names>R.</given-names></name><name><surname>Breuning</surname><given-names>A.</given-names></name><name><surname>Schmitz</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>48</volume>
<fpage>6832</fpage>&#x02013;<lpage>6842</lpage>. <pub-id pub-id-type="doi">10.1021/jm0501782</pub-id>
<?supplied-pmid 16250642?><pub-id pub-id-type="pmid">16250642</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>J. S.</given-names></name><name><surname>McIntosh</surname><given-names>K.</given-names></name></person-group> (<year>2005</year>). <article-title>History and recent advances in coronavirus discovery.</article-title>
<source><italic>Pediatr. Infect Dis. J.</italic></source>
<volume>24</volume>(11 Suppl), S223-S227.</mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karamitros</surname><given-names>T.</given-names></name><name><surname>Papadopoulou</surname><given-names>G.</given-names></name><name><surname>Bousali</surname><given-names>M.</given-names></name><name><surname>Mexias</surname><given-names>A.</given-names></name><name><surname>Tsiodras</surname><given-names>S.</given-names></name><name><surname>Mentis</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies.</article-title>
<source><italic>bioRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.03.27.009480</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>M.</given-names></name></person-group> (<year>1977</year>). <article-title>Anthelmintics.</article-title>
<source><italic>Drugs</italic></source>
<volume>13</volume>
<fpage>124</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-197713020-00002</pub-id>
<?supplied-pmid 319991?><pub-id pub-id-type="pmid">319991</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kernan</surname><given-names>W. N.</given-names></name><name><surname>Viscoli</surname><given-names>C. M.</given-names></name><name><surname>Makuch</surname><given-names>R. W.</given-names></name><name><surname>Brass</surname><given-names>L. M.</given-names></name><name><surname>Horwitz</surname><given-names>R. I.</given-names></name></person-group> (<year>1999</year>). <article-title>Stratified randomization for clinical trials.</article-title>
<source><italic>J. Clin. Epidemiol.</italic></source>
<volume>52</volume>
<fpage>19</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/S0895-4356(98)00138-3</pub-id><pub-id pub-id-type="pmid">9973070</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesel</surname><given-names>A. J.</given-names></name></person-group> (<year>2003</year>). <article-title>A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-Derived zinc-Chelating trioxa-adamantane-triol.</article-title>
<source><italic>Bioorg. Med. Chem.</italic></source>
<volume>11</volume>
<fpage>4599</fpage>&#x02013;<lpage>4613</lpage>. <pub-id pub-id-type="doi">10.1016/S0968-0896(03)00500-5</pub-id><pub-id pub-id-type="pmid">14527557</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khamitov</surname><given-names>R.</given-names></name><name><surname>Loginova</surname><given-names>S.</given-names></name><name><surname>Borisevich</surname><given-names>S.</given-names></name><name><surname>Maksimov</surname><given-names>V.</given-names></name><name><surname>Shuster</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <source><italic>Antiviral Activity of Arbidol and its Derivatives against the Pathogen of severe Acute Respiratory Syndrome in the Cell Cultures.</italic></source>
<fpage>9</fpage>&#x02013;<lpage>13</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/article/med/18756809">https://europepmc.org/article/med/18756809</ext-link>
<comment>(accessed June 10, 2020)</comment>.</mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>J. W.</given-names></name><name><surname>Kim</surname><given-names>V. N.</given-names></name><name><surname>Chang</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>The architecture of SARS-CoV-2 transcriptome.</article-title>
<source><italic>Cell</italic></source>
<volume>181</volume>
<fpage>914.e10</fpage>&#x02013;<lpage>921.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.011</pub-id>
<?supplied-pmid 32330414?><pub-id pub-id-type="pmid">32330414</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Lovell</surname><given-names>S.</given-names></name><name><surname>Tiew</surname><given-names>K.-C.</given-names></name><name><surname>Mandadapu</surname><given-names>S. R.</given-names></name><name><surname>Alliston</surname><given-names>K. R.</given-names></name><name><surname>Battaile</surname><given-names>K. P.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and Coronaviruses.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>86</volume>
<fpage>11754</fpage>&#x02013;<lpage>11762</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01348-12</pub-id>
<?supplied-pmid 22915796?><pub-id pub-id-type="pmid">22915796</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Mandadapu</surname><given-names>S. R.</given-names></name><name><surname>Groutas</surname><given-names>W. C.</given-names></name><name><surname>Chang</surname><given-names>K.-O.</given-names></name></person-group> (<year>2013</year>). <article-title>Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>97</volume>
<fpage>161</fpage>&#x02013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2012.11.005</pub-id>
<?supplied-pmid 23219425?><pub-id pub-id-type="pmid">23219425</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>U. J.</given-names></name><name><surname>Won</surname><given-names>E.-J.</given-names></name><name><surname>Kee</surname><given-names>S.-J.</given-names></name><name><surname>Jung</surname><given-names>S.-I.</given-names></name><name><surname>Jang</surname><given-names>H.-C.</given-names></name></person-group> (<year>2015</year>). <article-title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-&#x003b1; for Middle East respiratory syndrome: a case report.</article-title>
<source><italic>Antivir. Ther.</italic></source>
<volume>21</volume>
<fpage>455</fpage>&#x02013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.3851/IMP3002</pub-id>
<?supplied-pmid 26492219?><pub-id pub-id-type="pmid">26492219</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kipar</surname><given-names>A.</given-names></name><name><surname>Meli</surname><given-names>M. L.</given-names></name><name><surname>Baptiste</surname><given-names>K. E.</given-names></name><name><surname>Bowker</surname><given-names>L. J.</given-names></name><name><surname>Lutz</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>). <article-title>Sites of feline coronavirus persistence in healthy cats.</article-title>
<source><italic>J. Gen. Virol.</italic></source>
<volume>91</volume>
<fpage>1698</fpage>&#x02013;<lpage>1707</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.020214-0</pub-id>
<?supplied-pmid 20237226?><pub-id pub-id-type="pmid">20237226</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchheiner</surname><given-names>J.</given-names></name><name><surname>Keulen</surname><given-names>J.-T. H. A.</given-names></name><name><surname>Bauer</surname><given-names>S.</given-names></name><name><surname>Roots</surname><given-names>I.</given-names></name><name><surname>Brockm&#x000f6;ller</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.</article-title>
<source><italic>J. Clin. Psychopharmacol.</italic></source>
<volume>28</volume>
<fpage>78</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1097/JCP.0b013e318160f827</pub-id>
<?supplied-pmid 18204346?><pub-id pub-id-type="pmid">18204346</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J.-H.</given-names></name><name><surname>Seok</surname><given-names>H.</given-names></name><name><surname>Cho</surname><given-names>S. Y.</given-names></name><name><surname>Ha</surname><given-names>Y. E.</given-names></name><name><surname>Baek</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Challenges of convalescent plasma infusion therapy in Middle East respiratory Coronavirus infection: a single centre experience.</article-title>
<source><italic>Antivir. Ther.</italic></source>
<volume>23</volume>
<fpage>617</fpage>&#x02013;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.3851/IMP3243</pub-id>
<?supplied-pmid 29923831?><pub-id pub-id-type="pmid">29923831</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name><name><surname>Konishi</surname><given-names>M.</given-names></name><name><surname>Yokoi</surname><given-names>M.</given-names></name><name><surname>Kakehashi</surname><given-names>R.</given-names></name><name><surname>Kaito</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-&#x003b2;.</article-title>
<source><italic>Hepatology</italic></source>
<volume>18</volume>
<fpage>1319</fpage>&#x02013;<lpage>1325</lpage>. <pub-id pub-id-type="doi">10.1002/hep.1840180606</pub-id><pub-id pub-id-type="pmid">8244255</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C.-C.</given-names></name><name><surname>Shih</surname><given-names>T.-P.</given-names></name><name><surname>Ko</surname><given-names>W.-C.</given-names></name><name><surname>Tang</surname><given-names>H.-J.</given-names></name><name><surname>Hsueh</surname><given-names>P.-R.</given-names></name></person-group> (<year>2020</year>). <article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges.</article-title>
<source><italic>Int. J. Antimicrob. Agents</italic></source>
<volume>55</volume>:<issue>105924</issue>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105924</pub-id>
<?supplied-pmid 32081636?><pub-id pub-id-type="pmid">32081636</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>M. M.</given-names></name><name><surname>Stohlman</surname><given-names>S. A.</given-names></name></person-group> (<year>1981</year>). <article-title>Comparative analysis of RNA genomes of mouse hepatitis viruses.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>38</volume>
<fpage>661</fpage>&#x02013;<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.38.2.661-670.1981</pub-id>
<?supplied-pmid 6165837?><pub-id pub-id-type="pmid">6165837</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laing</surname><given-names>R.</given-names></name><name><surname>Gillan</surname><given-names>V.</given-names></name><name><surname>Devaney</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Ivermectin &#x02013; old drug. New Tricks?</article-title>
<source><italic>Trends Parasitol.</italic></source>
<volume>33</volume>
<fpage>463</fpage>&#x02013;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1016/j.pt.2017.02.004</pub-id>
<?supplied-pmid 28285851?><pub-id pub-id-type="pmid">28285851</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laplante</surname><given-names>J.</given-names></name><name><surname>St George</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Antiviral resistance in influenza viruses: laboratory testing.</article-title>
<source><italic>Clin. Lab. Med.</italic></source>
<volume>34</volume>
<fpage>387</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1016/j.cll.2014.02.010</pub-id>
<?supplied-pmid 24856534?><pub-id pub-id-type="pmid">24856534</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Vinayagamoorthy</surname><given-names>N.</given-names></name><name><surname>Han</surname><given-names>K.</given-names></name><name><surname>Kwok</surname><given-names>S. K.</given-names></name><name><surname>Ju</surname><given-names>J. H.</given-names></name><name><surname>Park</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus.</article-title>
<source><italic>Arthritis Rheumatol.</italic></source>
<volume>68</volume>
<fpage>184</fpage>&#x02013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1002/art.39402</pub-id>
<?supplied-pmid 26316040?><pub-id pub-id-type="pmid">26316040</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.-W.</given-names></name><name><surname>Cherney</surname><given-names>M. M.</given-names></name><name><surname>Huitema</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>James</surname><given-names>K. E.</given-names></name><name><surname>Powers</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Crystal structures of the main peptidase from the SARS Coronavirus Inhibited by a substrate-like aza-peptide epoxide.</article-title>
<source><italic>J. Mol. Biol.</italic></source>
<volume>353</volume>
<fpage>1137</fpage>&#x02013;<lpage>1151</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2005.09.004</pub-id>
<?supplied-pmid 16219322?><pub-id pub-id-type="pmid">16219322</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengauer</surname><given-names>T.</given-names></name><name><surname>Sing</surname><given-names>T.</given-names></name></person-group> (<year>2006</year>). <article-title>Bioinformatics-assisted anti-HIV therapy.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>4</volume>
<fpage>790</fpage>&#x02013;<lpage>797</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1477</pub-id>
<?supplied-pmid 16980939?><pub-id pub-id-type="pmid">16980939</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D. K.</given-names></name><name><surname>Chung</surname><given-names>R. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Overview of direct-acting antiviral drugs and drug resistance of hepatitis C Virus.</article-title>
<source><italic>Methods Mol. Biol. Clifton NJ</italic></source>
<volume>1911</volume>
<fpage>3</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-8976-8_1</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Bi</surname><given-names>Z.</given-names></name><name><surname>Song</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Lei</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Significant inhibition of re-emerged and emerging swine enteric coronavirus in vitro using the multiple shRNA expression vector.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>166</volume>
<fpage>11</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.03.010</pub-id>
<?supplied-pmid 30905822?><pub-id pub-id-type="pmid">30905822</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>W.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.</article-title>
<source><italic>Peptides</italic></source>
<volume>32</volume>
<fpage>1518</fpage>&#x02013;<lpage>1525</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2011.05.015</pub-id>
<?supplied-pmid 21620914?><pub-id pub-id-type="pmid">21620914</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Geng</surname><given-names>M.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Molecular immune pathogenesis and diagnosis of COVID-19.</article-title>
<source><italic>J. Pharm. Anal.</italic></source>
<volume>10</volume>
<fpage>102</fpage>&#x02013;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.001</pub-id>
<?supplied-pmid 32282863?><pub-id pub-id-type="pmid">32282863</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>N.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.</article-title>
<source><italic>Clin. Microbiol. Infect.</italic></source>
<volume>26</volume>
<fpage>917</fpage>&#x02013;<lpage>921</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.026</pub-id>
<?supplied-pmid 32344167?><pub-id pub-id-type="pmid">32344167</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lip</surname><given-names>K.-M.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Keng</surname><given-names>C.-T.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Oh</surname><given-names>H.-L. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>80</volume>
<fpage>941</fpage>&#x02013;<lpage>950</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.80.2.941-950.2006</pub-id>
<?supplied-pmid 16378996?><pub-id pub-id-type="pmid">16378996</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C. A.</given-names></name><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Dominy</surname><given-names>B. W.</given-names></name><name><surname>Feeney</surname><given-names>P. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.</article-title>
<source><italic>Adv. Drug Deliv. Rev.</italic></source>
<volume>46</volume>
<fpage>3</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-409x(00)00129-0</pub-id><pub-id pub-id-type="pmid">11259830</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipman</surname><given-names>N. S.</given-names></name><name><surname>Jackson</surname><given-names>L. R.</given-names></name><name><surname>Trudel</surname><given-names>L. J.</given-names></name><name><surname>Weis-Garcia</surname><given-names>F.</given-names></name></person-group> (<year>2005</year>). <article-title>Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources.</article-title>
<source><italic>ILAR J.</italic></source>
<volume>46</volume>
<fpage>258</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1093/ilar.46.3.258</pub-id>
<?supplied-pmid 15953833?><pub-id pub-id-type="pmid">15953833</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.</article-title>
<source><italic>Cell Discov.</italic></source>
<volume>6</volume>
<fpage>1</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id>
<?supplied-pmid 32194981?><pub-id pub-id-type="pmid">31934347</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>G. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Bat-to-human: spike features determining &#x02018;host jump&#x02019; of coronaviruses SARS-CoV, MERS-CoV, and beyond.</article-title>
<source><italic>Trends Microbiol.</italic></source>
<volume>23</volume>
<fpage>468</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2015.06.003</pub-id>
<?supplied-pmid 26206723?><pub-id pub-id-type="pmid">26206723</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusvarghi</surname><given-names>S.</given-names></name><name><surname>Bewley</surname><given-names>C. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Griffithsin: an antiviral lectin with outstanding therapeutic potential.</article-title>
<source><italic>Viruses</italic></source>
<volume>8</volume>:<issue>296</issue>. <pub-id pub-id-type="doi">10.3390/v8100296</pub-id>
<?supplied-pmid 27783038?><pub-id pub-id-type="pmid">27783038</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Chan</surname><given-names>C. Y.</given-names></name><name><surname>He</surname><given-names>M. L.</given-names></name></person-group> (<year>2007</year>). <article-title>RNA interference and antiviral therapy.</article-title>
<source><italic>World J. Gastroenterol.</italic></source>
<volume>13</volume>
<fpage>5169</fpage>&#x02013;<lpage>5179</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v13.i39.5169</pub-id>
<?supplied-pmid 17876887?><pub-id pub-id-type="pmid">17876887</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madhugiri</surname><given-names>R.</given-names></name><name><surname>Karl</surname><given-names>N.</given-names></name><name><surname>Petersen</surname><given-names>D.</given-names></name><name><surname>Lamkiewicz</surname><given-names>K.</given-names></name><name><surname>Fricke</surname><given-names>M.</given-names></name><name><surname>Wend</surname><given-names>U.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Structural and functional conservation of cis-acting RNA elements in coronavirus 5&#x02019;-terminal genome regions.</article-title>
<source><italic>Virology</italic></source>
<volume>517</volume>
<fpage>44</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2017.11.025</pub-id>
<?supplied-pmid 29223446?><pub-id pub-id-type="pmid">29223446</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marasco</surname><given-names>W. A.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>The growth and potential of human antiviral monoclonal antibody therapeutics.</article-title>
<source><italic>Nat. Biotechnol.</italic></source>
<volume>25</volume>
<fpage>1421</fpage>&#x02013;<lpage>1434</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1363</pub-id>
<?supplied-pmid 18066039?><pub-id pub-id-type="pmid">18066039</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Nao</surname><given-names>N.</given-names></name><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>S.</given-names></name><name><surname>Takayama</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>117</volume>
<fpage>7001</fpage>&#x02013;<lpage>7003</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2002589117</pub-id>
<?supplied-pmid 32165541?><pub-id pub-id-type="pmid">32165541</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauthe</surname><given-names>M.</given-names></name><name><surname>Orhon</surname><given-names>I.</given-names></name><name><surname>Rocchi</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Luhr</surname><given-names>M.</given-names></name><name><surname>Hijlkema</surname><given-names>K.-J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion.</article-title>
<source><italic>Autophagy</italic></source>
<volume>14</volume>
<fpage>1435</fpage>&#x02013;<lpage>1455</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2018.1474314</pub-id>
<?supplied-pmid 29940786?><pub-id pub-id-type="pmid">29940786</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonagh</surname><given-names>P.</given-names></name><name><surname>Sheehy</surname><given-names>P. A.</given-names></name><name><surname>Norris</surname><given-names>J. M.</given-names></name></person-group> (<year>2011</year>). <article-title>In vitro inhibition of feline coronavirus replication by small interfering RNAs.</article-title>
<source><italic>Vet. Microbiol.</italic></source>
<volume>150</volume>
<fpage>220</fpage>&#x02013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2011.01.023</pub-id>
<?supplied-pmid 21367541?><pub-id pub-id-type="pmid">21367541</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonagh</surname><given-names>P.</given-names></name><name><surname>Sheehy</surname><given-names>P. A.</given-names></name><name><surname>Norris</surname><given-names>J. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro.</article-title>
<source><italic>Vet. Microbiol.</italic></source>
<volume>176</volume>
<fpage>10</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2014.12.009</pub-id>
<?supplied-pmid 25596968?><pub-id pub-id-type="pmid">25596968</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>McAuley</surname><given-names>D. F.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Tattersall</surname><given-names>R. S.</given-names></name><name><surname>Manson</surname><given-names>J. J.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19: consider cytokine storm syndromes and immunosuppression.</article-title>
<source><italic>Lancet Lond. Engl.</italic></source>
<volume>395</volume>
<fpage>1033</fpage>&#x02013;<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>J. K.</given-names></name><name><surname>S&#x000e9;ron</surname><given-names>K.</given-names></name><name><surname>Labitt</surname><given-names>R. N.</given-names></name><name><surname>Danneels</surname><given-names>A.</given-names></name><name><surname>Palmer</surname><given-names>K. E.</given-names></name><name><surname>Whittaker</surname><given-names>G. R.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>133</volume>
<fpage>1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.07.011</pub-id>
<?supplied-pmid 27424494?><pub-id pub-id-type="pmid">27424494</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>A. M.</given-names></name><name><surname>Nelson</surname><given-names>M.</given-names></name><name><surname>Jayaweera</surname><given-names>D.</given-names></name><name><surname>Ruxrungtham</surname><given-names>K.</given-names></name><name><surname>Cassetti</surname><given-names>I.</given-names></name><name><surname>Girard</surname><given-names>P.-M.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.</article-title>
<source><italic>AIDS</italic></source>
<volume>23</volume>
<fpage>1679</fpage>&#x02013;<lpage>1688</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32832d7350</pub-id>
<?supplied-pmid 19487905?><pub-id pub-id-type="pmid">19487905</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>D.</given-names></name><name><surname>Mohandas</surname><given-names>E.</given-names></name><name><surname>Rajat</surname><given-names>R.</given-names></name></person-group> (<year>1981</year>). <article-title>Chloroquine psychosis: a chemical psychosis?</article-title>
<source><italic>J. Natl. Med. Assoc.</italic></source>
<volume>73</volume>
<fpage>1073</fpage>&#x02013;<lpage>1076</lpage>.<pub-id pub-id-type="pmid">7310924</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>J. M.</given-names></name><name><surname>Delaugerre</surname><given-names>C.</given-names></name><name><surname>Le Goff</surname><given-names>J.</given-names></name><name><surname>Mela-Lima</surname><given-names>B.</given-names></name><name><surname>Ponscarme</surname><given-names>D.</given-names></name><name><surname>Goldwirt</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.</article-title>
<source><italic>Med. Mal. Infect.</italic></source>
<volume>50</volume>:<issue>384</issue>. <pub-id pub-id-type="doi">10.1016/j.medmal.2020.03.006</pub-id>
<?supplied-pmid 32240719?><pub-id pub-id-type="pmid">32240719</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morra</surname><given-names>M. E.</given-names></name><name><surname>Van Thanh</surname><given-names>L.</given-names></name><name><surname>Kamel</surname><given-names>M. G.</given-names></name><name><surname>Ghazy</surname><given-names>A. A.</given-names></name><name><surname>Altibi</surname><given-names>A. M. A.</given-names></name><name><surname>Dat</surname><given-names>L. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis.</article-title>
<source><italic>Rev. Med. Virol.</italic></source>
<volume>28</volume>:<issue>e1977</issue>. <pub-id pub-id-type="doi">10.1002/rmv.1977</pub-id>
<?supplied-pmid 29664167?><pub-id pub-id-type="pmid">29664167</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullard</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 vaccine development pipeline gears up.</article-title>
<source><italic>Lancet</italic></source>
<volume>395</volume>
<fpage>1751</fpage>&#x02013;<lpage>1752</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31252-6</pub-id><pub-id pub-id-type="pmid">32505245</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>F.</given-names></name><name><surname>Middleton</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). &#x0201c;<article-title>45 - Cytostatic and cytotoxic drugs</article-title>,&#x0201d; in <source><italic>Side Effects of Drugs Annual A Worldwide Yearly Survey of New data in Adverse drug Reactions and Interactions</italic></source>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Aronson</surname><given-names>J. K.</given-names></name></person-group> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>731</fpage>&#x02013;<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-444-59499-0.00045-3</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mzayek</surname><given-names>F.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Mather</surname><given-names>F. J.</given-names></name><name><surname>Wasilevich</surname><given-names>E. C.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Hadi</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers.</article-title>
<source><italic>PLoS Clin. Trials</italic></source>
<volume>2</volume>:<issue>e6</issue>. <pub-id pub-id-type="doi">10.1371/journal.pctr.0020006</pub-id>
<?supplied-pmid 17213921?><pub-id pub-id-type="pmid">17213921</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="book"><collab>National Research Council (US) Committee on Applications of Toxicogenomic Technologies to Predictive Toxicology</collab> (<year>2007</year>). <source><italic>Application to the Study of Mechanisms of Action.</italic></source>
<publisher-loc>Washington DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>.</mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natoli</surname><given-names>S.</given-names></name><name><surname>Oliveira</surname><given-names>V.</given-names></name><name><surname>Calabresi</surname><given-names>P.</given-names></name><name><surname>Maia</surname><given-names>L. F.</given-names></name><name><surname>Pisani</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Does SARS-Cov-2 invade the brain? Translational lessons from animal models.</article-title>
<source><italic>Eur. J. Neurol.</italic></source>
<volume>22</volume>:<issue>10.1111/ene.14277</issue>. <pub-id pub-id-type="doi">10.1111/ene.14277</pub-id>
<?supplied-pmid 32333487?><pub-id pub-id-type="pmid">32333487</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keefe</surname><given-names>B. R.</given-names></name><name><surname>Giomarelli</surname><given-names>B.</given-names></name><name><surname>Barnard</surname><given-names>D. L.</given-names></name><name><surname>Shenoy</surname><given-names>S. R.</given-names></name><name><surname>Chan</surname><given-names>P. K. S.</given-names></name><name><surname>McMahon</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>84</volume>
<fpage>2511</fpage>&#x02013;<lpage>2521</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02322-09</pub-id>
<?supplied-pmid 20032190?><pub-id pub-id-type="pmid">20032190</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olearo</surname><given-names>F.</given-names></name><name><surname>Nguyen</surname><given-names>H.</given-names></name><name><surname>Bonnet</surname><given-names>F.</given-names></name><name><surname>Yerly</surname><given-names>S.</given-names></name><name><surname>Wandeler</surname><given-names>G.</given-names></name><name><surname>Stoeckle</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Impact of the M184V/I mutation on the efficacy of Abacavir/Lamivudine/Dolutegravir therapy in HIV treatment-experienced patients.</article-title>
<source><italic>Open Forum Infect. Dis.</italic></source>
<volume>6</volume>:<issue>ofz330</issue>. <pub-id pub-id-type="doi">10.1093/ofid/ofz330</pub-id>
<?supplied-pmid 31660328?><pub-id pub-id-type="pmid">31660328</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parris</surname><given-names>G. E.</given-names></name></person-group> (<year>2004</year>). <article-title>Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites.</article-title>
<source><italic>Med. Hypotheses</italic></source>
<volume>62</volume>
<fpage>354</fpage>&#x02013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2003.12.004</pub-id>
<?supplied-pmid 14975502?><pub-id pub-id-type="pmid">14975502</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). &#x0201c;<article-title>Chapter 17 - Family Coronaviridae</article-title>,&#x0201d; in <source><italic>Viruses</italic></source>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Payne</surname><given-names>S.</given-names></name></person-group> (<publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>149</fpage>&#x02013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-803109-4.00017-9</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>N. C.</given-names></name><name><surname>Black</surname><given-names>J. W.</given-names></name><name><surname>Boyle</surname><given-names>J. F.</given-names></name><name><surname>Evermann</surname><given-names>J. F.</given-names></name><name><surname>McKeirnan</surname><given-names>A. J.</given-names></name><name><surname>Ott</surname><given-names>R. L.</given-names></name></person-group> (<year>1984</year>). &#x0201c;<article-title>Pathogenic differences between various feline coronavirus isolates</article-title>,&#x0201d; in <source><italic>Molecular Biology and Pathogenesis of Coronaviruses Advances in Experimental Medicine and Biology</italic></source>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Rottier</surname><given-names>P. J. M.</given-names></name><name><surname>van der Zeijst</surname><given-names>B. A. M.</given-names></name><name><surname>Spaan</surname><given-names>W. J. M.</given-names></name><name><surname>Horzinek</surname><given-names>M. C.</given-names></name></person-group> (<publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>365</fpage>&#x02013;<lpage>380</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4615-9373-7_36</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>H. L.</given-names></name><name><surname>Jochmans</surname><given-names>D.</given-names></name><name><surname>de Wilde</surname><given-names>A. H.</given-names></name><name><surname>Posthuma</surname><given-names>C. C.</given-names></name><name><surname>Snijder</surname><given-names>E. J.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.</article-title>
<source><italic>Bioorg. Med. Chem. Lett.</italic></source>
<volume>25</volume>
<fpage>2923</fpage>&#x02013;<lpage>2926</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2015.05.039</pub-id>
<?supplied-pmid 26048809?><pub-id pub-id-type="pmid">26048809</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettitt</surname><given-names>J.</given-names></name><name><surname>Zeitlin</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>D. H.</given-names></name><name><surname>Working</surname><given-names>C.</given-names></name><name><surname>Johnson</surname><given-names>J. C.</given-names></name><name><surname>Bohorov</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Therapeutic intervention of ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.</article-title>
<source><italic>Sci. Transl. Med.</italic></source>
<volume>5</volume>
<fpage>ra113</fpage>&#x02013;<lpage>ra199</lpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3006608</pub-id>
<?supplied-pmid 23966302?><pub-id pub-id-type="pmid">23966302</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Sch&#x000f6;pf</surname><given-names>J.</given-names></name><name><surname>K&#x000f6;gl</surname><given-names>M.</given-names></name><name><surname>Friedel</surname><given-names>C. C.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M. A.</given-names></name><name><surname>Carbajo-Lozoya</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>The SARS-Coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>7</volume>:<issue>e1002331</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1002331</pub-id>
<?supplied-pmid 22046132?><pub-id pub-id-type="pmid">22046132</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prabakaran</surname><given-names>P.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Dimitrov</surname><given-names>D. S.</given-names></name></person-group> (<year>2004</year>). <article-title>A model of the ACE2 structure and function as a SARS-CoV receptor.</article-title>
<source><italic>Biochem. Biophys. Res. Commun.</italic></source>
<volume>314</volume>
<fpage>235</fpage>&#x02013;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2003.12.081</pub-id>
<?supplied-pmid 14715271?><pub-id pub-id-type="pmid">14715271</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preobrazhenskaya</surname><given-names>M. N.</given-names></name><name><surname>Olsufyeva</surname><given-names>E. N.</given-names></name></person-group> (<year>2004</year>). <article-title>Patents on glycopeptides of the vancomycin family and their derivatives as antimicrobials: January 1999 &#x02013; June 2003.</article-title>
<source><italic>Expert Opin. Ther. Pat.</italic></source>
<volume>14</volume>
<fpage>141</fpage>&#x02013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1517/13543776.14.2.141</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Printsevskaya</surname><given-names>S. S.</given-names></name><name><surname>Solovieva</surname><given-names>S. E.</given-names></name><name><surname>Olsufyeva</surname><given-names>E. N.</given-names></name><name><surname>Mirchink</surname><given-names>E. P.</given-names></name><name><surname>Isakova</surname><given-names>E. B.</given-names></name><name><surname>De Clercq</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>48</volume>
<fpage>3885</fpage>&#x02013;<lpage>3890</lpage>. <pub-id pub-id-type="doi">10.1021/jm0500774</pub-id>
<?supplied-pmid 15916441?><pub-id pub-id-type="pmid">15916441</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proskurnina</surname><given-names>E. V.</given-names></name><name><surname>Izmailov</surname><given-names>D. Y.</given-names></name><name><surname>Sozarukova</surname><given-names>M. M.</given-names></name><name><surname>Zhuravleva</surname><given-names>T. A.</given-names></name><name><surname>Leneva</surname><given-names>I. A.</given-names></name><name><surname>Poromov</surname><given-names>A. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Antioxidant potential of antiviral drug umifenovir.</article-title>
<source><italic>Molecules</italic></source>
<volume>25</volume>:<issue>1577</issue>. <pub-id pub-id-type="doi">10.3390/molecules25071577</pub-id>
<?supplied-pmid 32235534?><pub-id pub-id-type="pmid">32235534</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><collab>PubChem</collab> (<year>2005a</year>). <source><italic>Cyclosporin A.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/5284373">https://pubchem.ncbi.nlm.nih.gov/compound/5284373</ext-link>
<comment>(accessed April 1, 2020)</comment>.</mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><collab>PubChem</collab> (<year>2005b</year>). <source><italic>Mycophenolic Acid.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/446541">https://pubchem.ncbi.nlm.nih.gov/compound/446541</ext-link>
<comment>(accessed April 1, 2020)</comment>.</mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><collab>PubChem.</collab> (<year>2005c</year>). <source><italic>Ribavirin.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/37542">https://pubchem.ncbi.nlm.nih.gov/compound/37542</ext-link>
<comment>(accessed April 1, 2020)</comment>.</mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pukrittayakamee</surname><given-names>S.</given-names></name><name><surname>Tarning</surname><given-names>J.</given-names></name><name><surname>Jittamala</surname><given-names>P.</given-names></name><name><surname>Charunwatthana</surname><given-names>P.</given-names></name><name><surname>Lawpoolsri</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>S. J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Pharmacokinetic Interactions between Primaquine and Chloroquine.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>58</volume>
<fpage>3354</fpage>&#x02013;<lpage>3359</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02794-13</pub-id>
<?supplied-pmid 24687509?><pub-id pub-id-type="pmid">24687509</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyrc</surname><given-names>K.</given-names></name><name><surname>Bosch</surname><given-names>B. J.</given-names></name><name><surname>Berkhout</surname><given-names>B.</given-names></name><name><surname>Jebbink</surname><given-names>M. F.</given-names></name><name><surname>Dijkman</surname><given-names>R.</given-names></name><name><surname>Rottier</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>50</volume>
<fpage>2000</fpage>&#x02013;<lpage>2008</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01598-05</pub-id>
<?supplied-pmid 16723558?><pub-id pub-id-type="pmid">16723558</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabi</surname><given-names>F. A.</given-names></name><name><surname>Al Zoubi</surname><given-names>M. S.</given-names></name><name><surname>Kasasbeh</surname><given-names>G. A.</given-names></name><name><surname>Salameh</surname><given-names>D. M.</given-names></name><name><surname>Al-Nasser</surname><given-names>A. D.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 and Coronavirus disease 2019: what we know so far.</article-title>
<source><italic>Pathog. Basel Switz.</italic></source>
<volume>9</volume>:<issue>231</issue>. <pub-id pub-id-type="doi">10.3390/pathogens9030231</pub-id>
<?supplied-pmid 32245083?><pub-id pub-id-type="pmid">32245083</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramajayam</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>K.-P.</given-names></name><name><surname>Liu</surname><given-names>H.-G.</given-names></name><name><surname>Liang</surname><given-names>P.-H.</given-names></name></person-group> (<year>2010</year>). <article-title>Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.</article-title>
<source><italic>Bioorg. Med. Chem. Lett.</italic></source>
<volume>20</volume>
<fpage>3569</fpage>&#x02013;<lpage>3572</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2010.04.118</pub-id>
<?supplied-pmid 20494577?><pub-id pub-id-type="pmid">20494577</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ramos-Tovar</surname><given-names>E.</given-names></name><name><surname>Muriel</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). &#x0201c;<article-title>Chapter 9 - phytotherapy for the liver</article-title>,&#x0201d; in <source><italic>Dietary Interventions in Liver Disease</italic></source>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Watson</surname><given-names>R. R.</given-names></name><name><surname>Preedy</surname><given-names>V. R.</given-names></name></person-group> (<publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>101</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-814466-4.00009-4</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranieri</surname><given-names>V. M.</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V.</given-names></name><name><surname>Karvonen</surname><given-names>M. K.</given-names></name><name><surname>Jalkanen</surname><given-names>J.</given-names></name><name><surname>Nightingale</surname><given-names>P.</given-names></name><name><surname>Brealey</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effect of intravenous interferon &#x003b2;-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial.</article-title>
<source><italic>JAMA</italic></source>
<volume>323</volume>
<fpage>725</fpage>&#x02013;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2019.22525</pub-id>
<?supplied-pmid 32065831?><pub-id pub-id-type="pmid">32065831</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reguera</surname><given-names>J.</given-names></name><name><surname>Santiago</surname><given-names>C.</given-names></name><name><surname>Mudgal</surname><given-names>G.</given-names></name><name><surname>Ordo&#x000f1;o</surname><given-names>D.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name><name><surname>Casasnovas</surname><given-names>J. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Structural bases of coronavirus attachment to host aminopeptidase n and its inhibition by neutralizing antibodies.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>8</volume>:<issue>e1002859</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1002859</pub-id>
<?supplied-pmid 22876187?><pub-id pub-id-type="pmid">22876187</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reusken</surname><given-names>C. B.</given-names></name><name><surname>Raj</surname><given-names>V. S.</given-names></name><name><surname>Koopmans</surname><given-names>M. P.</given-names></name><name><surname>Haagmans</surname><given-names>B. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Cross host transmission in the emergence of MERS coronavirus.</article-title>
<source><italic>Curr. Opin. Virol.</italic></source>
<volume>16</volume>
<fpage>55</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2016.01.004</pub-id>
<?supplied-pmid 26826951?><pub-id pub-id-type="pmid">26826951</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roback</surname><given-names>J. D.</given-names></name><name><surname>Guarner</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Convalescent plasma to Treat COVID-19: possibilities and challenges.</article-title>
<source><italic>JAMA</italic></source>
<volume>323</volume>
<fpage>1561</fpage>&#x02013;<lpage>1562</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.4940</pub-id>
<?supplied-pmid 32219429?><pub-id pub-id-type="pmid">32219429</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>R. S.</given-names></name><name><surname>Yount</surname><given-names>B. L.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Baker</surname><given-names>S.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name></person-group> (<year>2006</year>). &#x0201c;<article-title>Renilla luciferase as a reporter to assess SARS-CoV mRNA transcription regulation and efficacy of ANTI-SARS-CoV agents</article-title>,&#x0201d; in <source><italic>The Nidoviruses Advances in Experimental Medicine and Biology</italic></source>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Holmes</surname><given-names>K. V.</given-names></name></person-group> (<publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>597</fpage>&#x02013;<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-33012-9_108</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>P.</given-names></name><name><surname>Thiberville</surname><given-names>S.-D.</given-names></name><name><surname>Dupuis-Maguiraga</surname><given-names>L.</given-names></name><name><surname>Lum</surname><given-names>F.-M.</given-names></name><name><surname>Labadie</surname><given-names>K.</given-names></name><name><surname>Martinon</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection.</article-title>
<source><italic>Viruses</italic></source>
<volume>10</volume>:<issue>268</issue>. <pub-id pub-id-type="doi">10.3390/v10050268</pub-id>
<?supplied-pmid 29772762?><pub-id pub-id-type="pmid">29772762</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>J.-F.</given-names></name></person-group> (<year>2014</year>). <article-title>Nitazoxanide: a first-in-class broad-spectrum antiviral agent.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>110</volume>
<fpage>94</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2014.07.014</pub-id>
<?supplied-pmid 25108173?><pub-id pub-id-type="pmid">25108173</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>J.-F.</given-names></name></person-group> (<year>2016</year>). <article-title>Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.</article-title>
<source><italic>J. Infect. Public Health</italic></source>
<volume>9</volume>
<fpage>227</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2016.04.001</pub-id>
<?supplied-pmid 27095301?><pub-id pub-id-type="pmid">27095301</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G.</given-names></name><name><surname>Ramos-Casals</surname><given-names>M.</given-names></name><name><surname>Brito-Zeron</surname><given-names>P.</given-names></name><name><surname>Khamashta</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.</article-title>
<source><italic>Ann. Rheum. Dis.</italic></source>
<volume>69</volume>
<fpage>20</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2008.101766</pub-id>
<?supplied-pmid 19103632?><pub-id pub-id-type="pmid">19103632</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saijo</surname><given-names>M.</given-names></name><name><surname>Morikawa</surname><given-names>S.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Mizutani</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>H.</given-names></name><name><surname>Nagata</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>66</volume>
<fpage>159</fpage>&#x02013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.01.003</pub-id>
<?supplied-pmid 15911031?><pub-id pub-id-type="pmid">15911031</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallard</surname><given-names>E.</given-names></name><name><surname>Lescure</surname><given-names>F.-X.</given-names></name><name><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><name><surname>Mentre</surname><given-names>F.</given-names></name><name><surname>Peiffer-Smadja</surname><given-names>N.</given-names></name></person-group> (<year>2020</year>). <article-title>Type 1 interferons as a potential treatment against COVID-19.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>178</volume>:<issue>104791</issue>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104791</pub-id>
<?supplied-pmid 32275914?><pub-id pub-id-type="pmid">32275914</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>C. E.</given-names></name></person-group> (<year>2001</year>). <article-title>Antiviral Actions of Interferons.</article-title>
<source><italic>Clin. Microbiol. Rev.</italic></source>
<volume>14</volume>
<fpage>778</fpage>&#x02013;<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.14.4.778-809.2001</pub-id>
<?supplied-pmid 11585785?><pub-id pub-id-type="pmid">11585785</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sanan-Mishra</surname><given-names>N.</given-names></name><name><surname>Chakraborty</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>D.</given-names></name><name><surname>Mukherjee</surname><given-names>S. K.</given-names></name></person-group> (<year>2017</year>). &#x0201c;<article-title>RNAi Suppressors: biology and Mechanisms</article-title>,&#x0201d; in <source><italic>Plant Epigenetics RNA Technologies</italic></source>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Rajewsky</surname><given-names>N.</given-names></name><name><surname>Jurga</surname><given-names>S.</given-names></name><name><surname>Barciszewski</surname><given-names>J.</given-names></name></person-group> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>199</fpage>&#x02013;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-55520-1_11</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayce</surname><given-names>A. C.</given-names></name><name><surname>Miller</surname><given-names>J. L.</given-names></name><name><surname>Zitzmann</surname><given-names>N.</given-names></name></person-group> (<year>2010</year>). <article-title>Targeting a host process as an antiviral approach against dengue virus.</article-title>
<source><italic>Trends Microbiol.</italic></source>
<volume>18</volume>
<fpage>323</fpage>&#x02013;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2010.04.003</pub-id>
<?supplied-pmid 20452219?><pub-id pub-id-type="pmid">20452219</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheller</surname><given-names>J.</given-names></name><name><surname>Rose-John</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Interleukin-6 and its receptor: from bench to bedside.</article-title>
<source><italic>Med. Microbiol. Immunol.</italic></source>
<volume>195</volume>
<fpage>173</fpage>&#x02013;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1007/s00430-006-0019-9</pub-id>
<?supplied-pmid 16741736?><pub-id pub-id-type="pmid">16741736</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Schwarz</surname><given-names>W.</given-names></name></person-group> (<year>2011</year>). <article-title>Emodin inhibits current through SARS-associated coronavirus 3a protein.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>90</volume>
<fpage>64</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2011.02.008</pub-id>
<?supplied-pmid 21356245?><pub-id pub-id-type="pmid">21356245</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>P. P.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Kaletsky</surname><given-names>R. L.</given-names></name><name><surname>Myers</surname><given-names>M. C.</given-names></name><name><surname>Purvis</surname><given-names>J. E.</given-names></name><name><surname>Jing</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.</article-title>
<source><italic>Mol. Pharmacol.</italic></source>
<volume>78</volume>
<fpage>319</fpage>&#x02013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1124/mol.110.064261</pub-id>
<?supplied-pmid 20466822?><pub-id pub-id-type="pmid">20466822</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>P. S.</given-names></name><name><surname>Schaffer</surname><given-names>D. V.</given-names></name></person-group> (<year>2011</year>). <article-title>Antiviral RNAi: translating science towards therapeutic success.</article-title>
<source><italic>Pharm. Res.</italic></source>
<volume>28</volume>
<fpage>2966</fpage>&#x02013;<lpage>2982</lpage>. <pub-id pub-id-type="doi">10.1007/s11095-011-0549-8</pub-id>
<?supplied-pmid 21826573?><pub-id pub-id-type="pmid">21826573</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugaraj</surname><given-names>B.</given-names></name><name><surname>Siriwattananon</surname><given-names>K.</given-names></name><name><surname>Wangkanont</surname><given-names>K.</given-names></name><name><surname>Phoolcharoen</surname><given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).</article-title>
<source><italic>Asian Pac. J. Allergy Immunol.</italic></source>
<volume>38</volume>
<fpage>10</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.12932/AP-200220-0773</pub-id>
<?supplied-pmid 32134278?><pub-id pub-id-type="pmid">32134278</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T. P.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Graham</surname><given-names>R. L.</given-names></name><name><surname>Menachery</surname><given-names>V. D.</given-names></name><name><surname>Gralinski</surname><given-names>L. E.</given-names></name><name><surname>Case</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.</article-title>
<source><italic>Sci. Transl. Med.</italic></source>
<volume>9</volume>:<issue>eaal3653</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aal3653</pub-id>
<?supplied-pmid 28659436?><pub-id pub-id-type="pmid">28659436</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T. P.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Leist</surname><given-names>S. R.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Won</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.</article-title>
<source><italic>Nat. Commun.</italic></source>
<volume>11</volume>
<fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id>
<?supplied-pmid 31924756?><pub-id pub-id-type="pmid">31911652</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T. P.</given-names></name><name><surname>Sims</surname><given-names>A. C.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Graham</surname><given-names>R. L.</given-names></name><name><surname>Pruijssers</surname><given-names>A. J.</given-names></name><name><surname>Agostini</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.</article-title>
<source><italic>Sci. Transl. Med.</italic></source>
<volume>6</volume>:<issue>eabb5883</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abb5883</pub-id>
<?supplied-pmid 32253226?><pub-id pub-id-type="pmid">32253226</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Desforges</surname><given-names>M.</given-names></name><name><surname>Talbot</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Safe and sensitive antiviral screening platform based on recombinant human Coronavirus OC43 expressing the luciferase reporter gene.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>60</volume>
<fpage>5492</fpage>&#x02013;<lpage>5503</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00814-16</pub-id>
<?supplied-pmid 27381385?><pub-id pub-id-type="pmid">27381385</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>D. H.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Jin</surname><given-names>Y. X.</given-names></name></person-group> (<year>2005</year>). <article-title>Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs.</article-title>
<source><italic>Cell Res.</italic></source>
<volume>15</volume>
<fpage>193</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cr.7290286</pub-id>
<?supplied-pmid 15780182?><pub-id pub-id-type="pmid">15780182</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shie</surname><given-names>J.-J.</given-names></name><name><surname>Fang</surname><given-names>J.-M.</given-names></name><name><surname>Kuo</surname><given-names>T.-H.</given-names></name><name><surname>Kuo</surname><given-names>C.-J.</given-names></name><name><surname>Liang</surname><given-names>P.-H.</given-names></name><name><surname>Huang</surname><given-names>H.-J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic &#x003b1;,&#x003b2;-unsaturated esters.</article-title>
<source><italic>Bioorg. Med. Chem.</italic></source>
<volume>13</volume>
<fpage>5240</fpage>&#x02013;<lpage>5252</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2005.05.065</pub-id>
<?supplied-pmid 15994085?><pub-id pub-id-type="pmid">15994085</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>J. S.</given-names></name><name><surname>Jung</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name><name><surname>Go</surname><given-names>Y. Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro.</article-title>
<source><italic>Viruses</italic></source>
<volume>10</volume>:<issue>283</issue>. <pub-id pub-id-type="doi">10.3390/v10060283</pub-id>
<?supplied-pmid 29795047?><pub-id pub-id-type="pmid">29795047</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>Y. L.</given-names></name><name><surname>Teoh</surname><given-names>K. T.</given-names></name><name><surname>Lo</surname><given-names>J.</given-names></name><name><surname>Chan</surname><given-names>C. M.</given-names></name><name><surname>Kien</surname><given-names>F.</given-names></name><name><surname>Escriou</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>82</volume>
<fpage>11318</fpage>&#x02013;<lpage>11330</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01052-08</pub-id>
<?supplied-pmid 18753196?><pub-id pub-id-type="pmid">18753196</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <source><italic>CureVac Bids to Develop First mRNA Coronavirus Vaccine.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.labiotech.eu/medical/curevac-coronavirus-outbreak-cepi/">https://www.labiotech.eu/medical/curevac-coronavirus-outbreak-cepi/</ext-link>
<comment>(accessed June 8, 2020)</comment></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperber</surname><given-names>S. J.</given-names></name><name><surname>Hayden</surname><given-names>F. G.</given-names></name></person-group> (<year>1989</year>). <article-title>Comparative susceptibility of respiratory viruses to recombinant interferons-&#x003b1;2b and -&#x003b2;.</article-title>
<source><italic>J. Interferon Res.</italic></source>
<volume>9</volume>
<fpage>285</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1089/jir.1989.9.285</pub-id>
<?supplied-pmid 2545792?><pub-id pub-id-type="pmid">2545792</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stocks</surname><given-names>P. A.</given-names></name><name><surname>Raynes</surname><given-names>K. J.</given-names></name><name><surname>Bray</surname><given-names>P. G.</given-names></name><name><surname>Park</surname><given-names>B. K.</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>P. M.</given-names></name><name><surname>Ward</surname><given-names>S. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 plasmodium falciparum.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>45</volume>
<fpage>4975</fpage>&#x02013;<lpage>4983</lpage>. <pub-id pub-id-type="doi">10.1021/jm0108707</pub-id>
<?supplied-pmid 12408708?><pub-id pub-id-type="pmid">12408708</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struck</surname><given-names>A.-W.</given-names></name><name><surname>Axmann</surname><given-names>M.</given-names></name><name><surname>Pfefferle</surname><given-names>S.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>94</volume>
<fpage>288</fpage>&#x02013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2011.12.012</pub-id>
<?supplied-pmid 22265858?><pub-id pub-id-type="pmid">22265858</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development.</article-title>
<source><italic>bioRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.02.16.951723</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Pu</surname><given-names>J.</given-names></name><name><surname>Voronin</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.</article-title>
<source><italic>Cell. Mol. Immunol.</italic></source>
<volume>17</volume>
<fpage>613</fpage>&#x02013;<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0400-4</pub-id>
<?supplied-pmid 32203189?><pub-id pub-id-type="pmid">32203189</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>T.</given-names></name><name><surname>Katoh</surname><given-names>Y.</given-names></name><name><surname>Doki</surname><given-names>T.</given-names></name><name><surname>Hohdatsu</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>99</volume>
<fpage>100</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.04.016</pub-id>
<?supplied-pmid 23648708?><pub-id pub-id-type="pmid">23648708</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takashita</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Influenza polymerase inhibitors: mechanisms of action and resistance.</article-title>
<source><italic>Cold Spring Harb. Perspect. Med.</italic></source>
<volume>2</volume>:<issue>a038687</issue>. <pub-id pub-id-type="doi">10.1101/cshperspect.a038687</pub-id>
<?supplied-pmid 32122918?><pub-id pub-id-type="pmid">32122918</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>E. L. C.</given-names></name><name><surname>Ooi</surname><given-names>E. E.</given-names></name><name><surname>Lin</surname><given-names>C.-Y.</given-names></name><name><surname>Tan</surname><given-names>H. C.</given-names></name><name><surname>Ling</surname><given-names>A. E.</given-names></name><name><surname>Lim</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Inhibition of SARS Coronavirus infection in vitro with clinically approved antiviral drugs.</article-title>
<source><italic>Emerg. Infect. Dis.</italic></source>
<volume>10</volume>
<fpage>581</fpage>&#x02013;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.3201/eid1004.030458</pub-id>
<?supplied-pmid 15200845?><pub-id pub-id-type="pmid">15200845</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>J. A.</given-names></name><name><surname>Zheng</surname><given-names>B.-J.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Watt</surname><given-names>R. M.</given-names></name><name><surname>Jiang</surname><given-names>J.-Q.</given-names></name><name><surname>Wong</surname><given-names>K.-L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS Coronavirus.</article-title>
<source><italic>Chem. Biol.</italic></source>
<volume>12</volume>
<fpage>303</fpage>&#x02013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1016/j.chembiol.2005.01.006</pub-id>
<?supplied-pmid 15797214?><pub-id pub-id-type="pmid">15797214</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>M. Y. F.</given-names></name><name><surname>Fraser</surname><given-names>J. E.</given-names></name><name><surname>Chan</surname><given-names>W. K. K.</given-names></name><name><surname>Moreland</surname><given-names>N. J.</given-names></name><name><surname>Rathore</surname><given-names>A. P.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Nuclear localization of dengue virus (DENV) 1&#x02013;4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>99</volume>
<fpage>301</fpage>&#x02013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.06.002</pub-id>
<?supplied-pmid 23769930?><pub-id pub-id-type="pmid">23769930</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>S. M.</given-names></name><name><surname>Brugge</surname><given-names>J. S.</given-names></name></person-group> (<year>1997</year>). <article-title>Cellular functions regulated by Src family kinases.</article-title>
<source><italic>Annu. Rev. Cell Dev. Biol.</italic></source>
<volume>13</volume>
<fpage>513</fpage>&#x02013;<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.cellbio.13.1.513</pub-id>
<?supplied-pmid 9442882?><pub-id pub-id-type="pmid">9442882</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <source><italic>The Oxford Vaccine Centre COVID-19 Phase II/III Clinical Trial Explained. COVID-19 Oxf. Vaccine Trial.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://covid19vaccinetrial.co.uk/phase-iiiii-trial-explained">https://covid19vaccinetrial.co.uk/phase-iiiii-trial-explained</ext-link>
<comment>(accessed July 1, 2020)</comment>.</mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toniati</surname><given-names>P.</given-names></name><name><surname>Piva</surname><given-names>S.</given-names></name><name><surname>Cattalini</surname><given-names>M.</given-names></name><name><surname>Garrafa</surname><given-names>E.</given-names></name><name><surname>Regola</surname><given-names>F.</given-names></name><name><surname>Castelli</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia. Italy.</article-title>
<source><italic>Autoimmun. Rev.</italic></source>
<volume>19</volume>:<issue>102568</issue>. <pub-id pub-id-type="doi">10.1016/j.autrev.2020.102568</pub-id>
<?supplied-pmid 32376398?><pub-id pub-id-type="pmid">32376398</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>A. L.</given-names></name><name><surname>Bavari</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Broad-spectrum coronavirus antiviral drug discovery.</article-title>
<source><italic>Expert Opin. Drug Discov.</italic></source>
<volume>14</volume>
<fpage>397</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2019.1581171</pub-id>
<?supplied-pmid 30849247?><pub-id pub-id-type="pmid">30849247</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Y.-F.</given-names></name><name><surname>Chien</surname><given-names>C.-S.</given-names></name><name><surname>Yarmishyn</surname><given-names>A. A.</given-names></name><name><surname>Lin</surname><given-names>Y.-Y.</given-names></name><name><surname>Luo</surname><given-names>Y.-H.</given-names></name><name><surname>Lin</surname><given-names>Y.-T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A review of SARS-CoV-2 and the ongoing clinical trials.</article-title>
<source><italic>Int. J. Mol. Sci.</italic></source>
<volume>21</volume>:<issue>2657</issue>. <pub-id pub-id-type="doi">10.3390/ijms21072657</pub-id>
<?supplied-pmid 32290293?><pub-id pub-id-type="pmid">32290293</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullah</surname><given-names>H.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Dakshanamurthy</surname><given-names>S.</given-names></name><name><surname>Tang</surname><given-names>Q.</given-names></name></person-group> (<year>2019</year>). <article-title>Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>10</volume>
<fpage>3209</fpage>&#x02013;<lpage>3226</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.26907</pub-id>
<?supplied-pmid 31143369?><pub-id pub-id-type="pmid">31143369</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Un&#x000fc;bol</surname><given-names>M.</given-names></name><name><surname>Ayhan</surname><given-names>M.</given-names></name><name><surname>Guney</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis.</article-title>
<source><italic>J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis.</italic></source>
<volume>17</volume>
<fpage>46</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1097/RHU.0b013e3182098e1f</pub-id>
<?supplied-pmid 21169846?><pub-id pub-id-type="pmid">21169846</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ursing</surname><given-names>J.</given-names></name><name><surname>Rombo</surname><given-names>L.</given-names></name><name><surname>Eksborg</surname><given-names>S.</given-names></name><name><surname>Larson</surname><given-names>L.</given-names></name><name><surname>Bruvoll</surname><given-names>A.</given-names></name><name><surname>Tarning</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>High-dose chloroquine for uncomplicated plasmodium falciparum malaria is well tolerated and causes similar QT interval prolongation as standard-dose chloroquine in children.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>64</volume>:<issue>e01846-19</issue>. <pub-id pub-id-type="doi">10.1128/AAC.01846-19</pub-id>
<?supplied-pmid 31907183?><pub-id pub-id-type="pmid">31907183</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Bushmaker</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>D. H.</given-names></name><name><surname>Holbrook</surname><given-names>M. G.</given-names></name><name><surname>Gamble</surname><given-names>A.</given-names></name><name><surname>Williamson</surname><given-names>B. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>382</volume>
<fpage>1564</fpage>&#x02013;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id>
<?supplied-pmid 32182409?><pub-id pub-id-type="pmid">32182409</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>F. S.</given-names></name><name><surname>Kaukinen</surname><given-names>P.</given-names></name><name><surname>Gl&#x000e4;sker</surname><given-names>S.</given-names></name><name><surname>Bespalov</surname><given-names>M.</given-names></name><name><surname>Hanski</surname><given-names>L.</given-names></name><name><surname>Wennerberg</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses.</article-title>
<source><italic>Antiviral Res.</italic></source>
<volume>126</volume>
<fpage>117</fpage>&#x02013;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.12.012</pub-id>
<?supplied-pmid 26752081?><pub-id pub-id-type="pmid">26752081</pub-id></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vass&#x000e3;o</surname><given-names>R. C.</given-names></name><name><surname>de Franco</surname><given-names>M. T.</given-names></name><name><surname>Hartz</surname><given-names>D.</given-names></name><name><surname>Modolell</surname><given-names>M.</given-names></name><name><surname>Sippel</surname><given-names>A. E.</given-names></name><name><surname>Pereira</surname><given-names>C. A.</given-names></name></person-group> (<year>2000</year>). <article-title>Down-regulation of bgp1a viral receptor by interferon-&#x003b3; Is related to the antiviral state and resistance to mouse hepatitis virus 3 infection.</article-title>
<source><italic>Virology</italic></source>
<volume>274</volume>
<fpage>278</fpage>&#x02013;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1006/viro.2000.0463</pub-id>
<?supplied-pmid 10964771?><pub-id pub-id-type="pmid">10964771</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villegas-Rosales</surname><given-names>P. M.</given-names></name><name><surname>M&#x000e9;ndez-Tenorio</surname><given-names>A.</given-names></name><name><surname>Ortega-Soto</surname><given-names>E.</given-names></name><name><surname>Barr&#x000f3;n</surname><given-names>B. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Bioinformatics prediction of siRNAs as potential antiviral agents against dengue viruses.</article-title>
<source><italic>Bioinformation</italic></source>
<volume>8</volume>
<fpage>519</fpage>&#x02013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.6026/97320630008519</pub-id>
<?supplied-pmid 22829722?><pub-id pub-id-type="pmid">22829722</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>M. J.</given-names></name><name><surname>Bergeron</surname><given-names>E.</given-names></name><name><surname>Benjannet</surname><given-names>S.</given-names></name><name><surname>Erickson</surname><given-names>B. R.</given-names></name><name><surname>Rollin</surname><given-names>P. E.</given-names></name><name><surname>Ksiazek</surname><given-names>T. G.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.</article-title>
<source><italic>Virol. J.</italic></source>
<volume>2</volume>:<issue>69</issue>. <pub-id pub-id-type="doi">10.1186/1743-422X-2-69</pub-id>
<?supplied-pmid 16115318?><pub-id pub-id-type="pmid">16115318</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname><given-names>W.</given-names></name><name><surname>Khan</surname><given-names>M. B.</given-names></name><name><surname>Fischer</surname><given-names>C.</given-names></name><name><surname>Arutyunova</surname><given-names>E.</given-names></name><name><surname>Lamer</surname><given-names>T.</given-names></name><name><surname>Shields</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.</article-title>
<source><italic>bioRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.05.03.073080</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A. C.</given-names></name><name><surname>Park</surname><given-names>Y.-J.</given-names></name><name><surname>Tortorici</surname><given-names>M. A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A. T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.</article-title>
<source><italic>Cell</italic></source>
<volume>181</volume>
<fpage>281e6</fpage>&#x02013;<lpage>292.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id>
<?supplied-pmid 32155444?><pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Drabek</surname><given-names>D.</given-names></name><name><surname>Okba</surname><given-names>N. M. A.</given-names></name><name><surname>van Haperen</surname><given-names>R.</given-names></name><name><surname>Osterhaus</surname><given-names>A. D. M. E.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>A human monoclonal antibody blocking SARS-CoV-2 infection.</article-title>
<source><italic>Nat. Commun.</italic></source>
<volume>11</volume>:<issue>2251</issue>. <pub-id pub-id-type="doi">10.1038/s41467-020-16256-y</pub-id>
<?supplied-pmid 32366817?><pub-id pub-id-type="pmid">32366817</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.</article-title>
<source><italic>Cell Res.</italic></source>
<volume>30</volume>:<fpage>269</fpage>&#x02013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>
<?supplied-pmid 32020029?><pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China.</article-title>
<source><italic>medRxiv [Preprint]</italic></source>
<pub-id pub-id-type="doi">10.1101/2020.03.06.20032342</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Du</surname><given-names>G.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020d</year>). <article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.</article-title>
<source><italic>Lancet</italic></source>
<volume>395</volume>
<fpage>1569</fpage>&#x02013;<lpage>1578</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id><pub-id pub-id-type="pmid">32423584</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Pan</surname><given-names>R.</given-names></name><name><surname>Zeng</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis.</article-title>
<source><italic>J. Virol.</italic></source>
<volume>89</volume>
<fpage>8416</fpage>&#x02013;<lpage>8427</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00948-15</pub-id>
<?supplied-pmid 26041293?><pub-id pub-id-type="pmid">26041293</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>T. K.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Lo</surname><given-names>M. K.</given-names></name><name><surname>Ray</surname><given-names>A. S.</given-names></name><name><surname>Mackman</surname><given-names>R. L.</given-names></name><name><surname>Soloveva</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.</article-title>
<source><italic>Nature</italic></source>
<volume>531</volume>
<fpage>381</fpage>&#x02013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1038/nature17180</pub-id>
<?supplied-pmid 26934220?><pub-id pub-id-type="pmid">26934220</pub-id></mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>S. R.</given-names></name><name><surname>Navas-Martin</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome Coronavirus.</article-title>
<source><italic>Microbiol. Mol. Biol. Rev.</italic></source>
<volume>69</volume>
<fpage>635</fpage>&#x02013;<lpage>664</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.69.4.635-664.2005</pub-id>
<?supplied-pmid 16339739?><pub-id pub-id-type="pmid">16339739</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>C. C.</given-names></name><name><surname>Kuo</surname><given-names>Y. H.</given-names></name><name><surname>Jan</surname><given-names>J. T.</given-names></name><name><surname>Liang</surname><given-names>P. H.</given-names></name><name><surname>Wang</surname><given-names>S. Y.</given-names></name><name><surname>Liu</surname><given-names>H. G.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>50</volume>
<fpage>4087</fpage>&#x02013;<lpage>4095</lpage>. <pub-id pub-id-type="doi">10.1021/jm070295s</pub-id>
<?supplied-pmid 17663539?><pub-id pub-id-type="pmid">17663539</pub-id></mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><collab>WHO</collab> (<year>2020a</year>). <source><italic>Clinical management of COVID-19.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19">https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19</ext-link>
<comment>(accessed June 8, 2020)</comment></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><collab>WHO</collab> (<year>2020b</year>). <source><italic>Novel Coronavirus (2019-nCoV) Situation Reports.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</ext-link>
<comment>(accessed July 04, 2020)</comment></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><collab>WHO</collab> (<year>2020c</year>). <source><italic>Q&#x00026;A: Hydroxychloroquine and COVID-19.</italic></source> Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-and-covid-19">https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-and-covid-19</ext-link>
<comment>(accessed July 5, 2020)</comment></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>J. R.</given-names></name><name><surname>Lane</surname><given-names>S. J.</given-names></name><name><surname>Lee</surname><given-names>T. H.</given-names></name></person-group> (<year>1991</year>). <article-title>Effects of corticosteroids on cytokine generation and expression of activation antigens by monocytes in bronchial asthma.</article-title>
<source><italic>Int. Arch. Allergy Immunol.</italic></source>
<volume>94</volume>
<fpage>220</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1159/000235365</pub-id>
<?supplied-pmid 1834579?><pub-id pub-id-type="pmid">1834579</pub-id></mixed-citation></ref><ref id="B243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>R. C.</given-names></name><name><surname>Doudna</surname><given-names>J. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Molecular mechanisms of RNA interference.</article-title>
<source><italic>Annu. Rev. Biophys.</italic></source>
<volume>42</volume>
<fpage>217</fpage>&#x02013;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biophys-083012-130404</pub-id>
<?supplied-pmid 23654304?><pub-id pub-id-type="pmid">23654304</pub-id></mixed-citation></ref><ref id="B244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K. S.</given-names></name><name><surname>Goldsmith</surname><given-names>J. A.</given-names></name><name><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.</article-title>
<source><italic>Science</italic></source>
<volume>367</volume>:<issue>1260</issue>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id>
<?supplied-pmid 32075877?><pub-id pub-id-type="pmid">32075877</pub-id></mixed-citation></ref><ref id="B245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.-J.</given-names></name><name><surname>Jan</surname><given-names>J.-T.</given-names></name><name><surname>Chen</surname><given-names>C.-M.</given-names></name><name><surname>Hsieh</surname><given-names>H.-P.</given-names></name><name><surname>Hwang</surname><given-names>D.-R.</given-names></name><name><surname>Liu</surname><given-names>H.-W.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>48</volume>
<fpage>2693</fpage>&#x02013;<lpage>2696</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.48.7.2693-2696.2004</pub-id>
<?supplied-pmid 15215127?><pub-id pub-id-type="pmid">15215127</pub-id></mixed-citation></ref><ref id="B246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name></person-group> (<year>2020</year>). <article-title>The SARS-CoV-2 outbreak: what we know.</article-title>
<source><italic>Int. J. Infect. Dis.</italic></source>
<volume>94</volume>
<fpage>44</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.004</pub-id>
<?supplied-pmid 32171952?><pub-id pub-id-type="pmid">32171952</pub-id></mixed-citation></ref><ref id="B247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Fu</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Effective treatment of severe COVID-19 patients with tocilizumab.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>117</volume>:<issue>202005615</issue>. <pub-id pub-id-type="doi">10.1073/pnas.2005615117</pub-id>
<?supplied-pmid 32350134?><pub-id pub-id-type="pmid">32350134</pub-id></mixed-citation></ref><ref id="B248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.</article-title>
<source><italic>Science</italic></source>
<volume>367</volume>
<fpage>1444</fpage>&#x02013;<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id>
<?supplied-pmid 32132184?><pub-id pub-id-type="pmid">32132184</pub-id></mixed-citation></ref><ref id="B249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Leibowitz</surname><given-names>J. L.</given-names></name></person-group> (<year>2015</year>). <article-title>The structure and functions of coronavirus genomic 3&#x02019; and 5&#x02019; ends.</article-title>
<source><italic>Virus Res.</italic></source>
<volume>206</volume>
<fpage>120</fpage>&#x02013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2015.02.025</pub-id>
<?supplied-pmid 25736566?><pub-id pub-id-type="pmid">25736566</pub-id></mixed-citation></ref><ref id="B250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>T.-T.</given-names></name><name><surname>Qian</surname><given-names>J.-D.</given-names></name><name><surname>Zhu</surname><given-names>W.-Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>G.-Q.</given-names></name></person-group> (<year>2020a</year>). <article-title>A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus&#x02014;A possible reference for coronavirus disease-19 treatment option.</article-title>
<source><italic>J. Med. Virol.</italic></source>
<volume>92</volume>
<fpage>556</fpage>&#x02013;<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25729</pub-id> n/a., <?supplied-pmid 32104907?><pub-id pub-id-type="pmid">32104907</pub-id></mixed-citation></ref><ref id="B251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Cui</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>9</volume>:<issue>ciaa237</issue>. <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id>
<?supplied-pmid 32150618?><pub-id pub-id-type="pmid">32150618</pub-id></mixed-citation></ref><ref id="B252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yogo</surname><given-names>Y.</given-names></name><name><surname>Hirano</surname><given-names>N.</given-names></name><name><surname>Hino</surname><given-names>S.</given-names></name><name><surname>Shibuta</surname><given-names>H.</given-names></name><name><surname>Matumoto</surname><given-names>M.</given-names></name></person-group> (<year>1977</year>). <article-title>Polyadenylate in the Virion RNA of Mouse Hepatitis Virus.</article-title>
<source><italic>J. Biochem.</italic></source>
<volume>82</volume>
<fpage>1103</fpage>&#x02013;<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a131782</pub-id>
<?supplied-pmid 200604?><pub-id pub-id-type="pmid">200604</pub-id></mixed-citation></ref><ref id="B253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zha</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Tefsen</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>French</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19).</article-title>
<source><italic>Med. J. Aust.</italic></source>
<volume>212</volume>
<fpage>416</fpage>&#x02013;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.5694/mja2.50577</pub-id>
<?supplied-pmid 32266987?><pub-id pub-id-type="pmid">32266987</pub-id></mixed-citation></ref><ref id="B254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name></person-group> (<year>2020a</year>). <article-title>Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.</article-title>
<source><italic>Int. J. Antimicrob. Agents</italic></source>
<volume>55</volume>:<issue>105954</issue>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105954</pub-id>
<?supplied-pmid 32234467?><pub-id pub-id-type="pmid">32234467</pub-id></mixed-citation></ref><ref id="B255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>Z.</given-names></name></person-group> (<year>2020b</year>). <article-title>Rational use of tocilizumab in the treatment of novel coronavirus pneumonia.</article-title>
<source><italic>Clin. Drug Investig.</italic></source>
<volume>26</volume>
<fpage>1</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s40261-020-00917-3</pub-id>
<?supplied-pmid 32337664?><pub-id pub-id-type="pmid">32337664</pub-id></mixed-citation></ref><ref id="B256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.-Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Kemnitzer</surname><given-names>W.</given-names></name><name><surname>Tseng</surname><given-names>B.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name><name><surname>Michaelis</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>49</volume>
<fpage>1198</fpage>&#x02013;<lpage>1201</lpage>. <pub-id pub-id-type="doi">10.1021/jm0507678</pub-id>
<?supplied-pmid 16451084?><pub-id pub-id-type="pmid">16451084</pub-id></mixed-citation></ref><ref id="B257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chakraborti</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Sheahan</surname><given-names>T.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>104</volume>
<fpage>12123</fpage>&#x02013;<lpage>12128</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0701000104</pub-id>
<?supplied-pmid 17620608?><pub-id pub-id-type="pmid">17620608</pub-id></mixed-citation></ref></ref-list></back></article>